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Abstract
Polyclonal antibodies to 7-hydroxycoumarin - the main metabolite of coumarin, a plant 
constituent with many clinical applications - were produced, purified and characterised. This 
antibody preparation was used to develop a competitive immunoassay for 7- 
hydroxycoumarin which was carried out on the BIAcore, an optical biosensor based on the 
phenomenon of surface plasmon resonance (SPR). The immunoassay was optimised and 
internally validated.
Monoclonal antibodies were generated by somatic cell fusion using the spleens of mice 
immunised with a 7-hydroxycoumarin-protein conjugate. The screening of cell culture 
supernatants by BIAcore and ELISA was compared, and all of 13 clones isolated by limiting 
dilution were found to be reactive to the drug-protein conjugate, but not to free drug.
The panning of phage displayed antibodies from a naïve library using the BIAcore was 
investigated, and, although the amount of bound phage was insufficient to generate an SPR 
signal, subsequent analysis of eluate demonstrated that enrichment had taken place.
BIAcore was also used to affinity rank a panel of 3 genetically-produced single chain Fv 
antibodies against coumarin-BSA and to examine kinetic and affinity data for the interaction 
of one of these antibodies with immobilised drug-protein conjugate.
The interaction of two antibody preparations against the fungal toxin aflatoxin Bi (AFBj), a 
member of the coumarin family, was studied using both BIAcore and ELISA methods. High 
affinity constants rendered the monoclonal and polyclonal antibodies unsuitable for use in 
regenerable immunosensor formats. A range of competitive and sandwich ELISAs for the 
detection of AFBi were developed using both types of antibody. In addition, methods to 
facilitate better design of formats for use with BIAcore were established using ELISA to 
mimic regeneration conditions on the sensor chip surface, and to calculate equilibrium 
affinity constants.
Supercoiled plasmid DNA was also immobilised on the BIAcore sensor surface, and the 
inhibition of the enzyme topoisomerase II by the coumarin antibiotic novobiocin, as well as 
the direct binding of a range of coumarin-protein conjugates to nucleic acids, were 
investigated.
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C H A P T E R  1 
I N T R O D U C T I O N
1.0 Introduction
The work described in this thesis concerns the use of an optical immunosensor and other 
analytical techniques to study members of the coumarin family and their immunological 
interactions. The first part of this chapter describes the chemistry, biosynthesis, metabolism 
and clinical and analytical uses of coumarin compounds. The second half of the chapter 
deals with biosensor technology in general, and the use of optical immunosensors in 
particular.
1.1 Coumarins
The coumarins belong to a group of compounds known as the benzopyrones, all of which 
consist of a benzene ring joined to a pyrone - a six-membered heterocyclic ring containing 
one oxygen atom and five sp2-hybridised carbons. Both y- and a-pyrones exist, with the 
prefixes referring to the position at which the oxygen atom is found. The structure of a- 
pyrone is shown below:
Coumarin (shown below) and the other members of the coumarin family are benzo-a- 
pyrones, while the other main members of the group - the flavonoids - contain the y-pyrone 
group.
5 4
The coumarins display a characteristic fluorescence upon excitation with ultra-violet light, 
in addition to having a large range of physiological activity.
1.1.1 History of coumarins
The name coumarin is derived from Coumarouna odorata, the botanical name for the tonka 
tree -  one of the many plant sources in which the compound is found. The molecule was
1
first isolated in 1820 by Vogel, who extracted coumarin both from the tonka bean and 
clover. It is the presence of coumarin in the latter which is responsible for the distinctive 
odour of new-mown hay. The structure of the compound was determined in 1868.
1.1.2 Chemistry of coumarins
Many coumarins are comprised of isoprenoid chains joined to one of the carbons of the 
nucleus, or to an oxygen atom, for example, a phenolic oxygen. The isoprenoid chains may 
consist of one, two or three units, and many variations of this type of structure are to be 
found among the coumarins. Interactions of the prenyl group with an ort/zo-phenolic group 
can lead to the formation of another heterocyclic ring. Oxidative interaction may also occur. 
As the vast majority of the coumarins are oxygenated at C-7, 7-hydroxycoumarin is 
frequently considered to be the parent compound for the more structurally complex 
members of the family. Coumarins may also be found in nature in combination with sugars, 
as glycosides. A variety of chromatographic and spectroscopic methods for the 
identification of coumarins exist. The coumarins can be roughly categorised as follows:
a) Simple
These members of the coumarin family are the hydroxylated, alkoxylated and 
alkylated derivatives of the parent compound, coumarin, along with their glycosides. 
7-hydroxycoumarin, a member of this group, is shown here:
b) Furanocoumarins
These compounds consist of a five-membered furan ring attached to the coumarin 
nucleus. Most of the members of this group are derivatives of the linear 
furanocoumarin, psoralen, or its more stable angular isomer, angelicin. (The terms 
“ linear” and “ angular” refer to the orientation of the furan ring with respect to the 
coumarin nucleus.) The dihydrofuranocoumarins are also members of this group.
2
Angel icin:
c) Pyranocoumarins
Members o f  this group are analogous to the iuranocoumarins, and contain a six- 
membered ring. As with the iuranocoumarins, linear and angular types exist, e.g.:
O
Xanthyletin:
Seselin:
O
d) Coumarins substituted in the pyrone ring
Examples o f  this group include 4-hydroxy coumarin and the 3-methyl-4- 
hydroxycoumarins, such as autumnariol:
OH
O
4-hydroxycoumarin:
3
HAutumnariol:
1.1.3 Nomenclature of coumarins
The nomenclature of coumarin compounds is frequently problematic. The parent 
compound, coumarin, is variously known as 2-oxo-l,2-benzo-pyran, 5,6-benzo-a-pyrone, 
5,6-benzo-2-pyrone, 1,2-benzopyrone, 2i7-l-benzopyran-2-one, cis-o-coumaric acid 
lactone, 2//-benzo[6]pyran-2-one, coumarinic anhydride and 2//-chromen-2-one. Members 
of the coumarin family have been isolated from hundreds of species of plants and 
microorganisms, giving rise to another problem in the naming of the compounds. Many of 
the coumarins that have been isolated are known by common names, which are generally 
derived from the Latin or colloquial name of the plant in which they have been discovered, 
or from the place where the plant grows, resulting in the same compound having several 
different trivial names. Frequently, the trivial name which has been assigned to such a 
compound gives little or no information as to its structural composition; and in some cases 
may even be misleading. For example, 7-hydroxy coumarin is also known as umbelliferone, 
(due to its occurrence in members of the Umbelliferae), skimmetin, hydrangin and Dichrin
1.1.4 Occurrence
Although most of the natural coumarins in existence have been isolated from the higher 
plants, some members of the family have been discovered in miroorganism and animal 
sources. Yeast of the genus Streptomyces produce antibiotics like novobiocin, chartreusin, 
(shown below) and coumermycin At:
4
Chartreusin:
The aflatoxins are a group of highly toxic fungal metabolites, which occur in the fungus 
Aspergillus sp. The most commonly-occurring member of the group is aflatoxin B, (AFBj), 
which is produced by Aspergillus flavus and A parasiticus:
Dasycladus vermicularis - a member of the green algal family Dasycladaceae - has been 
shown to produce 3,6,7-lrihydroxycoumarin (Menzel et a/., 1983):
The mould Emericella desertorum produces desertorin A, B and C (Nozawa et al., 1997), 
the first of which is shown below:
5
Me OMe
O
Necatorin (below) has been extracted from the wild mushroom Lactarius necator (Suortti 
and von Wright, 1983):
O
Lamillarin A, B, C and D are metabolites of the mollusc Lamellaria sp (Andersen et al., 
1985). The structure of lamillarin D is shown below:
6
The Castoreum pigments are also of animal origin, having been extracted from secretions of 
the beaver scent gland (Dean, 1963):
As stated above, though, most coumarins occur in the higher plants, with the richest sources 
being the Rutaceae and Umbelliferae, in which all parts of the plant have been discovered to 
contain coumarins. The coumarins belong to a group known as the secondary products of 
plant metabolism, the exact roles of which in plant physiology are not clearly understood. 
While being distributed throughout all parts of the plant, the coumarins occur at the highest 
levels in the fruits, followed - in order of decreasing occurrence - by the roots, stems and 
leaves. In addition, seasonal changes and environmental conditions may affect the 
occurrence in various parts of the plant.
Murray et al. (1982) and Keating and O’Kennedy (1997) have given a comprehensive 
overview of the chemistry and occurrence of natural coumarins, including tables of the 
botanical sources of all of the coumarin compounds known at time of publication.
1.1.5 Biosynthesis of coumarins
In the higher plants, coumarins are generally produced via the shikimate-chorismate 
biosynthetic pathway, as a derivative of cinnamic acid, which is also a precursor of many 
other natural products, such as methyl salicylate, cinnamic aldehyde and amygdalin. The 
shikimate-chorismate pathway is responsible for the formation of the aromatic amino acids. 
Phosphoryl group transfer from ATP followed by nucleophilic displacement results in the 
formation of 3-enolpyruvyl-shikimate-5-phosphate from shikimate, and the elimination of 
phosphate gives chorismate:
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COOH COOH COOH
OH
CH,
I 0 -<f
OH A,COOH
O
Shikimate 3-Enolpyruvyl-shikimate-5-phosphate Chorismate
The enzyme chorismate mutase then catalyses the rearrangement of chorismate to 
prephenate, which is converted to phenylpyruvate by means of a 1,4 elimination. A 
glutamate-dependant transamination results in the formation of phenylalanine:
COOH
CH
OH
o-c
COOH
Chorismate
O
h o o c  c h 2 - c - c o o h
OH
Prephenate
COOH
c=o
I
CHo
Phenylpyruvate
COOH
h - c n h 3+
Phenylalanine
Phenylalanine is then converted to irans-cinnamic acid by the action of the enzyme 
phenylalanine ammonia-lyase, which eliminates NH3+:
COOH
H - C - N H ,
I 0 
CHo
+
Phenylalanine
COOH
Trans-cinnamic acid
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From this point, simple coumarins which are oxygenated at C-7 follow a biosynthetic route 
different to those which are not oxygenated at this position. In the latter case, the trans- 
cinnamic acid is first 2 '-hydroxylated, then glucosylated to give trans-2'- 
glucosyloxycinnamic acid. This is then converted to the cw-isomer:
trans-Cinnamic acid
COOH 
O-glucosyl
cis-2 '-Glucosyloxycinnamic acid
OH
trans-2'-Hydroxycinnamic acid
< ^ C O O H
O-glucosyl
trans-2 '-Glucosyloxycinnamic acid
m-2'-Glucosyloxycinnamic acid is also known as coumarinyl glucoside, and is the bound 
form in which coumarin exists in plants. The hydroxylation and glucosylation of the trans- 
cinnamic acid are enzyme-catalysed reactions, while the trans-cis isomérisation is mediated 
by UV light.
The 7-oxygenated simple coumarins arise as a result of ^ ara-hydroxylation, rather than the 
ori^o-hydroxylation which is the first step in the formation of the non-oxygenated 
compounds. As in the previous reaction scheme, a glucosylation reaction is also involved, 
followed by UV-dependent trans-cis isomérisation. The scheme below shows the formation 
of cw-2'-glucosyl-4-methoxycinnamic acid, the bound form of hemiarin:
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% ^C O O H
trans-Cinnamic acid
coon
OH
trans-4 '-Hydroxycinnamic acid
OMe
COOH
O-glucosyl
COOH
cis-2 '-Glucosyloxy-4-methoxycinnamic acid
OMe O-glucosyl
trans-2 '-Glucosyloxy-4-methyoxycinnamic acid
The structure of the unbound compound, hemiarin, is shown below:
The furanocoumarins (both linear and angular) are produced using 7-hydroxycoumarin as 
the parent compound, with the other two carbons of the furan ring coming from malevonic 
acid. The malevonate derivative dimethyllallylpyrophosphate, below, is involved in the 
prénylation of position 6 of 7-hydroxycoumarin to form the furanocoumarin precursor 
demethylsuberosin (DMS).
c h 2 o p 2 o 63
It is thought that the double bond of the prenyl group in DMS undergoes epoxidation prior 
to cyclisation to a dihydrofuranocoumarin, which is then converted into a furanocoumarin, 
as in the synthesis of psoralen illustrated below:
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7-Hydroxycoumarin Demethylsuberosin (DMS)
HO
Psoralen Marmesin
The formation of angular furanocoumarins proceeds by an analagous series of reactions, 
with - for example - angelicin being formed from 7-hydroxy coumarin via colombianetin, 
following prenylation at position 8 to give osthenol. In the case of furanocoumarins which 
possess hydroxyl or methyl ether groups, O-mcthylation and hydroxylation appear to occur 
after psoralen or angelicin have been fully formed.
It seems most likely that the linear and angular pyranocoumarins are formed by a 
biosynthetic route similar to that of the furanocoumarins, differing only in the last 
cyclisation step.
Although the shikimate-chorismate pathway is the predominant route for the biosynthesis of 
coumarin compound, including the 4-hydroxycoumarins, exceptions do exist. The 
phenylcoumarins, such as coumestrol, have been found to originate partly from the 
shikimate-chorismate pathway and partly from the polyketide pathway, while the aflatoxins 
are synthesised entirely from acetate via polyketide intermediates like averufm and 
versicolorin A.
In plants, it seems that the main site of coumarin synthesis is in the leaves, although 
synthesis in other parts of the plant - notably the roots and aerial organs - also takes place.
1.1.6 Chemical synthesis
The classical reaction for the formation of coumarin - Perkin’s reaction - involves heating o- 
hydroxybenzaldehyde with sodium acetate and acetic anhydride at 180°C:
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Ac 2 O 
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NaOAc
O OAc
OAc
Ac 2 O NaOAc
OAc
OAc
OAc
Since this reaction was first used for the preparation of coumarin in 1868, a wide range of 
the natural coumarins have been chemically synthesised. The synthesis of simple 
coumarins with methoxy or hydroxy groups is generally still carried out by means of the 
Perkin reaction, despite the fact that yields are frequently poor.
As the formation of the pyrone ring is the most important step in many of the chemical 
syntheses of coumarin, a variety of methods have been developed to introduce functional 
groups into this structure. One strategy is to prepare a phenol which contains the desired 
substituents of the coumarin before the pyrone ring is formed. Alternatively the coumarin 
nucleus may be synthesised first, and a process such as C- or O-alkylation or nuclear 
oxygenation employed to produce the required compound.
1.1.7 Coumarin metabolism
The main phase I metabolite of coumarin in man is 7-hydroxycoumarin, and the 
hydroxylation reaction is catalysed by a specific cytochrome P450 enzyme in the liver, 
called CYP2A6, which has an absolute requirement for nicotine adenine dinucleotide 
phosphate (NADPH). 7-hydroxycoumarin is then glucuronidated - a common metabolic 
fate for xenobiotics, which renders them more water-soluble and results in detoxification. 
The glucuronidation reaction is catalysed by uridine diphosphate glucuronyl transferase 
(UDPGT). The UDPGTs are a group of membrane-bound enzymes which conjugate 
glucuronic acid to compounds with oxygen-, nitrogen-, sulphur- and carbon-containing 
functional groups. The metabolic fate of coumarin in man is illustrated in Figure 1.1.
1 2
Figure 1.1 The metabolic fate of coumarin in man. Coumarin is rapidly hydroxylated to 
form 7-hydroxycoumarin by a cytochrome P450 enzyme with an absolute requirement for 
NADPH. 7-hydroxycoumarin is then conjugated to UDP-glucuronic acid by the enzyme 
UDP glucuronyl transferase (UDPGT) to form 7-hydroxycoumarin-glucuronide, Another 
enzyme, p-glucuronidase, can deconjugate this glucuronide.
NADPH Cytochrome P450
COOH
O
OH
OH
7-hydroxycoumarin UDP-glucuronic acid
P-glucuronidase UDPGT
COOH
O
OH
7- hydroxycoumarin-glucuronide
13
Coumarin metabolism is subject to major interspecies differences, and hydroxylation at all 
available positions, as well as opening of the pyrone ring, has been documented. This 
metabolic diversity is mirrored by dissimilarities in the toxicity of coumarin in different 
species. In rats, for example, 3-hydroxylation followed by ring-opening appears to be the 
main metabolic route, and this pathway - relatively insignificant in man - seems to result in 
the highest degree of hepatotoxicity. The metabolism of coumarin has been reviewed 
recently by Pelkonen et al. (1997), and the primary mammalian metabolites are shown in 
Figure 1.2.
In all of the metabolic pathways investigated, a hydroxylation step is necessary for phase II 
conjugation to take place by means of UDP-glucuronosyl transferases and 
sulphotransferases.
In man, as in all other species studied, metabolism of coumarin is rapid and almost 
complete, with the free drug having a half-life of only one hour after either oral or 
intravenous administration.
As coumarin is so quickly metabolised, it is thought to be a prodrug for 7-hydroxycoumarin, 
to which compound the clinical effects of coumarin are usually attributed. It has been 
shown (Sharifi et al., 1993a) that both free and glucuronidated 7-hydroxycoumarin can be 
detected in circulation many days after adminstration, and a cyclic system of conjugation 
and deconjugation has been postulated for the action of the drug in vivo (Casely-Smith and 
Casely-Smith, 1986).
1.1.8 Clinical applications
Plants which naturally contain biologically-active coumarins seem to benefit from immunity 
from infections by fungal pathogens, and some plants also repel beetles and other insects. 
In addition, the strong absorption of ultra-violet light characteristic of coumarin and its 
derivatives shields young plants from damage by sunlight. Over the years, a variety of 
physiological effects in man have been attributed to the coumarins, ranging from 
bacteriostatic action to diuretic effects to narcotic properties. (It is interesting to note that 
many of the biologically-active coumarins contain a 7-hydroxy group.) These reports have 
lead to many animal and clinical trials being undertaken with coumarins for the treatment of 
a large variety of disorders.
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Fig 1.2 The metabolism of coumarin in mammals. Hydroxylation at all available positions, 
and the opening of the pyrone ring, have been documented. (Taken from Bogan, 1996)
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Most of the studies have been carried out on the parent compound and its primary 
metabolite in man, 7-hydroxycoumarin, although the synthetic 4-hydroxycoumarin warfarin 
is currently in the most widespread use.
One of the most exciting potential uses of coumarin is in the treatment of cancer. Unlike 
many other chemotherapeutic agents, the use of coumarin is associated with relatively few 
side-effects. The major problem with oral administration of the drug has been nausea 
brought on by the aromatic nature of the parent compound, a problem which can be 
circumvented by the substitution of 7-hydroxycoumarin. The in vivo action of the drug in 
several types of cancer has been demonstrated, and - together with results from cell-cuture 
experiments - these findings have pointed to a number of different possible mechanisms for 
the anti-tumour action of coumarins.
The programmed cell death necessary for normal growth, and for the removal of damaged 
and senescent cells, is known as apoptosis, and interference with this process - leading to an 
increase in the number of rapidly-dividing cells - is a characteristic of malignant cells. In 
experiments on tumour cells in culture, coumarin, 7-hydroxycoumarin and the derivative o- 
coumaric acid were seen to exhibit dose-dependant cytotoxic effects at high drug 
concentrations (100 -500 mg/ml). The dead cells were shown to display morphology 
consistent with apoptosis, such as shrinkage and compaction of chromatin (Marshall et al., 
1991a; Rosskopf et al., 1992; Kahn et al., 1994).
In addition to these cytotoxic effects, coumarins have also been shown to possess a 
cytostatic activity, on both normal and cancerous cells. One example of this is the action of 
esculetin on muscle cells (Huang et al., 1993), which is thought to be due to a decrease in 
tyrosine kinase activity. The synthetic derivative 8-mtro-7-hydroxycoumarin has been 
shown to possess both cytotoxic and cytostatic activity (Egan et al., 1997).
The growth of normal cells is strictly controlled at various stages of the cell cycle such as 
cell division and DNA replication. Many tumour cells, though, display abnormalities in the 
cell cycle, allowing the reproduction of damaged DNA. In a model system, coumarin has 
been shown to modulate the cell cycle, decreasing the number of cells undergoing DNA 
replication, and leading to a reduction in cell proliferation (Tseng et al., 1987).
A range of substances known as growth factors have been linked to the regulation of cell 
growth. The binding of these factors to specialised receptors control signalling pathways
16
within the cell. When both growth factor and receptor are produced by the same cell, the 
regulatory process is known as an "autocrine loop". Examples of growth factors are 
epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), It is thought 
that aberrations of growth factors and their specific receptors play a part in some types of 
cancer. Glioma is a malignant condition of the glial cells. It has been demonstrated in in 
vitro studies that treatment of glioma cells with 7-hydroxycoumarin leads to an inhibition of 
cell growth, with concomitant reduction in levels of PDGF (Seliger and Pettersson, 1994). 
This suggests that 7-hydroxycoumarin controls glioma cell growth by inhibition of an 
autocrine loop.
Coumarins also exert an anti-tumour activity by affecting the body's immune system 
("immunomodulatory effects"), causing defence mechanisms to be activated which can 
remove tumours and prevent recurrence of surgically-removed tumours (Zlabinger, 1997).
A variety of clinical trials of coumarins in the treatment of cancer, in which one or more of 
the above mechanisms were thought to be operative, have been carried out.
Marshall et al. (1991b) carried out a phase I trial on patients with advanced malignancies, in 
which coumarin was administered along with cimetidine - a substance with known 
immunomodulatory effects. Thirty-seven of the fifty-four patients treated were suffering 
from metastatic renal cell carcinoma, among which group there was a response rate of 
approximately 20%, with the best results occurring in patients with metastases in the lung, 
with low tumour burdens, and who had undergone prior nephrectomy. A subsequent study 
(Kokron et al., 1991), carried out solely on patients with renal cell carcinoma, reported a 
comparable number of responders, with similar profiles.
A clinical trial on patients with metastatic prostate cancer (Mohler et al., 1992), in which 3 g 
of coumarin was administered daily, gave a response rate of 8% (3 of 40 individuals). 
Favourable results have also been obtained in a trial of coumarin on patients with malignant 
melanoma (Thornes et al., 1989).
The evidence from all of the clinical trials so far conducted is that coumarin is most 
effective in cancer treatment when used as a secondary (or "adjuvant") therapy in patients 
with good performance status and small tumour loads. In general, the drug appears to be of 
most use in the prevention of tumour recurrence following radical surgery.
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One area in which coumarin, although not yet in routine use, has proved to be of very 
significant benefit, is in the treatment of high-protein oedema. An oedema is a medical 
condition characterised by the accumulation of plasma protein in tissue, leading to swelling 
of the affected tissue (as a result of osmosis) and pain. High-protein oedemas (defined as 
those in which protein concentrations in tissues are at or above 10  g/1) cause blood vessels to 
be damaged, and may result in secondary bacterial and fungal infections, and even death.
All of the coumarins tested have been shown to be effective at reducing high-protein 
oedemas. They do this by increasing the number and proteolytic activity of macrophages at 
the site of the oedema. It is thought that they may also exert an influence on other cell types 
involved in the response to injury. The excess proteins present are broken down, and the 
fluid returns to the blood-stream. Coumarin, in common with most other benzopyrones, 
binds to proteins in vivo. One study using radio-labelled coumarin administered to rats has 
demonstrated that 66% of the drug is bound to serum proteins (Piller and Schmitt, 1977). 
This protein binding allows coumarin to enter tissues easily, and greatly enhances its 
efficacy in the treatment of oedema.
In a clinical trial, administration of 400 mg per day of coumarin was reported to decrease the 
size of oedemas by 20% in patients with elephantiasis (Casely-Smith et al., 1993).
Oedema is also associated with diseases which cause chronic inflammation, and disorders 
ranging from bedsores to brucellosis (Thornes, 1983) have been shown to respond to 
treatment with coumarin. In another study on animal tissue, coumarin, 7-hydroxycoumarin, 
and 4-hydroxycoumarin were found to possess an anti-inflammatory activity, as evinced by 
their inhibition of prostaglandin formation (Lee et al., 1981).
In vivo, approximately 20-30% of administered 7-hydroxycoumarin will be bound to red 
blood cells, upon which it produces a haemmorheological effect - increasing the flexibility 
of erythrocytes and reducing aggregation. This property, along with its anti-oedema 
activity, is the basis for the use of coumarin in the treatment of venous disorders. Variocose 
veins and haemorrhoids have been treated using coumarin, and a combination of coumarin 
and troxerutin has been tested on patients with chronic venous insufficiency (CVI), with 
good results (Bosse et al, 1985).
The action of coumarins on oedema, together with other effects such as those on the 
functions of the lymphatic system and glucose uptake by red blood cells, indicate that the
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drugs - while not currently in widespread use - may also prove clinically important in the 
treatment of bums (Piller, 1997).
Coumarin and 7-hydroxycoumarin are also of interest for their ability to scavenge free 
radicals, which cause damage to blood vessels and cell membranes. This property may be 
of use in the treatment of AIDS and HIV infection, of which disorders such oxidative stress 
is symptomatic (Greenspan and Aruoma, 1994).
Despite the antimicrobial effects of novobiocin (and the other coumarin antibiotics), and the 
spasmolytic activity of hymecromen, neither have gained general clinical acceptance. The 
furanocoumarin 8-methoxypsoralen, however, is significant for its use in the treatment of 
dermatological diseases such as psoriasis.
As mentioned above, warfarin and its derivatives are currently the most clinically important 
of the coumarins. Warfarin (3-(a-acetonylbenzyl)-4-hydroxycoumarin) was first 
synthesised by Ikawa et al. in 1944. The activity of warfarin and the other coumarin anti­
coagulants is based on their inhibition of vitamin K-dependant clotting factors, culminating 
in the production of abnormal prothrombin, which is unable to bind the calcium ions 
necessary for the proper operation of the clotting mechanism. Warfarin is in widespread 
clinical use as an oral anticoagulant in the treatment of acute myocardial infarction, 
threatened stroke, and venous thrombosis. It has also been investigated for use in other 
disorders.
The effects of warfarin upon the cellular immune system were studied in a clinical test on 
patients with Herpes simplex infection (Berkarda, 1993). Patients receiving a low (non­
anticoagulant) dose of the drug displayed a 4-fold lower instance of recurrence of cold sores 
than those in the control group.
IgA nephropathy is a disorder caused by accumulation of the immunoglobulin IgA in cells 
of the kidney, leading to renal failure. Macrophage-like cells in the kidney are instrumental 
in the progression of the disease, which has been shown to be arrested by administration of 
non-anticoagulant doses of warfarin, along with two other drugs - cyclophosphamide and 
dipyridamole (Woo et al., 1987).
In a clinical trial, treatment with warfarin has been demonstrated to increase survival and 
tumour reduction in patients with small cell carcinoma of the lung (SSCL), a malignant 
condition associated with a coagulative effect (Zacharski et al., 1981).
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Coumarins are so-called "suicide substrates" for serine proteases, binding irreversibly to the 
enzyme. One such enzyme is the HIV-1 protease responsible for the spread of the causative 
organism of AIDS. Coumarins also block the production of the naturally-occurring 
tripeptide glutathione (GSH), which is implicated in the regulation of HIV replication. In an 
in vitro study (Bourinbaiar et al., 1993a) low doses of warfarin (10 9 - 10"8 M) inhibited the 
infection of lymphocytes - by both adjacent infected cells and free virus - by 50%. These 
results were corroborated by a second study which also reported a similar activity for 7- 
hydroxycoumarin (Bourinbaiar et al., 1993b). In a separate study, a structurally-related 4- 
hydroxycoumarin, phenprocoumon, was found to possess a greater inhibitory activity than 
warfarin (Thaisrivongs et al., 1994). The data from all sets of experiments indicates that the 
antiviral effect of the coumarins tested was at least as specific as that of AZT. In addition, 
the coumarins exhibit greater oral availibility and less rapid excretion than the 
peptidomimetic compounds previously studied as protease inhibitors.
The clinical applications of coumarins are summarised in Table 1.1.
1.1.9 Other uses of coumarin
In addition to their clinical applications, the coumarins are also widely used in analytical 
science as labelling and derivatising agents and as dyes in laser applications. Many of these 
applications are linked to the characteristic fluorescence of coumarins, and have recently 
been reviewed by Cooke et al. (1997). The compound 7-amino-4-methyl-coumarin-3-acetic 
acid (AMCA) is commonly used as a fluorescent label for proteins. The compound has a 
relatively large Stake's shift of 100 nm, does not change the isoelectric point of labelled 
proteins, and is resistant to photobleaching. N-hydroxysuccinimide and sulphosuccinyl 
esters of AMCA are available, and have been used to label antibodies (Khalfan et al., 1986), 
cell surface antigens (Aubry et al., 1990) and nucleic acids (Wiegant et al., 1993). 
4-methyl-7-hydroxycoumarin (or 4-methylumbelliferone) and its derivatives are frequently 
used as fluorescent substrates for enzyme assays, due to the fact that conjugates of these 
compounds exhibit little or no flourescence until the coumarin moiety is released by 
enzymic cleavage.
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Table 1.1 A summary of the clinical applications of coumarins which have been 
investigated to date.
Compound Clinical application Reference
Coumarin Cell cycle modulation Tseng et al., 1987
Reduction of oedema Casely-Smith et al., 1993
Haemorrheological effect Bosse et al., 1985
Bum treatment Piller, 1997
7-hydroxycoumarin Induction of apoptosis Marshall et al., 1991
Autocrine loop inhibition Seliger and Petterssen, 1994
Immunomodulation Zlabinger, 1997
Free radical scavenging Greenspan and Aruoma ,1994
Esculetin Cytostatic activity Huang et al., 1993
8-nitro-7 -hydroxycoumarin Cytostatic/cytotoxic action Egan et al., 1997.
4-hydroxycoumarin Anti-inflammatory effect Lee et al., 1981
Phenprocoumon Protease inhibition Thaisrivongs et al., 1994
Warfarin Anticoagulant Ikawaeia/., 1944
Immunomodulation Berkarda, 1993
Macrophage reduction Woo et al., 1987
Protease inhibition Bourinabaiar etal., 1993a
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A variety of conjugates of 4-methylumbelliferone are currently available for use in assays 
for enzymes as diverse as glucuronidase (Mead et al., 1955) and lysozyme (Yang and 
Hamaguchi, 1980). They are also of value in the identification of bacterial strains, such as 
coliforms (Parked/., 1995).
Peptide derivatives of 7-amino-4-methylcoumarin (AMC) have been used for the 
measurement of protease activity (Kunugi et al., 1985). Derivatives of 7-amino-4- 
trifluoromethyl coumarin (AFC) are both chromogenic and fluorogenic, and have also been 
used for the detection of proteases, such as those produced by Gram-negative bacteria 
(Agban et al., 1990).
The fluorescence of coumarin compounds is sensitive to the presence of various ionic 
species - a phenomenon which has lead to the use of molecules such as esculin and 
umbelliferone as pH indicators (Dement, 1995) and 3-acety 1-4-hydroxy coumarin for the 
detection of metal ions (Bhat and Jain, 1960). Coumarin-based compounds have also been 
used for the measurement of intracellular ion concentrations. One example of this is the use 
of fluorescent probes containing a coumarin moiety for the detection of intracellular 
calcium (Iatridou et al., 1994).
Coumarins such as 4-bromo-7-methoxycoumarin (BrMmC) and 4-bromomethyl-7- 
acetoxycoumarin (BrMaC) can react with carboxylic acids or imidic nitrogens to form 
fluorescent compounds, and have been used for the detection of a range of chemically and 
biologically important substances - such as prostaglandins (Wintersteiger and Juan, 1984) - 
following initial derivatisation and separation by HPLC. Derivatisation with coumarins can 
also be used to detect biological compounds bearing hydroxy and thiol groups.
The degree of formation of 7-hydroxycoumarin from administered coumarin by the 
cytochrome P450 enzyme CYP2A6 can be measured fluorescently, and has been used 
clinically as a test of liver function (Sotaniemi et al., 1995). The measurement of other 
compounds such as 7-ethoxycoumarin and 7-vinyloxycoumarin may also be used to 
monitor cytochrome P450 activity. Kobayashi et al. (1998) monitored the rate of 
production of 7-hydroxycoumarin from 7-alkoxycoumarins by mutant cytochrome p450 
enzymes expressed by E. coli, in a study on the active site of the enzyme.
The broad absorption and fluorescent spectra of coumarin dyes has lead to their use in the 
tuning of lasers to desired wavelengths. One example of this is the use of the coumarin 500
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dye to set a laser to 488 ran for the fluorescence imaging of DNA samples undergoing 
capillary electrophoresis (Nilsson et al., 1995). Coumarin 120 has been used as a dye for 
the matrix-assisted laser desorption ionisation (MALDI) mass spectrometric analysis of 
monosulphated oligosaccharides (Dai et al., 1997).
1.2 Biosensors
Many different types of analyte have been studied using biosensor technology. The 
substances investigated have ranged from large proteins to smaller molecular weight 
analytes such as toxins and drugs. A biosensor is an analytical device consisting of a 
biological element integrated with a physico-chemical transducer to form a specific sensing 
system. The transducer translates the response of the biological component into a readable 
electrical signal. The first reported biosensor was the "enzyme electrode" described by 
Clark and Lyons in 1962. This sensor employed the enzyme glucose oxidase, which was 
immobilised at the surface of a platinum electrode. Glucose in samples was oxidised by the 
enzyme to form gluconic acid and hydrogen peroxide, and the concomitant decrease in 0 2 
concentration was detected at the electrode. Since then, a wide and varied selection of 
different biological components and transduction technologies have been combined to 
produce biosensors for the detection of a diverse range of analytes. These biosensors have 
been used in applications ranging from environmental monitoring (Dennison and Turner, 
1995) to industrial process control (Ludi et al., 1991) and medicine (Connolly, 1995).
1.2.1 The biological element
The biological element of a biosensor should possess a high degree of specificity and 
stability, should not contaminate the sample, and should retain biological activity when 
immobilised (Hall, 1990). The operation of the biological component in a biosensor is 
based on its specific recognition of analyte, and biosensors may be divided into two 
categories on the basis of this recognition. Catalytic biosensors employ molecules which 
bind to, and then alter, the analyte. The products of this catalytic reaction are then detected 
by the sensor. The other type of biosensor, the affinity sensor, detects the binding event 
itself.
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The range of biological components which have been used in biosensors, and their 
immobilisation onto sensor surfaces, have been reviewed recently by McCormack et al. 
(1998). Enzymes, cells, tissues, antibodies, antigens, receptors and nucleic acids have all 
been employed.
The use of glucose oxidase in the first biosensor has already been mentioned. Enzymes are 
the most frequently used biological component of catalytic biosensors, and glucose 
biosensors have probably been the most successful (Schumann and Schmidt, 1992). The 
action of oxidoreductases, involves the transfer of electrons in oxidation/reduction reactions, 
making them especially well-suited for use in biosensors which detect electrochemical 
changes.
The inherent lack of stability exhibited by purified enzymes can be overcome by using 
complete cell or tissue sample as the biological element. Xuili et al. (1992) reported a 
tissue-based biosensor in which rabbit thymus tissue was used to detect adenosine, due to 
the action of adenosine deaminase. A novel tissue-based biosensor for the detection of the 
swellfish tetrodotoxin, employing an immobilised frog bladder membrane, was reported by 
Cheun et al. (1996). The membrane contains Na+ channels which control the passage of the 
ion. The blocking of these channels by tetrodotoxin is measured by an attached Na+ 
electrode. Svitel et al. (1998) immobilised intact Gluconobacter oxydans, Saccharomyces 
cerevisiae and Kluyveromyces marxianus cells at the surface of an oxygen electrode, to 
construct biosensors for the detection of glucose, sucrose and lactose, respectively.
Cell receptors have been used in the production of affinity biosensors. Molecular cell 
receptors are proteins which bind to specific substances such as hormones, and undergo 
conformational change. The interaction between receptors and their specific ligand can be 
detected by means of mass change. As with enzymes, however, purified receptors often 
display decreased stability. Rogers et al. (1991) described the use of the nicotinic 
acetylcholine receptor AChR to measure fluorescently-labelled neurotoxins. The binding of 
a range of bacterial toxins to glycolipid cell receptors was investigated by MacKenzie et al. 
(1997), using an optical sensing system.
The binding of complementary strands of DNA is known as hybridisation, and, as it is 
highly specific in nature, has been used as the basis for affinity biosensors. In this type of 
sensor, DNA with a particular sequence is immobilised at the sensor surface, and the
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binding of DNA with a complementary sequence is monitored, generally by mass change. 
Fawcett et al. (1988) reported such a biosensor for the detection of Salmonella typhimurium 
in food samples. Bianchi et al. (1997) described a similar hybridisation biosensor method 
for the detection of HIV-1 sequences in PCR products. This method was simple, fast and 
reproducible, and -due to the amplification step -  could detect low levels of analyte. 
DNA-protein interactions have also been studied using biosensors. The binding of 
regulatory proteins to particular stretches of DNA controls the translation of various genes. 
Parsons et al. (1995) immobilised double-stranded DNA on a sensor surface to investigate 
the binding of lactose repressor protein to the LAC-operon.
Another class of biological affinity ligands which may be used in biosensors are the lectins. 
These are molecules which bind to carbohydrate groups with high affinity, and usually 
possess broad specificity, binding to several different carbohydrates. The use of an 
immobilised lectin, concanavalin A, in a biosensor to detect the binding of red blood cells 
has been described (Quinn et al., 1997).
The main group of molecules used in affinity biosensors, however, are antibodies, and 
analytical devices which exploit the selectivity and sensitivity of these specialised 
recognition molecules are known as immunosensors.
1.2.2 Immunosensors
Immunosensors may employ either the antibody or its specific antigen as the immobilised 
component, and both indirect and direct types of immunosensor may be constructed. 
Indirect immunosensors utilize labels such as fluorophores and enzymes, and can generally 
be used only for end-point analysis. Direct immunosensors, however, detect the binding of 
antibody and antigen by measuring changes in parameters such as mass, heat and potential, 
and can be used for real-time monitoring (Morgan et al., 1996). The ideal immunosensor 
should possess an intrinsic signal-generation property, a fast response time, and should 
exhibit reversible binding (Byfield and Abuknesha, 1994). Immunosensors using a variety 
of different transduction methods have been reported, and some examples these are shown 
in Table 1.2.
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Table 1.2 Some examples of immunosensors based on different transduction
technologies.
Transduction method Analyte Reference
Potentiomentric
Gas-sensing Digoxin Keating and Rechnitz, 1985
Ionophoric Prostaglandin Connell et al., 1983
FET Atrazine Colapicchioni et al., 1991
PSA HSA Wang etal., 1998
Amperometric Factor VIII Manning et al., 1994
Conductimetric IgG Sergeyeva et al., 1998
Piezoelectric
QCM 2,4-Dichlorophenylacetic acid Skladal et al., 1994
SAW HSA Weischeia/., 19 96
Calorimetric Pro-insulin Bimbaum et al., 1986
Optical
Chemiluminescent HCG Starodub et al., 1994
TIR flourescence Cocaine Ogert et al., 1992
FCFD Prostate-specific antigen Daniels, 1995
Ellipsometry y-Interferon Ruzgas et al., 1992
Interferometry HCG Heideman et al., 1993
IAsys CLq Gorgiani et al., 1997
BIOS-1 Pesticides Bier and Schmid, 1994
SPR fluorescence hCG Attridge et al., 1991
BIAcore Biotin Haines et al., 1995
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1.2.2.1 Potentiometric ini mu nosensors
Potentiometric transduction is based on the accumulation of potential across a 
membrane/sample interface. Many potentiometric biosensors employ ion-selective 
electrodes (ISEs), in which only particular ions can pass through the membrane, generating 
a potential which is proportional to the concentration of ions. The most common example 
of an ISE is a pH electrode, which is sensitive to hydrogen ions. Gas sensitive 
potentiometers can be constructed by coupling a pH electrode to a gas-permeable 
membrane, and measuring the change in pH caused by dissolved gas. A gas-sensing 
electrode of this type was used by Keating and Rechnitz (1985) to measure digoxin 
concentrations in an immunosensor utilising an immobilised decarboxylating enzyme in 
conjunction with a carbon dioxide electrode.
Antibody-sensitive potentiometric immunosensors have also been described, in which 
ionophoric antigen (or antigen conjugated to an ionophore) is immobilised at the surface of 
an ISE.
An ionophore is a neutral carrier ligand which can complex metal ions, and the binding of 
antibody to these antigens alters their ionophoric properties, causing a change in potential. 
An immunosensor of this type has been reported for the measurement of prostaglandin 
concentration (Connell et al., 1983). An alternate configuration involves the immobilisation 
of monoclonal antibody at the electrode membrane (Bush and Rechnitz, 1987).
Field effect transistors (FETs) are basically miniaturised potentiometers in which a 
semiconductor such as silicon is used to measure charge accumulation. With the addition of 
an ion-selective electrode to form an ISFET, the background interference and high sample 
consumption of ISEs can be considerably reduced. The small size of ISFETs also makes 
them ideal for in vivo electrolyte monitoring. Colapicchioni et al. (1991) reported an 
ISFET-based immunosensor for the detection of human IgG and the herbicide atrazine, in 
which glucose oxidase-labelled antibodies were immobilised onto the ISFET. Binding of 
the analyte to antibody affected the enzymatic production of H+ ions, which were monitored 
by the ISFET.
Wang et al. (1998) have described a disposable immunosensor based on potentiometric 
stripping analysis (PSA) for the detection of HSA. Anti-HSA was immobilised at the 
sensor surface, and HSA in samples was allowed to compete with bismuth-labelled HSA for
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binding sites. Following the removal of unbound labelled species, Bi3+ was released and 
detected by PSA.
In general, however, potentiometric-based immunosensors have been less than successful, 
due to their low signal-to-noise ratios and dependence upon environmental conditions, such 
as pH and ionic strength, which are caused by the low charge density of most biomolecules 
compared to background interferences (Morgan et a l, 1996).
1.2.2.2 Amperometric immunosensors
Amperometric transducers measure the flow of current through an electrochemical cell at 
constant voltage. The redox reaction of analyte at the sensing electrode generates a current 
directly proportional to the analyte concentration. Many molecules such as proteins, 
however, are not inherently electroactive, and must be labelled with oxidoreductase 
enzymes in order to generate electroactive species. The biological component of an 
amperometric immunosensor is generally immobilised on a selectively permeable electrode 
membrane, to prevent protein fouling of the electrode surface and control mass transport 
(Vagdama and Crump, 1992).
Alkaline phosphatase has been used to label antibodies in a range of immunoassays, 
including a method for the detection of a-acid glycoprotein with a reported limit of 
detection of 1 ng/ml (Doyle et al., 1984).
An amperometric immunoassay for theophylline was reported by Athey et al. (1993). In 
this assay system, glucose-6-phosphate dehydrogenase-labelled theophylline was 
immobilised at the electrode surface, and competed with unlabelled theophylline in the 
sample for binding to anti-theophylline antibody. Binding of antibody to labelled enzyme 
blocked the production of NADH. NADH was detected electrochemically, and the current 
was directly proportional to the concentration of free theophylline in solution.
Manning et al. (1994) described an amperometric immunosensor for the determination of 
the glycoprotein factor VIII in which factor VIII was immobilised on the surface of a glassy 
carbon electrode. The immobilised protein and factor VIII in samples competed for binding 
sites on horseradish peroxidase-labelled anti-factor VIII antibody. Hydrogen peroxide and 
hydroquinone were then added, and horseradish peroxidase (HRP) catalysed the reaction
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leading to the production of benzoquinone. Benzoquinone was then reduced 
electrochemically, and the current was measured.
Santandreu et al. (1997) have reported a novel amperometric immunosensor employing a 
biocomposite which contains graphite, rabbit IgG and resin. The biocomposite acts as both 
the reservoir for the biomolecule and the transducer. This immunosensor was used in a 
model system for the detection of rabbit IgG.
Rishpon and Ivnitski (1997) developed a disposable amperometric immunoassay format 
based on enzyme channelling, which was used in a model system for the detection of 
bacterial cells and viral antigens.
1.2.2.3 Conductimetric immunosensors
Conductimetric transducers measure the overall conductance of a solution - a property 
which is frequently altered by chemical reactions. Enzyme-based conductimetric biosensors 
can be constructed by immobilising an enzyme on a set of electrodes and measuring the 
conductance of a substrate-containing solution upon application of an electric field. 
Although little work on the development of immunosensors based on this principle has been 
carried out, Sandberg (1993) described a polymer-based conductimetric immunosensor for 
pesticide detection. Recently, Sergeyeva et al. (1998) reported a new approach to 
conductimetric immunosensors which employed an iodine-selective thin film composed of 
phthalocyanine. This system was used to detect IgG in buffer and serum samples.
1.2.2.4 Piezoelectric immunosensors
Piezoelectric immunosensors measure the mass change that results from antibody-antigen 
binding, and are based on a natural property of asymmetric crystals. Piezoelectricity occurs 
when anisotropic crystals are subjected to mechanical stress, causing the generation of 
electrical charge. If an AC voltage at the resonance frequency is applied to the crystals, 
oscillations are induced, and the optimal resonance frequency at which this takes place is 
dependent upon the mass at the crystal surface. The relationship between the change of 
mass at the crystal surface (Am) and the change in oscillating frequency (Af) is defined by 
the Sauerbrey equation:
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Equation 1.2.2.4.1 Af = - 2{-lAm 
A^ qP<,
Where f Q is the resonance frequency of the unloaded crystal, A is its surface area, /\iq is the 
shear modulus, and pq the density. This phenomenon has led to the use of piezoelectric 
crystals for the transduction of mass change in immunosensors. Although a variety of 
naturally abundant crystals, and some man-made polymers and ceramics, possess 
piezoelectric properties, quartz is the most frequently used. For immunosensor applications, 
the crystal, situated between two electrodes, is coated with either antigen or antibody, and 
AC voltage is applied, causing the crystal to oscillate at its normal frequency. Specific 
binding of the other interactant decreases the frequency of oscillation, which can be related 
to analyte concentration. This type of immunosensor is known as a quartz crystal 
microbalance (QCM). The main drawback of QCM-based immunosensors is that the 
crystals are prone to interference from solvent adsorption and viscous drag when used in 
liquid phases (Walton et al., 1991). Non-specific binding to the surface is also frequently 
problematic (Morgan et al., 1996). In order to overcome the problems of liquid phase 
measurement, the resonance frequency of the crystal can be determined in air prior to the 
addition of sample. The crystal may then be dried, and any change in resonance frequency 
due to biospecific binding can be calculated. This so-called "dip and dry" method has been 
used for antibody-based QCM determination of analytes such as pesticides (Guilbault et al., 
1992) and Herpes virus (Konig and Gratzel, 1994).
Skladal et al. (1994) reported a piezoelectric crystal-based method for the direct real-time 
investigation of the binding of monoclonal antibodies to the herbicide 2,4- 
dichlorophenoxyacetic acid in solution. Harteveld et al. (1997) developed a piezoelectric 
competitive immunosensor for the detection of the biological warfare agent Staphylococcal 
enterotoxin B (SEB) in solution, which had a limit of detection of 0.1 p,g/ml.
Surface acoustic wave - or SAW - transduction also involves the use of piezoelectric 
crsytals. In this system, the oscillation of the crystal is at a higher frequency. By applying a 
voltage across a group of interlaced metal electrodes known as an interdigital transducer 
(IDT), an acoustic wave can be generated, and is detected by another IDT situated 
millimeters away. Any adsorbed substance on the crystal surface, such as a biomolecule,
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slows the acoustic wave, and this change in velocity is proportional to the concentration of 
adsorbed material. The type of SAW transducer most commonly used in biosensors is 
known as a shear horizontal acoustic plate mode device (SH-APM). SAW biosensors are 
still at a developmental stage, although Weisch et al. (1996) monitored the binding of anti­
human serum albumin (HSA) to HAS. Gizeli et al. (1997) also reported a SAW-based 
model immunosensor to detect binding and rate constants for rabbit anti-goat IgG.
1.2.2.5 Calorimetric immunosensors
Calorimetric transduction is based on the measurement of heat generated by a biological 
reaction, using a thermistor. The biological component can either be directly attached to the 
thermistor, or bound to a column in which the thermistor is embedded. Although of most 
use in biosensors based on enzymes, due to their associated heat production, the advent of 
miniaturised thin-film thermistors lead to the construction of several calorimetric 
immunosensors. One such device was reported by Mattiasson et al. (1977) for the detection 
of gentamicin. Bimbaum et al. (1986) reported a similar method for the measurement of 
human pro-insulin, which had a limit of detection of 100  ng/ml.
1.2.3 Optical immunosensors
Possibly the largest group of transducers used in immunosensor technology has been the 
optical transducers. Optical immunosensors do not require the use of a reference cell, do not 
consume analyte and possess the potential for multi-analyte sensing (Byfield and 
Abuknesha, 1994). A variety of different types of optical immunosensor format have been 
reported.
As with the other transduction technologies discussed above, both direct and indirect optical 
immunosensors can be designed. Enzyme labels which generate fluorescent or luminescent 
products can be used to produce indirect optical immunosensors. The production of 
luminescent species removes the need for a light source, and chemiluminescence-based 
immunosensors for the detection of human chorionic gonadotropin (hCG) and IgG have 
been described by Starodub et al. (1994).
In a direct optical immunosensor, light is directed towards the sensing surface, and then 
reflected out again. Information about the physical events occurring at the surface can be
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obtained from the reflected light. Most sensors of this type, and all commercially available 
immunosensors, are based on total internal reflection and the generation of an evanescent 
wave.
1.2.3.1 The evanescent wave
The refractive index of a material is a measure of its ability to bend light, and is the ratio of 
the speed of light in that material compared to the speed of light in a vacuum. When light is 
directed through a medium of high refractive index at an angle greater than or equal to the 
critical angle, total internal reflection (TIR) takes place - in other words, all of the incident 
light is reflected out of the high refractive index medium, and no refraction occurs. If an 
interface exists between the high refractive index material (for example, the glass in a prism) 
and a medium of lower refractive index, then a high-frequency electromagnetic field, known 
as the evanescent wave, is generated parallel to the interface (Sutherland and Dahne, 1987). 
The evanescent wave is a fraction of the wavelength of the incident light, and penetrates a 
short distance (in the order of one wavelength) into the medium of lower refractive index. 
The evanescent wave generated at the interface between a glass prism (high refractive 
index) and a layer of buffer (lower refractive index) is illustrated in Figure 1.3.
1.2.3.2 Fibre-optic immunosensors
Many of the optical immunosensors which have been described make use of optical fibre 
technology. Fibre-optic waveguides consist of a high refractive index cylindrical core, 
composed of glass, quartz or polymer, surrounded by a cladding. If the cladding is 
removed, and the core of the fibre immersed in sample solution, an evanescent wave can be 
propagated at the core/sample interface. Optical fibres are inexpensive, flexible, do not 
experience electrical interference, and can carry several wavelengths of light simultaneously 
(McCormack, 1995).
In the optical immunosensor format known as TIR fluorescence, the evanescent wave 
excites fluorescent molecules close to the sensor surface, and the resultant fluorescence is 
coupled back into the waveguide and measured by a photodetector. This allows 
fluoroimmunoassays, performed on the fibre surface, to be monitored in real-time, and 
removes the need for a separation step.
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Figure 1.3 The evanescent wave. Light directed into a glass prism at an angle greater 
than the critical angle undergoes total internal reflection. At the interface between the 
prism and a lower refractive index buffer layer, an electromagnetic field component of the 
light, the evanescent wave, is propagated parallel to the interface.
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Ogert et al. (1992) reported a flow immunosensor for cocaine based on TIR fluorescence. 
Antibody to the drug was immobilised on the surface of an optical fibre, and fluorescently- 
labelled antigen was allowed to bind. Sample was then passed over the surface, and any 
cocaine present displaced the labelled drug from antibody binding sites. The fluorescent 
signal obtained was thus inversely proportional to the amount of cocaine in the sample.
A fibre-optic immunosensor for the detection of the pesticide atrazine was described by 
Oroszlan el al. (1993). In this sensor, anti-atrazine antibodies were immobilised on the fibre 
core, and atrazine in samples competed with pesticide labelled with fluorescein 
isothiocyanate (FITC) for antibody binding sites. This assay had a measuring range of 0.5 - 
200 nM.
Hanbuiy el al. (1997) developed a fibre-optic immunosensor for the detection of myoglobin. 
In this system, fluorophore-labelled anti-myoglobin was entrapped within a polyacrylamide 
gel at the distal end of an optical fibre. Binding of myoglobin to antibody resulted in 
quenching of fluorescence due to energy transfer between the fluorophore and the haem 
group of myoglobin.
1.2.3.3 Fluorescence capillary flow device (FCFD)
Another type of fluorescent immunosensor is the fluorescence capillary flow device 
(FCFD), first described by Badley et al. (1987). In this device, two parallel glass plates are 
held 0.1 mm apart. The lower plate bears immobilised antibody of the required specificity 
and fluorescently-labelled antigen is dosed onto the upper plate in such a way that it 
dissolves in the presence of sample. When sample is added, free and fluorophore-labelled 
analyte compete for antibody binding sites.
A light source is focussed onto the lower plate, and when light is directed at the plate, 
antibody-bound fluorophore becomes excited by the evanescent wave. An aperture in front 
of the photodetector ensures that only fluorescence from antibody-bound molecules is 
detected. The observed fluorescence is inversely proportional to the amount of analyte in 
the sample. This system was used by Daniels (1995) for the measurement of prostate- 
specific antigen in blood samples, with a limit of detection of 3.3 x 10'12 M.
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1.2.3.4 Attenuated total internal reflection
The technique of attenuated total internal reflection in based on the measurement of the 
reduced intensity of reflected light due to the absorption of energy by the evanescent wave. 
An optical film absorbs reflected incident light, and the attenuated light intensity is 
calculated as a fraction of the incident wavelength. A reflectance method of this type has 
been reported for monitoring immunological reactions (Arwin and Lundstrom, 1985), but 
the system is not in widespread use.
1.2.3.5 Diffraction grating
Tsay et al. (1991) described a direct optical immunosensor based on the action of a 
diffraction grating. Antibody or antigen was immobilised on a silicon surface, onto which 
light was directed. Interaction with the other binding partner resulted in the formation of a 
grating on the surface, which caused the diffraction of light.
1.2.3.6 Ellipsometry
The optical technique of ellipsometry measures the change of phase of polarisation state of 
light as a result of reflection from a planar surface, and can be used to study the binding of 
proteins. Light is directed onto a mirrored surface, and any changes in phase and amplitude 
of reflected light are related to the amount of absorbed protein on the surface. This method 
has been used in immunosensors for the determination of gamma-interferon and human 
serum albumin (Ruzgas et al., 1992).
1.2.3.7 Integrated optics (IO) immunosensors
Planar optical waveguides are an alternative to optical fibres, and have been used in the 
construction of optical immunosensors. These waveguides consist of a high refractive index 
dielectric film sandwiched between two dielectric materials of lower refractive index. (A 
dielectric medium is a solid which contains no free charges.) Materials currently employed 
in waveguides include glass, silica and lithium niobate. The use of miniaturised waveguides 
in biosensors is known as integrated optics (IO), and several IO-based immunosensors have 
been reported.
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1.2.3.7.1 Interferometry
The optical technique of interferometry is based on characteristic interference of light 
beams, and, if combined with a flow cell, can be used to measure biomolecular interactions. 
A single polarised light wave is composed of two partial waves: an electric field (TE) and a 
magnetic field (TM). A ligand is immobilised on the surface of a waveguide and a polarised 
laser is directed into the waveguide, causing the excitation of TE and TM fields. The 
evanescent wave generated within the waveguide interacts with immobilised ligand, and 
binding of analyte causes a change in the effective refractive indices of TE and TM fields. 
These are reflected backwards and forwards between mirrored surfaces in the device, and 
each time light is reflected, some couples out. TE and TM waves which are coupled out of 
the waveguide interfere with each other, and changes in refractive index at the sensor 
surface can be measured by continuously monitoring changes in the relative phase between 
TE and TM. This method was used by Heideman et al. (1993) to study the binding of 
immobilsed anti-hCG antibody to its specific antigen. Brecht and Gauglitz (1995) used 
interferometry to measure the concentration of atrazine in drinking water, in a competitive 
immunosensor with a limit of detection of 0.1 ppb.
1.2.3.7.2 IAsys biosensor
A waveguide-based biosensor which combines the action of the evanescent wave with 
interferometry has been described by Cush et al. (1993), and is marketed as IAsys by Fisons 
Applied Sensor Technology. The sensor consists of a glass prism coated with a thin layer of 
silica and a high refractive index resonant layer (usually titanium), which is in contact with 
the sample solution. A laser beam is directed into the prism, where it undergoes total 
internal reflection. At a specific angle - the resonance angle - a fraction of this light is 
directed towards the resonant layer. An evanescent wave is generated at the interface 
between sample and resonant layer, and travels along this interface for a short distance 
(approximately 1 mm), before coupling back into the prism. The angle of incident light at 
which this occurs can be detected by monitoring the phase of reflected TE and TM modes. 
These two modes are in phase before resonance in reached, but the coupling of light into the 
resonant layer produces a delay in the reflected light, and causes TE and TM to shift out of
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phase. The binding of biomolecules at the sensing surface changes the resonance angle at 
which this occurs, and can be measured in real-time.
The IAsys biosensor utilises a disposable micro-cuvette sample cell consisting of the prism, 
silica coupling layer and resonant layer coated with dextran for covalent attachment of 
biomolecules (Fortune, 1993). The micro-cuvette is stirred constantly, which reduces any 
mass transport limitation of analyte to the sensor surface, and the use of a well-based system 
also minimises sample consumption.
Hall and Winzor (1997) immobilised a monoclonal antibody to apocarboxypeptidase A on 
the surface of the IAsys sensor, and used a stepwise titration procedure to 
thermodynamically characterise the interaction between antibody and apocarboxypeptidase 
A. The equilibrium association constant for the interaction was calculated.
Gorgiani et al. (1997) used the IAsys instrument to derive affinity constants for the 
interaction between the complement component CLq and human and rabbit IgG
1.2.3.7.3 Grating coupler biosensor
A grating coupler is a set of fine corrugations which is etched into the surface of a planar 
waveguide film, causing light to couple in and out of the waveguide. An 10 biosensor 
employing a grating coupler has been described by Tiefenthaler (1993), and is marketed by 
Artificial Biosensing systems as the BIOS-1. In this sensor the grating coupler is located 
between the glass substrate and the waveguiding film. The sample layer is situated on the 
other side of the film. A laser directs polarised light into the waveguide, and the grating 
causes it to couple in and out, creating an evanescent wave. The coupling angle of the input 
laser beam is proportional to the amount of binding at the sample/waveguide interface. This 
"incoupling angle" is continuously monitored by rotating the sensor surface against a fixed- 
angle beam of light, affording real-time analysis of biomolecular binding events. A BIOS-1 
based immunosensor for the detection of nanomolar amounts of pesticides has been reported 
by Bier and Schmid (1994).
1.2.3.8 Surface plasmon resonance (SPR)
Several immunosensors based on the phenomenon of surface plasmon resonance (SPR) 
have been reported. SPR is a physical phenomenon related to the evanescent wave. If the
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interface between the medium of higher and lower refractive indices is coated with a thin 
layer of metal, then the propagation of the evanescent wave will interact with the electrons 
of the metal layer. Metals contain electron clouds at their surface which can couple with 
incident light at certain angles. These electrons are called plasmons, and the passage of the 
evanescent wave through the metal layer causes the plasmons to resonate, forming a 
quantum mechanical wave known as a surface plasmon. This surface plasmon wave takes 
up some of the energy of the incident light, and this can be observed as a "dip" in the 
intensity of reflected light at a certain angle (Panayotou et al., 1993). The angle at which 
this dip occurs as called SPR angle, and is dependent upon the refractive indices of the 
prism, metal and sample layers, as well as the wavelength and polarisation state of the 
incident light. If all the other factors are constant, however, the SPR angle measures the 
refractive index at the metal film side of the interface. The refractive index is directly 
proportional to concentration, and it is this property which is exploited to monitor 
biomolecular interactions.
Attridge et al. (1991) combined a fluorescent label with an SPR detector to create an SPR 
fluoroimmunosensor for the determination of hCG in serum. Severs and Schasfoort (1993) 
reported an enhanced SPR-based immunoassay which they called the Enhanced SPR 
Inhibition Test (ESPRIT). In this system, a competition is set up at the SPR sensor surface 
for antibody binding sites. Binding of antibody to the sensor surface is thus inversely 
proportional to the amount of free analyte in solution. In a second enhancement step, latex 
particles coated with antigen are added. These particles bind to the antibody at the sensor 
surface, and increase the SPR signal.
1.2.3.8.1 BIAcore
The most popular SPR-based biosensor in current use is the BIAcore, manufactured by 
Pharmacia (Jonsson, 1991; Fagerstam and O’Shannessy, 1993). This is a fully automated 
system which combines continuous flow and SPR detection to perform label-free real-time 
biospecific interaction analysis (BIA). The operation of SPR in the BIAcore instrument is 
shown in Figure 1.4.
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Figure 1.4 The operation of surface plasmon resonance (SPR) in BIAcore. Light from a 
high-intensity LED is directed into a prism, and the evanescent wave which is generated 
excites surface electrons (“plasmons”) in a gold layer, leading to a dip in the intensity of 
reflected light at a particular angle known as the SPR angle. This SPR angle is sensitive 
to the refractive index at the gold film side of the interface, and any biospecific 
interaction, for example, the binding of antibody to antigen, changes the SPR angle.
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The basic disposable sensor chip used with BIAcore is illustrated in Figure 1.5, and consists 
of a glass slide covered in a 50 nm thick gold film, onto which a carboxymethylated dextran 
matrix is attached by a hydroxyalkyl thiol linker layer. (Gold is very suited for use in SPR, 
as it is chemically inert and generates sharp reflectance minima.) The carboxymethylated 
dextran (CM-dextran) layer is about 100 nm thick, and facilitates the covalent attachment of 
biomolecules by a variety of different immobilisation chemistries.
This sensor chip docks with the optical system of the instrument via an opto-interface layer 
of silicone polymer. A wedge-shaped beam of light from a near-infrared high-intensity 
light-emitting diode (LED) passes through the prism, generating SPR at the gold film 
surface, and a 2 -dimensional photodiode array at the other side of the prism measures the 
intensity of reflected light at all angles. The change in SPR angle caused by biomolecular 
interaction at the sensor surface is shown in Figure 1.6. In the BIAcore, this change is 
monitored continuously and displayed on a PC in the form of a sensorgram, in which 
resonance units (RUs) are plotted against time. All proteins, regardless of amino acid 
sequence, give the same refractive index change, and a signal of 1,000 RU corresponds to a 
0.1° shift in the SPR angle, which is equivalent to a protein concentration of 1 ng/mm2 at the 
sensor surface. The dynamic range of the instrument is between 1 and 30,000 RU.
A typical sensorgram for binding of a biomolecule to immobilised ligand is shown in Figure 
1.7. The initial level baseline is due to running buffer flowing over the sensor surface. 
Injection of sample over this surface causes an initial sharp rise in signal. This is due to a 
difference in bulk refractive index between the running buffer and the sample plug. The 
binding of the two interactants can be seen as a steady increase in signal over the course of 
the injection. A sharp decrease in signal at the end of the injection indicates that running 
buffer of lower refractive index is again passing over the surface. The difference in 
response units (RU) between the signal after the injection and the initial baseline 
corresponds to the amount of sample which remains bound to the surface.
The BIAcore possesses several advantages over other optical biosensor systems based on 
evanescent wave or SPR sensing. The use of the novel CM-dextran hydrogel provides a 
convenient attachment for biomolecules and acts as a physical barrier to protect the gold 
film from the non-specific adsorption of protein to which previously-reported SPR sensors 
were prone (Cullen and Lowe, 1990).
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Figure 1.5 Diagrammatic representation of a BIAcore sensor chip. The SPR signal is 
generated at a 50 nm gold layer on a glass slide. A hydroxyalkyl thiol linker layer 
connects this gold film to a carboxymethylated dextran gel, onto which biomolecules may 
be covalently immobilised.
CARBOXYMETHYLATED
DEXTRAN
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Figure 1.6 The SPR angle can be seen as a dip in the intensity of reflected light. In the 
BIAcore, light reflected through the prism is analysed by a 2-dimensional photodiode array. 
Biomolecular interaction at the sensor chip surface causes a mass change, and an increase 
in the SPR angle. The change in SPR angle is monitored continuously and displayed as a 
sensorgram.
SPR angle (Pixel number)
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Figure 1.7 A typical BIAcore sensorgram for binding of analyte to immobilised ligand. 
The initial steady baseline is due to flow of running buffer over the immobilised ligand 
surface. Injection of sample causes an initial sharp signal increase due to differing bulk 
refractive index. The binding of the two interactants can then be seen as a gradual increase 
in signal. The signal falls sharply at the end of the sample injection, as lower refractive 
index buffer again flows over the surface. The difference in RUs between the initial 
baseline and the signal after the sample injection represents the amount of analyte bound.
Time (Sec)
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On average, only 40% of the carboxy groups on the dextran matrix are derivatised in a 
typical immobilisation procedure, and the electrostatic repulsion caused by the remaining 
COO' groups confers 3-dimensional mobility upon the covalently-bound biomolecules. The 
movement of immobilised molecules thus approximates their behaviour in solution.
The delivery of sample to the sensor surface is carried out by an autosampler, together with 
an integrated micro-fluidics system (IFC), which optimises sample transport while 
minimising consumption. A sample recovery feature reduces sample consumption still 
further. The IFC consists of a series of precision-cast channels in a hard silicon polymer, 
with small diameter sample loops and a low dead volume (approximately 0.4 |il) which is 
controlled by a set of pneumatically operated diaphragm valves, enabling the accurate 
delivery of samples between 1 and 50 (j,l in volume (Sjolander and Urbaniczky, 1991). 
Larger sample volumes (up to 750 |il) can be injected directly from the autosampler needle. 
Upon docking with the sensor chip, the IFC forms four parallel flow cells - each of which is 
50 fim thick with a volume of 60 nl - allowing four different interactants to be immobilised 
and studied separately. The flow of running buffer and sample through the system is 
controlled by precision pumps, and flow rates of 1 - 100 (_il can be used. The programmable 
autosampling facility allows for extensive unattended operation, and can accommodate large 
sample numbers and replicates.
Data collection is handled by the controlling PC, and sensorgrams are displayed 
instantaneously. Dedicated software is available for the determination of concentration, 
kinetic and affinity data. The instrument has a large dynamic measuring range and 
concentrations from 10'11 to 10'3 M, affinity constants from 105 to 1010 M'1, and rate 
constants from 103 to 106 have been determined (Griffiths and Hall, 1993).
The BIAcore system does have some inherent drawbacks. Due to the nature of SPR 
detection, only molecules with a relatively high molecular mass (> 2,000 Da) can be directly 
sensed. The interaction of smaller molecules must be detected by indirect methods such as 
competitive assays. Binding events involving large structures like cells may also be 
difficult to detect due to the limited penetration depth of the evanescent wave 
(approximately 1 p,m). In addition to these intrinsic problems, the high cost of BIAcore 
sensor chips must be considered.
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The BIAcore instrument described here was the first to be made commercially available. 
Several other related products have since been launched on the market. The BIAlite system 
is a miniaturised BIAcore, which lacks autosampling and programming facilities. BIAcore 
X, a similar instrument, has a wider dynamic range and lower detection limit in terms of 
analyte molecular weight (approximately 200 Da). The most recent product, BIAcore 2000, 
combines these features with an increased signal-to-noise ratio and multi-channel operation. 
BIAcore has been used to study a wide range of biomolecular interactions including the 
specific binding of antibody to antigen, enzyme to substrate, receptor to ligand and the 
interaction between complementary sequences of DNA. Perhaps the most interesting aspect 
of the system is its ability to detect biospecific binding in real-time, allowing the 
determination of association and dissociation rates.
The use of the technique in immunosensor systems for concentration determination, kinetic 
and affinity analyses, and antibody production - as well as nucleic acid studies - is described 
in the following chapters.
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Aim s
The aim of this project was to investigate the use of optical biosensor technology for the 
study of the coumarin family of compounds. The performance of BIAcore, an optical 
biosensor based on the phenomenon of surface plasmon resonance (SPR), was compared to 
more established methods of analysis.
Chapter 3 describes the production of polyclonal antibodies to 7-hydroxy coumarin, their 
purification and use in a competitive ELISA. Hybridomas generated by somatic cell fusion, 
using animals immunised with 7-hydroxycoumarin-BSA, were tested for specific antibody 
production using ELISA and BIAcore. A genetically generated antibody fragment to a joint 
coumarin-BSA epitope was studied using BIAcore, and kinetic and affinity constants were 
derived. The possibility of using BIAcore for the panning of naive libraries of phage 
display antibodies was also examined.
In Chapter 4, the polyclonal antibodies to 7-hydroxycoumarin were used in the development 
of a BIAcore-based competitive immunosensor for the detection of free drug in serum 
samples. The method displayed good reproducibility and linearity.
Chapter 5 concerns comparative BIAcore and ELISA studies on two commercial antibody 
preparations against the coumarin aflatoxin B,. Competitive and direct immunoassay 
formats, using both direct and indirect immobilisation, were investigated. The importance 
of antibody affinity, and the use of ELISA methods for initial optimisation of 
immunosensor performance, are discussed.
In Chapter 6 the action of the coumarin antibiotic on the DNA-modifying enzyme 
topoisomerase II was investigated. Supercoiled plasmid DNA was labelled with biotin and 
immobilised on the surface of the BIAcore sensor chip and the inhibition of topoisomerase- 
DNA binding was visualised in real-time. Direct interactions between coumarin-protein 
conjugates and immobilised DNA were also studied.
46
CHAPTER 2 
MATERIALS AND METHODS
2.1 M ate ria ls  and equipm ent
All reagents used were of analytical grade, and with the exception o f those tabulated below, 
all reagents were purchased from Sigma Chemical Co., Poole, England, as were all 
commercial antibody preparations.
Reagent S upp lie r
Acetic acid 
Hydrochloric acid 
Sodium chloride 
Tween 20
Riedel de-Haen, Hannover, Germany
Bicinchoninic acid assay (BCA) kit Pierce and Warriner (UK) Ltd., Chester, England
Biotin-Chem-Link kit Boehringer-Mannheim Ltd., Lewes, East Sussex, 
England
BriClone
Normal Rat Kidney (NRK) cells
BioResearch Ireland, Dublin City University, Ireland
CM-Dextran Fluka Chemicals, Gillingham, Dorset, England
HPLC-grade solvents Lab-Scan, Stillorgan, Dublin, Ireland
Hydrogen peroxide BDH Chemicals Ltd., Poole, Dorset, England
Topoisomerase I I United States Biochemical Corp., Cleveland, Ohio, 
USA.
Wizard Plus Mini-prep kit Promega, Madison, WI, USA
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The equipment used and its suppliers are listed below.
E quipm ent S upp lie r
Beckman L8-70M Ultracentrifuge Beckman Instruments Ltd., Fullerton, CA, USA
BIAcore 1000 Pharmacia Biosensor AB, Uppsala, Sweden
Diaphot Inverted Microscope Nikon, Tokyo, Japan
Eppendorf tubes 
Sterile universal containers
Sarstedt, Wexford, Ireland
Heraeus Labofuge GL 
Titretek Twinreader Plus
Medlabs, Dublin, Ireland
HB 2448K Laminar flow cabinet Holten, Allerod, Denmark
NUNC Maxisorb plates 
NUNC Covalink plates
NUNC, Kamstrup DK, Roskilde, Denmark
PREM PCR machine Wessex Instrumentation Ltd., Hampshire, England
3015 pH meter Jenway Ltd., Essex, England
Orbital incubator Gallenkamp, Leicester, England
RM6 Lauda waterbath AGB Scientific Ltd., Glasnevin, Dublin, Ireland
SB1 Blood tube rotator Stuart Scientific, London, England.
Sterile cell culture lab-wear Brownes, Foxrock, Dublin, Ireland
UY-160A spectrophotometer Shimadzu Corp., Kyoto, Japan
UVP ImageStore 7500 gel 
documentation system
Ultra Violet Products, Upland, CA, USA.
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M ethods
2.2.1 Licensing
All procedures involving animals were approved and licensed by the Department of Health, 
and every care was taken to minimise the level of distress caused.
2.2.2 Im m unisa tion  p ro toco l fo r the p roduction  o f ra b b it an ti-7 - 
hydroxycoum arin  antisera
Phosphate buffered saline, containing 0.15 M NaCl, 2.5 mM potassium chloride, 10 mM 
disodium hydrogen phosphate and 18 mM sodium dihydrogen phosphate, pH 7.4, was 
prepared. This buffer will be referred to throughout as PBS. A 1.5 mg/ml solution of 7- 
hydroxycoumarin-thyroglobulin in PBS was prepared. An equal volume of Freund's 
Complete Adjuvant was added, and the mixture was vortexed until it formed an emulsion. 1 
ml of this preparation was then injected subcutaneously at several sites into a New Zealand 
White rabbit. This procedure was repeated 21 days later, with Freund's Incomplete 
Adjuvant being used. The animal was bled from the marginal ear vein 11-13 days after this 
immunisation, and the cycle of reboosting and bleeding was continued until a sufficiently 
high specific antibody titre in the serum was obtained.
2.2.3 Im m unisa tion  pro toco l fo r B A LB /c m ice fo r the p roduction  o f 
m onoclonal antibodies
A 2 mg/ml solution of 7-hydroxycoumarin-ovalbumin conjugate in PBS was prepared. An 
equal volume of Freund's Complete Adjuvant was added, and the mixture was vortexed 
until it formed an emulsion. 6-10 week old BALB/c mice were anaesthetised with 
Halothane, and 250 (j.1 of the immunogen was injected subcutaneously at several sites at 
volumes of approximately 250 (jl. On day 21, a similar dose of immunogen in Freund's 
Incomplete Adjuvant was administered intraperitoneally, and on day 28 a blood sample was 
taken from the tail. Intraperitoneal boosts followed by blood sampling were continued until 
a satisfactory titre was obtained.
2.2 Antibody production
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3-4 days prior to being sacrificed, the mice were injected with 250 |xl of 2 mg/ml 7- 
hydroxycoumarin protein conjugate in PBS. This was administered intravenously via the 
tail vein.
2.3 P repara tion o f serum
2.3.1 P repara tion o f ra b b it serum
For estimation of titre, 5 ml blood samples from the marginal ear vein, collected in Sterilin
universal containers, were allowed to clot for 2 h at room temperature, and the clot allowed 
to tighten overnight at 4°C, before being centrifuged at 4,000 rpm for 20 minutes. The 
supernatant was then removed and stored at -20°C. For purification of polyclonal antisera, 
the animal was anaesthetised and sacrificed by cardiac puncture, and the collected whole 
blood treated as described above.
2.3.2 P repara tion o f mouse serum
For the estimation of specific antibody titre in mouse blood, 10-20 (il of blood was taken 
from the tail, and allowed to clot at room temperature for 30 minutes Following 
centrifugation at 13,000 rpm for 20 minutes the supernatant was removed and stored at - 
20°C.
2.4 Polyclonal antibody p u rifica tio n
Rabbit serum was first partially purified by saturated ammonium sulphate precipitation, and 
then affinity-purified by column chromatography using protein G.
2.4.1 Saturated am m onium  sulphate p rec ip ita tio n
To 10 ml of rabbit serum on ice, an equal volume of cold saturated - 100% (w/v) - 
ammonium sulphate was added dropwise with stirring. The mixture was stirred on ice for 1 
h, and then centrifuged at 3000 rpm for 20 minutes. The supernatant was discarded and the 
precipitate washed twice in 10 ml of 45% (w/v) ammonium sulphate. The final pellet was 
dissolved in 5 ml of PBS and dialysed overnight at 4°C against 5 1 PBS.
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2.4.2 P rote in G  chrom atography
A protein G column was prepared by pouring 1 ml of protein G immobilised on sephadex 
into a 5 ml syringe. The column was equilibrated with 20 ml PBS. 2.5 ml of the dialysate 
from ammonium sulphate precipitation was added to the column. 1 ml PBS was added to 
the eluate, and the whole amount was then re-applied to the column. 4 ml PBS was added 
to this eluate before reapplication. All the collected eluate was then applied to the column 
again. The column was then washed with 25 ml of PBS. Bound immunoglobulin was then 
eluted by addition of 0.1 M glycine/HCl, pH 2.5, to the column. Twelve 1 ml fractions were 
collected in eppendorf tubes to which 100 f_il of 1.5 M Tris/HCl, pH 8.7, had been added in 
order to neutralise the pH and prevent denaturation of antibody.
The presence of protein in fractions was determined by monitoring their absorbance at 280 
nm, and those fractions containing protein were pooled and dialysed overnight at 4°C 
against 5 1 PBS, with two changes of buffer. The protein G column was stored for re-use at 
4°C in PBS containing 20% (v/v) ethanol.
2.5 B ic inchon in ic acid (B C A ) p ro te in  assay
Standard protein solutions from 0 . 1 - 1  mg/ml in PBS were prepared using either bovine 
serum albumin (BSA) or - if determining immunoglobulin concentrations - IgG. To 10 pi 
of standard or sample in wells of 96-well microtitre plates, 190 p,l of BCA working reagent 
was added. After gentle mixing, the plate was incubated at 37°C for 30 minutes The 
absorbance of the wells at 560 nm was then measured using a microtitre plate-reader, and a 
standard curve was constructed from which the protein concentrations of samples were 
calculated.
2.6 Polyacrylam ide gel electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to assess antibody purity.
The composition of gels, electrophoresis buffer and sample loading buffer are given in 
Table 2.1. Samples were diluted with sample loading buffer (4:1, sample : buffer) and 
boiled for 10 minutes 10 jo.1 of samples were loaded onto the gel.
51
Table 2.1 Composition of stacking gel, resolving gel, electrophoresis buffer and sample 
loading buffer for SDS-PAGE.
Stacking gel 5% (w/v) acrylamide 
0.13% (w/v) bis-acrylamide 
125 mM Tris 
0.1% (w/v) SDS
0.15% (w/v) ammonium persulphate 
0.25% (v/v) TEMED
Resolving gel 10% (w/v) acrylamide 
0.27% (w/v) bis-acrylamide 
375 mM Tris 
0.1% (w/v) SDS
0.08% (w/v) ammonium persulphate 
0.08% (v/v) TEMED
Electrophoresis b u ffe r 25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS
Sample load ing  b u ffe r 60 mM Tris
25% (v/v) glycerol
2% (w/v) SDS
14.4 mM 2-mercaptoethanol
0.1% (w/v) bromophenol blue
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Pre-stained molecular weight markers containing carbonic anhydrase (29 kDa), 
ovalbumin (45 kDa), BSA (66 kDa), phosphorylase B (97.4 kDa), (3-galactosidase (116 
kDa) and myosin (205 kDa) were also loaded. The gel was electrophoresed at 200mV 
until the dye had migrated to the bottom. Gels were stained for 20 minutes in 0.1% (w/v) 
Coomassie Brilliant Blue in acetic acid : methanol : water (2:9:9 v/v/v), and destained 
overnight in acetic acid : methanol : water (1:1:8 v/v/v). Destained gels were visualised 
using a UVP ImageStore 7500 gel documentation system.
2.7 Enzym e-linked im m unosorbent assay (E L IS A )
A range of different ELISA methods were used for the detection of antibodies in rabbit and 
mouse serum and hybridoma supernatants, the quantitative determination of 7- 
hydroxycoumarin and aflatoxin B„ and assessment of the cross-reactivity of purified 
antibody. In addition, ELISAs were used to study regeneration conditions for an 
immunosensor, and to derive an equilibrium affinity constant for a monoclonal antibody. 
Both sandwich and competitive ELISA formats were employed. PBS containing 0.05% 
(v/v) Tween 20 was used to wash microtitre plates, and is referred to throughout as PBST.
2.7.1 E stim ation o f ra b b it antibody titre s
Levels of specific antibody in serum from immunised rabbits were measured using ELISA. 
7-hydroxycoumarin-BSA (10 (.ig/ml) was added to wells of a 96-well microtitre plate 
(NUNC Maxisorb) at 100 (j.l/well, and incubated at 37°C for 1 h. The plate was then 
washed three times in PBST and once in PBS. 150 fxl/well of 1% (w/v) BSA in PBS 
(blocking solution) was then added to the plate, which was again incubated for 1 h at 37°C. 
The plate was then washed three times in PBST and once in PBS. (For both coating and 
blocking of plates, incubation steps could also be carried out at 4°C overnight.)
Serum from both immunised and control (unimmunised) rabbits was then diluted from 
1/200 to 1/50000 in PBS and added to appropriate wells at 100 jj. 1/well. The plate was 
incubated for 1 h at 37°C. The plate was washed three times in PBS and once in PBST. 
Commercial anti-rabbit IgG antibody labelled with horseradish peroxidase (HRP) at a 
dilution of 1/10,000 in PBS was then added to the plate at 100 (xl/well. The plate was 
incubated for 1 h at 37°C.
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After washing three times in PBST and once in PBS, chromogenic substrate for HRP (10 
mg o-phenylenediamine (OPD) in 25 ml of citrate/phosphate buffer, pH 5.0, with 5 (4.1 of 
30% (v/v) H20 2) was added to the plate at 100 fil/well. The plate was incubated at 37°C for 
15-30 minutes, or until the colour produced was sufficiently strong. The absorbance of the 
wells at 405 nm was then measured using a microtitre plate-reader.
2.7.2 D eterm ination o f the w o rk ing  d ilu tio n  o f p u rifie d  ra b b it 
antibody in  a com petitive E L IS A  fo r 7 -hydroxycoum arin .
A 96-well microtitre plate (NUNC Maxisorb) was coated with 10 (j,g/ml of 7- 
hydroxycoumarin-BSA and blocked with 1% (w/v) BSA as described in section 2.7.1. A 1 
mg/ml stock solution of 7-hydroxycoumarin in a mixture of 30% (v/v) ethanol and 70% 
(v/v) PBS was prepared by dissolving 10 mg of the drug in 3 ml of absolute ethanol, and 
slowly adding 7 ml PBS. This stock solution was diluted in PBS to prepare standard 
solutions of 100, 80, 40, 20, 10, and 5 jig/ml. Dilutions of purified rabbit anti-7- 
hydroxycoumarin in PBS with 1% (w/v) BSA from 1/50 to 1/2,000 were prepared.
A set of standard curves at each different antibody dilution was produced by adding 50 fil of 
appropriate standard and 50 (il of diluted antibody to each well, mixing gently, and 
incubating for 1 h at 37°C. After washing three times with PBST and once with PBS, 100 
jj,l/well of a 1/10,000 dilution of commercial HRP-labelled anti-rabbit antibody were added, 
and colour was developed and read as in section 2.7.1.
2.7.3 Covalent coupling o f 7-hydroxycoum arin-4-acetic acid to 
C ova link plates fo r estim ation o f an tibody cross-reactiv ity
EDC-mediated N-hydroxysuccinimide (NHS) esterification was used to directly link 7- 
hydroxycoumarin to amine groups on derivatised 96-well microtitre plates. To solutions of 
7-hydroxycoumarin-4-acetic acid (1-5 mg/ml) in absolute ethanol, equimolar amounts of 
NHS and 3-ethyl-3(3-diethylaminopropyl)carbodiimide (EDC) were added. The reaction 
mixtures were transferred to 10 ml blood tubes and mixed at room temperature on a blood 
tube rotator for 30 minutes 150 j_l1 of the mixtures was then added to wells of a NUNC 
Covalink plate, and incubated for 1 h at 37°C (or overnight at room temperature). The wells 
were washed three times in PBST and once in PBS.
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150 |-il of blocking solution was then added to each well, and the plate was incubated for 1 h 
at 37°C - or overnight at room temperature. The plate was then washed three times in PBST 
and once in PBS.
2.7.3.1 E stim ation o f cross-reactiv ity o f p u rifie d  po lyc lona l an ti-7 -
hydroxycoum arin
NUNC Covalink plates were coated with 7-hydroxycoumarin and blocked as described in 
section 2.7.3. Stock solutions of coumarin, 4-hydroxycoumarin, 7-hydroxycoumarin, 7- 
hydroxycoumarin-4-acetic acid, warfarin and 7-hydroxywarfarin were prepared in methanol, 
and diluted in PBS to a range of concentrations - 50, 25, 12.5, 6.25 and 3.125 (ig/ml. 50 (j,1 
of each solution was added to appropriate wells of the microtitre plate along with 50 |_il of 
purified polyclonal anti-7-hydroxycoumarin (1/200 in PBS). The plates were incubated for 
1 h at 37°C and then washed three times in PBST and once in PBS. 100 (xl/well of HRP- 
labelled anti-rabbit IgG was then added, and the plate incubated for 1 h at 37°C. Colour was 
developed and read as in section 2.7.1.
2.7.4 E stim ation o f mouse antibody titres
Levels of specific antibody in serum from immunised mice was estimated by ELISA. 96- 
well microtitre plates were coated with 100 (j. 1/well of ovalbumin, BSA, and two different 7- 
hydroxycoumarin-BSA conjugates (diazo- and NHS/EDC-coupled) at 50 jig/ml and 
incubated for 1 h at 37°C. The plates were blocked with 5% (v/v) FCS as in section 2.7.3. 
Serum from both immunised and control (unimmunised) mice was then diluted from 1/200 
to 1/12,800 in PBS containing 1% (w/v) BSA and 5% (v/v) FCS and added to appropriate 
wells of the above plates, and to wells of a Nunc Covalink plate which had been coated as in 
section 2.7.3, using a 5 mg/ml solution of 7-hydroxycoumarin-4-acetic acid. In addition, 
similar dilutions of polyclonal anti-7-hydroxycoumarin antibody, purified as in section 2.4, 
were added. The plates were then incubated at 37°C for 1 h. After washing three times with 
PBST and once with PBS, 100 |j,l/well of either HRP-labelled anti-mouse or anti-rabbit IgG 
diluted 1/5,000 with PBS containing 1% (w/v) BSA and 5% (v/v) FCS was added to each 
plate. Colour was developed and read as described in section 2.7.1.
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2.7.5 Screening o f hybridom a supernatants
Cell culture supernatants from hybridomas produced by cell fusion were screened for 
specific antibody production by ELISA. 96-well microtitre plates were coated with 100 
jil/well of 7-hydroxycoumarin-protein conjugate or native protein at 50 (4g/ml and blocked 
with 5% (v/v) FCS as in section 2.7.3.
Neat hybridoma supernatant and positive control (1/200 polyclonal anti-7-hydroxycoumarin 
antibody) were added to both plates at 100 (j, 1/well, followed by incubation for 1 h at 37°C. 
After washing three times in PBST and once in PBS, HRP-labelled antibodies were added 
and colour developed and read as in section 2.7.1.
2.7.6 C om petitive E L IS A  fo r the quan tita tive  de term ination  o f a fla tox in  B,.
Commercially available monoclonal and polyclonal antibodies were used in a competitive 
ELISA format for the detection of aflatoxin B, (AFB,). 96-well microtitre plates were 
coated with 300 (j,l/well of 0.5 (J.g/ml of aflatoxin B, - BSA conjugate in PBS, and incubated 
for lhat37°C .
The plates were then washed three times with PBST and once with PBS. 350 (il/well of 5% 
(v/v) FCS in PBS (blocking solution) was then added to the plates, which was again 
incubated for 1 h at 37°C. The plates were then washed three times in PBST and once in 
PBS. (For both coating and blocking of plates, incubation steps could also be carried out at 
4°C overnight.)
Stock AFBj solution was prepared at a concentration of 2 mg/ml in methanol, and this was 
diluted in PBS containing 5% (v/v) FCS to produce a set of standard solutions ranging in 
concentration from 1 (ig/ml to 10 pg/ml. 100 (j,l/well of each standard was then added to the 
coated plates, together with 100 (4,1/well of either monoclonal or polyclonal anti-AFBj 
antibody. Following gentle mixing, the plates were incubated at 37°C for 1 hour. After 
washing three times in PBST and once in PBST, 100 |4,l/well of HRP-labelled secondary 
antibody (either anti-mouse or anti-rabbit) was added, and the plates again incubated for 1 h 
at 37°C. After another washing step, HRP substrate was added, and the absorbance at 405 
run determined, as in section 2.7.1.
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2.7.7 D ire c t sandwich E L IS A  fo r A F B , determ ination.
A sandwich assay for AFB, was performed with either polyclonal or monoclonal anti-AFB! 
directly coated onto the ELISA plate. A 1/5,000 dilution of anti-AFBj in PBS was coated 
onto wells of a 96-well microtitre plate at 100 (il/well and incubated for 1 h at 37°C. The 
plate was washed and blocked with 5% (v/v) FCS as in section 2.7.6.
Stock AFB,-BSA solution was prepared at 1 mg/ml in PBS, and this was diluted in PBS 
containing 5% (v/v) FCS to produce a set of standard solutions ranging in concentration 
from 10 pg/ml to 1 jag/ml. 100 (il of each standard was added to appropriate wells of the 
plate, which was then incubated for 1 h at 37°C. After washing three times with PBST and 
once with PBS, 100 |i 1/well of a 1/5000 dilution of complementary anti-AFB, was added, 
and the plate again incubated for 1 h at 37°C. Washing, addition of labelled anti-species 
antibody, and development of colour were performed as in section 2.7.1.
2.7.8 Sandwich E LIS A s fo r AFB1 using p ro te in  A  capture
Protein A was used to capture polyclonal and monoclonal anti-AFB! for use in a sandwich 
assay. A 96-well microtitre plate was coated with 100 jxl/well of 0.5 fj-g/ml protein A, and 
the plate blocked with 5% (v/v) FCS as in section 2.7.6. 100 p.l/well of a 1/5,000 dilution of 
either polyclonal or monoclonal anti-AFB, was then added, and the plates incubated for 1 h 
at 37°C. The sandwich assays were then performed as in section 2.7.7.
2.7.9 Sandwich AFB, E L IS A  using an anti-m ouse an tibody fo r capture
A sandwich ELISA for AFBi was performed in which a commercially available anti-mouse 
IgG antibody was employed to capture monoclonal anti-AFB,. A 96-well microtitre plate 
was coated with 100 jj,l/well of a 1/500 dilution of anti-mouse IgG (Fc specific) in PBS, and 
incubated for 1 h at 37°C. The plate was washed and blocked with 5% (v/v) FCS as in 
section 2.7.6. After a further washing step, 100 |i 1/well of a 1/5000 dilution of monoclonal 
anti-AFB, in PBS containing 5% (v/v) FCS was then added, and the plate was again 
incubated for 1 h at 37°C, and then washed three times with PBST and once with PBS. 
Standard solutions of AFB,-BSA were then prepared, and from this point on the assay was 
performed as in section 2.7.7.
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2.7.10 E L IS A  to  examine the efficiency and effects o f regeneration on
im m obilised antibody surfaces
In an experiment to examine the efficiency of regenerating antibody immobilised at a 
biosensor surface, two 96-well microtitre plates were coated with 100 (il/well of a 1/5,000 
dilution of either mouse monoclonal or rabbit polyclonal anti-AFBl5 and incubated for 1 h at 
37°C.
The plates were then washed three times in PBST and once in PBS, and then blocked with 
5% (v/v) FCS as in section 2.7.6. After washing, 100 ^ 1/well of 0.5 (J,g/ml AFBr BSA in 
PBS was added to the plates, which were then incubated at 37°C for 1 h.
A set of solutions of NaOH was then prepared, ranging in concentration from 5 to 1000 
mM. AFB,-BSA solution was aspirated from the plates, and they were washed three times 
in PBST and once in PBS. 100 (_tl of each of the NaOH solutions were then added to 
appropriate wells, and the plates were incubated for 10 minutes at room temperature. 
Following incubation, the plates were washed three times in PBST and once in PBS.
100 (j,l/well of complementary anti-AFB, antibody - 1/5,000 in PBS containing 5% (v/v) 
FCS - was then added. Monoclonal antibody was added to the plate coated with polyclonal 
antibody, and polyclonal antibody to the plate coated with monoclonal antibody.
The plates were then incubated at 37°C for 1 h. After washing three times in PBST and 
once in PBS, 100 fal of appropriate HRP-labelled anti-species antibody diluted 1/5000 in 
PBS containing 5% (v/v) FCS was added. The plates were washed again, and colour was 
developed and read as in section 2.7.1.
To examine the effect of the regeneration reagent upon the antibody surfaces, the assay was 
re-run as before, except that the NaOH solutions were added to the wells immediately after 
the blocking step. Following washing, the AFBr BSA solution was added, and then the 
complementary anti-AFB, antibody.
2.7.11 E L IS A  to examine the efficiency and effects o f regeneration on an
im m obilised A F B j-B S A  surface
In an experiment to examine the efficiency of regenerating conjugate immobilised at a 
biosensor surface, two 96-well microtitre plates were coated with AFB,-BSA and blocked 
with 5% (v/v) FCS as described in section 2.7.6.
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After washing, 100 (al/well of a 1/5000 dilution of either monoclonal or polyclonal anti- 
AFB, in PBS containing 5% (v/v) FCS was added to the plates, and they were then 
incubated at 37°C for 1 hour.
A set of solutions of NaOH was then prepared, ranging in concentration from 2 to 1000 
mM. Antibody solution was aspirated from the plates, and they were washed three times in 
PBST and once in PBS. 100 (¿1 of each of the NaOH solutions were then added to 
appropriate wells, and the plates were incubated for 10 minutes at room temperature. 
Following incubation, the plates were washed three times in PBST and once in PBS.
100 ji 1/well of appropriate HRP-labelled anti-species antibody - 1/5,000 in PBS containing 
5% (v/v) FCS - was then added, and the plates incubated at 37°C for 1 hour. After washing 
three times in PBST and once in PBS, substrate was added, and the absorbance of wells at 
405 nm read.
To examine the effect of the regeneration reagent upon the conjugate surface, the assay was 
re-run as before, except that the NaOH solutions were added to the wells immediately after 
the blocking step. Following washing, the monoclonal and polyclonal antibodies were 
added, and then HRP-labelled anti-species antibodies.
2.7.12 M easurem ent o f the e q u ilib riu m  a ffin ity  constant fo r m onoclonal
an ti-A F B ,
Determination of the affinity constant for the monoclonal anti-AFB, antibody was carried 
out by a variation of the method of Friguet et al. (1985).
A 96-well microtitre plate was coated with 200 jj.l/well of AFB,-BSA conjugate in PBS, and 
blocked with 250 |il/well of 5% (v/v) FCS, as in section 2.7.6. A range of standards of free 
aflatoxin B, were prepared by diluting stock AFB, (2 mg/ml in methanol) in PBS. 
Standards ranged in concentration from 7.82 x 10~7 M to 8 x 10^ M. 100 (J,l of each standard 
was added to 100 j_il of a 1/10,000 dilution of monoclonal anti-AFB,, and the mixture was 
incubated overnight at room temperature. 100 (al of each reaction mixture was then added 
to the conjugate-coated wells. A series of dilutions of monoclonal anti-AFB, in PBS, from 
1/10,000 to 1/20,000,000 were also prepared, and added at 100 ^1/well to a separate series 
of wells on the same plate.
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The plate was incubated for 1 h at 37°C, and then washed three times in PBST and once in 
PBS. 100 jxl/well of HRP-labelled anti-mouse IgG was then added, and the plate again 
incubated at 37°C for 1 hour. Substrate was added, and colour developed and read, as in 
section 2.7.1.
The linear portion of the antibody dilution curve was used to calculate the amount of 
unbound antibody in the equilibrium solutions, and a Klotz plot was constructed (see section 
5.5).
2.7.13 M easurem ent o f an tibody concentration in  hyb ridom a supernatant
A microtitre plate was coated with 100 fil/well of anti-mouse IgG (Fc specific) and blocked 
with 5% (v/v) FCS as described in section 2.7.3. Culture supernatant from hybridomas was 
spiked with mouse IgG at concentrations of 0.625, 1.25, 2.5, 5 and 10 fxg/ml and these 
solutions were added to the plate at 100 ^1/well and incubated for 1 h at 37°C. The wells 
were washed three times in PBST and once in PBS, and then 100 (a, 1/well of HRP-labelled 
anti-mouse IgG was added. After a further 1 h incubation at 37°C, colour was developed 
and read as in section 2.7.1. A set of standard curves were constructed, and the 
concentration of monoclonal antibody in the original supernatants was calculated from the 
y-axis intercept.
2.8 C e ll cu ltu re  techniques
All cells were cultured aseptically in a laminar flow cabinet, and incubated at 37°C in a 
humid 5% (v/v) C 02 atmosphere.
2.8.1 C u ltu re  o f SP2 cells
Semi-adherent SP2 cells were cultured in Dulbecco's Modification of Eagle's Medium 
(DMEM) containing 10% (v/v) FCS, 2 mM L-glutamine, 10 mM HEPES buffer, and 25 
|j,g/ml gentamicin (referred to as S10). 1 ml of frozen cell suspension was thawed in a 
waterbath at 37°C and diluted slowly with 9 ml of medium, before being centrifuged for 10 
minutes at 2000 rpm. The cell pellet was then resuspended in 5 ml of medium and 
incubated in a 25 cm3 tissue culture flask (T25).
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For subsequent passages, cells were taken into suspension by gently washing the surface of 
the flask with medium, using a sterile pasteur pipette.
2.8.2 C u ltu re  o f adherent cell lines
Adherent normal rat kidney (NRK) cells were cultured in SI0 medium. When cells had 
grown to confluency in culture flasks, the medium was poured off, and the flask rinsed three 
times with 10 ml of sterile PBS. 2 ml of trypsin solution containing 0.25% (w/v) trypsin 
and 0.02% (w/v) EDTA was added to the cells, which were incubated at 37°C.
The cells were inspected under the microscope, and when none remained adhering to the 
surface, 10 ml of SI0 medium was added. The cell suspension was then centrifuged, and 
resuspended in S10 medium.
2.8.3 C e ll counting
Cells were counted by mixing an equal volume of cell suspension and Trypan Blue stain. 
After 1-2 minutes the mixture was examined on an Improved Neubauer Haemocytometer, 
and the number of viable cells (those which had not taken up the dye) was recorded.
2.8.4 M ycoplasm a testing
Mouse myeloma cell lines were tested for the presence of mycoplasma before being used 
for cell fusion procedures. The Hoechst stain was used for visualisation of mycoplasma. 
NRK cells were grown up for at least three passages in antibiotic-free medium.
Glass coverslips were prepared by washing in detergent, rinsing in deionised water and 
methanol, drying with a lint-free cloth and sterilising in a hot air oven at 160°C for 1 h After 
trypsinisation, NRK cells were counted and diluted to lxlO4, and 1 ml aliquots were placed 
onto sterile coverslips in petri-dishes, and incubated overnight at 37°C. The following day, 
2 ml of conditioned medium from the cell lines to be tested were added to the NRK cells 
growing on coverslips, and cultured for a further 2 days. The coverslips were then removed 
and gently washed 3 times in PBS. The cells were then fixed by incubating for 6 minutes in 
cold Camoy’s fixative (glacial acetic acid : methanol, 1:3 v/v), and the coverslips were again 
washed 3 times in PBS.
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Hoechst stain 33258 was prepared at 50 ng/ml in sterile PBS and the coverslips were 
incubated in this solution for 10 minutes, before being washed and mounted onto slides and 
examined under an oil immersion lens at a magnification of lOOx, using a fluorescence 
microscope. Uncontaminated cells show strong fluorescence in the nuclei only, whereas 
cells cells contaminated with mycoplasma also exhibit cytoplasmic staining.
2.8.5 Freezing o f cell lines
Cells which had reached 50% confluency (covered 50% of the surface) in 75 cm3 tissue 
culture flasks (T75s) were suitable for freezing. The cell suspension was centrifuged at
2,000 rpm for lOminutes.
The resulting pellet was resuspended in 1 ml of FCS with 10% (v/v) dimethylsulfoxide 
(DMSO) and transferred to a sterile cryotube, which was initially lowered gradually into the 
gas phase and then the liquid phase of liquid nitrogen in a cryocontainer.
2.8.6 P roduction o f antibodies by som atic cell fusion
Two different types of media were used in the course of this procedure. Serum-free medium 
- DMEM containing 2 mM L-glutamine and 10 mM HEPES - was used for all steps up to 
and including addition of PEG. For subsequent steps, DMEM containing 10% (v/v) FCS, 2 
mM L-glutamine, 5% (v/v) BriClone, 25 ug/ml gentamicin, 100 nM hypoxanthine, 400 [iM 
aminopterin, and 16 nM thymidine - referred to as S,0-HAT - was used.
500 |_il/well of S10-HAT was added to eight 48-well cell culture plates, which were then 
placed in the incubator. SP2 cells in the log phase of growth were counted and a volume of 
cell suspension containing lx l0 7 cells was centrifuged for 10 minutes at 2,000 rpm. The 
cell pellet was then washed twice in serum-free medium, and the final pellet resuspended in 
this medium and placed in the incubator.
A BALB/c mouse, immunised as in section 2.2.3, was sacrificed by cervical dislocation. 
The spleen was removed aseptically, and transferred to a petri dish containing 5 ml of 
serum-free medium in a laminar flow cabinet. Using a needle bent at mid-point and a 5 ml 
syringe, holes were pricked in the spleen, and medium was drawn up and washed through it 
to remove splenocytes. This was repeated until the spleen capsule appeared pale.
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The splenocyte suspension was then centrifuged for 10 minutes at 2,000 rpm, and a cell 
count was performed. Typically, a spleen will yield in the region of lx l0 8 cells. The spleen 
cell pellet was then resuspended in 5 ml of serum-free medium, and mixed with the 
previously prepared SP2 suspension to give a spleen cell to SP2 ratio of approximately 10:1. 
The cell mixture was centrifuged at 2,000 rpm for 10 minutes and then washed twice in 
serum-free medium.
Ater the final washing step, all supernatant was removed from the pellet using a sterile 
pasteur pipette. 1 ml of 50% (w/v) PEG (molecular weight 1540 Da), which had been pre­
heated to 37°C, was added slowly to the pellet using a 1 ml pipette, and a stopwatch was 
started:
For the first 30 seconds the mixture was taken up and aspirated.
30 seconds after addition of PEG the pipette was removed.
95 seconds after addition of PEG 0.5 ml of Sl0-HAT was added slowly.
2 minutes after addition of PEG 1 ml of SI0-HAT was added slowly.
3 minutes after addition of PEG 1 ml of S10-HAT was added slowly.
4 minutes after addition of PEG 1 ml of S10-HAT was added slowly.
5 minutes after addition of PEG 5 ml of S10-HAT were added slowly.
The mixture was then centrifuged at 2,000 rpm for 10 minutes, resuspended gently in 10 ml 
of S10-HAT, and incubated for 15 minutes at room temperature. A further 5 ml of S10-HAT 
was then added, and one drop from a 10 ml pipette was added to each well o f seven of the 
previously-prepared 48-well cell culture plates.
As a negative control, 5 ml of SP2 cell suspension was prepared in S10-FLAT and added, 
dropwise, to the remaining 48-well cell culture plate.
The plates were left undisturbed in the incubator for 12 days, after which time they were 
inspected under the microscope. By this stage, hybridoma colonies could be seen growing 
in some wells of the plates, while SP2 cells in the control plate were dead. The cells were 
then fed by gently removing half of the supernatant and adding a similar volume of S10-HAT 
containing 10 mM HEPES. Supernatants from wells containing hybridomas were screened 
for antibody production as described in section 2.7.5.
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Antibody-secreting hybridomas were scaled up from 48-well plates into 24-well plates, and, 
after subsequent rounds of screening, into 12-well and 6-well plates. After 2-3 weeks, 
aminopterin was removed from the medium. When cells had been scaled up into 12-well 
plates, hypoxanthine, thymidine and BriClone were removed from the medium.
2.8.7 C lon ing  o f hybridom as by lim itin g  d ilu tio n
Monoclonality of hybridomas was ensured by means of cloning by limiting dilution. 
Positive hybridomas were cultured to 50 - 70% confluence in 6-well plates. A cell count 
was performed, and 100 |iil of hybridoma suspension in S]0-BriClone was added to each well 
of two 96-well cell culture plates at a concentration of 10 cells per well.
When cells had reached confluence in the 96-well plates, supernatants were screened for 
specific antibody production, and positive hybridomas were scaled up. When growth had 
reached 50-70% confluence in 6-well plates and cells had been weaned off BriClone, the 
hybridomas were plated out in S10-BriClone at 1 cell per well into 96-well plates. Wells 
seen to contain single clones were then screened for monoclonal antibody production and 
scaled up.
2.9 B IA core  studies
CM5 research grade sensor chips were used in all cases. Running buffer for all BIAcore 
experiments was HBS buffer, pH 7.4, containing 10 mM HEPES, 150 mM NaCl, 3.4M 
EDTA, and 0.005% Tween 20. All solutions were filtered (0.22 (im) and running buffer 
was degassed by sonication prior to use.
2.9.1 Preconcentration studies
For all investigations, proteins were immobilised on the sensor surface by means of N- 
hydroxysuccinimide esterification. The standard conditions used lead to activation of 30- 
40% of the carboxyl groups on the dextran, and allow covalent attachment of biomolecules 
via primary amine groups. In order for the coupling reaction to proceed satisfactorily, it is 
necessary for an initial "preconcentration" step, resulting from electrostatic binding of 
protonated amine groups on the biological component to negatively-charged carboxyl 
groups on the chip surface, to take place.
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For the native form of a protein, preconcentration can be facilitated by adjusting the pH 
below the isolectric point (pi). However, modification of proteins by, for example, 
conjugation to drug molucules often radically alters the pi. Therefore, when dealing with 
modified proteins, the correct pH for preconcentration had to be determined experimentally. 
This was done by preparing protein solutions in 10 mM sodium acetate at a range of 
different pHs, passing these solutions over an underivatised chip surface, and monitoring the 
degree of electrostatic binding. The highest pH at which satisfactory preconcentration was 
observed was chosen as the pH for immobilisation.
2.9.2 Im m ob ilisa tion  o f in teractants
The carboxymethylated dextran surface of the sensor chip was first derivatised by injection 
of a 1:1 mixture of 3-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) and N- 
hydroxysuccinimide (NHS), at concentrations of 400 mM and 100 mM, respectively. The 
interactant to be immobilised was diluted in 10 mM sodium acetate at the appropriate pH, 
and at a typical concentration of 200-1,000 pg/ml. This solution was then injected over the 
derivatised chip surface for 20 minutes. Unreacted NHS groups were capped, and non- 
covalently bound protein removed, by injection of 1 M ethanolamine hydrochloride, pH 8.5, 
for 7 minutes.
2.9.3 B IA core  in h ib itive  7-hydroxycoum arin  im m unoassay
An indirect inhibition assay system was used for the detection of 7-hydroxycoumarin in 
human serum samples. All additions of reagents and incubation steps were automated. A 
flow rate of 10 pl/min was used throughout.
10,000 RU of diazo-coupled 7-hydroxycoumarin-BSA conjugate was immobilised on 
sensor chips as in section 2.9.1.
Human serum was centrifuged at 13,000 rpm and filtered (0.22 pm) to remove any 
precipitate formed by freeze-thawing. Standard solutions in the range 0.5 to 80 pg/ml were 
prepared by spiking serum with a stock solution of 1 mg/ml 7-hydroxycoumarin in a 
mixture of 30% (v/v) ethanol : 70% (v/v) PBS. Samples were prepared by spiking serum 
with a stock solution of 7-hydroxycoumarin-glucuronide (1 mg/ml in a mixture of 30% 
(v/v) methanol: 70% (v/v) ultrapure water).
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The majority of 7-hydroxycoumarin in serum is present as a glucuronide conjugate, which is 
not recognised by the polyclonal antiserum and must be deconjugated prior to analysis. The 
enzyme used for deconjugation of 7-hydroxycoumarin-glucuronide was ^-glucuronidase, 
which was at a concentration of 5,000 units/ml in 10 mM sodium acetate, pH 5.0. 180 jil of 
enzyme solution was added to an equal volume of sample or standard, mixed, and incubated 
at 37°C for 2 hours. BIAcore sample blocks were brought up to a temperature of 37°C by 
means of an attached waterbath.
Purified polyclonal anti-7-hydroxycoumarin antibody (see section 2.4) was diluted to a 
protein concentration of 0.8 mg/ml in PBS containing 4% BSA, 4 mg/ml CM-dextran and 
0.2% Tween 20. 45 |il of this antibody solution was added to 45 |jl of the enzyme-sample 
mixture, mixed, and incubated for 10 minutes. 20 (il of this mixture was then injected over 
the immobilised 7-hydroxycoumarin-BSA surface, and the change in response recorded. 
After binding of excess antibody, the surface was regenerated by injecting a 1 minute pulse 
of 5 mM NaOH, one of 20 mM HC1 and another pulse of 5 mM NaOH.
A calibration curve was constructed by plotting the change in response (in RU) for each 
standard against the log of concentration, and sample concentrations were determined from 
this curve.
The intra-day variability of the assay was investigated by running a set of five standards 
across the linear range five times in one day, and determining the coefficient of variation 
(CV) between the calculated 7-hydroxycoumarin concentrations for each set of five.
The inter-day variability of the assay was assessed by running five sets of standards across 
the linear range on five different days, and determining the CV between the calculated 7- 
hydroxycoumarin concentrations for the standards from each of the five standard curves.
2.9.4 A fla to x in  studies
Stock solutions of AFB, and AFB,-BSA were prepared as in sections 2.7.6 and 2.7.7. 
Monoclonal and polyclonal antibodies to AFB,, as well as protein A and Fc-specific anti­
mouse IgG, were immobilised as in section 2.9.1.
AFB,-BSA was separated from any free toxin by means of size exclusion chromatography. 
A PD-10 column was first equilibrated with 25 ml of PBS. 1 ml of AFB,-BSA was then 
made up to 2.5 ml with PBS, and this was applied to the column.
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3.5 ml of PBS was then added to the column to elute AFBr BSA. The column was stored in 
PBS containing 0.02% (w/v) sodium azide. Flow rates throughout all aflatoxin BIAcore 
studies were 5 (xl/min.
2.9.5 D N A  studies
Streptavidin was immobilised on the sensor chip at a concentration of 50 |J.g/ml in 10 mM 
sodium acetate, pH 4.8, as described in section 2.9.1. This surface was used to capture 
biotin-labelled plasmid DNA. Flow rates throughout all BIAcore DNA studies were 2 
(il/min.
2.10 Phage counts
E. coli TGI cells were cultured in 2x TY medium - 1.6% (w/v) tryptone, 1% (w/v) yeast 
extract and 0.5% (w/v) sodium chloride - containing 1% (w/v) glucose. The cells were 
grown to late log phase at 37°C with shaking. Samples of phage which had been eluted from 
the BIAcore were serially diluted in 2x TY medium, and 50 jxl of each dilution was added to 
50 (il of E. coli TGI and incubated at 37°C for 30 minutes. The infected E. coli samples 
were plated onto solid medium containing 1% (w/v) glucose and 0.1% (w/v) carbenicillin, 
and incubated overnight at 37°C with shaking. The number of plaques on the agar plates 
was then counted, and the number of phage present in the original samples was calculated 
and reported as titre-forming units per millilitre (TFU/ml).
2.11 E x trac tion  o f supercoiled p lasm id D N A
E. coli TGl(pHENl) cells were cultured in 2x TY medium containing 1% (w/v) glucose 
and 0.01% (w/v) glucose, and incubated overnight at 37°C with shaking. The culture was 
then centrifuged at 4000 rpm for 10 minutes, and the supernatant was aspirated. A Wizard 
Mini-prep kit was used to extract plasmid DNA. The cell pellet was resuspended in 400 fxl 
of cell resuspension solution (50 mM Tris, pH 7.5, 10 mM EDTA, 100 (ag/ml RNase A) and 
transferred to a sterile eppendorf tube. 400 jal of cell lysis solution (0.2 M NaOH, 1% (w/v) 
SDS) were added, and the eppendorf tube was inverted 4 times. 800 j_tl of neutralisation 
solution (1.32 M potassium acetate) were added, and the mixture was incubated for 10 
minutes at room temperature and then centrifuged for 10 minutes at 13,000 rpm.
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The supernatant was added to the barrel of a sterile 5 ml syringe, along with 1 ml of DNA 
purification resin. The mixture was then passed through an attached Minicolunm, followed 
by 2 ml of 4.2 M guanidine hydrochloride in a mixture o f 40% (v/v) isopropanol and 60% 
(v/v) ultrapure water. 2 ml of column wash solution (80 mM potassium acetate, 8.3 M Tris- 
HC1, pH 7.5, 40 jxM EDTA and 55% (v/v) ethanol) were then passed through the column, 
which was then centrifuged in a sterile eppendorf tube for 2 minutes at 13,000 rpm, to 
remove any remaining wash solution. DNA was eluted by adding 50 (J.1 of ultrapure water 
to the column and centrifuging at 13,000 rpm for 2 minutes in a sterile eppendorf tube.
The concentration of the extracted DNA was calculated by measuring the absorbance at 260 
nm. An absorbance reading of 1.00 indicated a DNA concentration of 50 |ig/ml.
The extracted plasmid DNA was kept at -20°C for long-term storage, and at 4°C for short­
term storage.
2.12 B io tin  labe lling  o f extracted D N A
Extracted DNA was labelled with biotin using a Boehringer-Mannheim Biotin-Chem-Link 
kit. 50 p.g of DNA were added to 50 ^1 of Biotin-Chem-Link Reagent (a cw-platinum- 
biotin complex) in a sterile eppendorf and incubated for 30 minutes at 85°C on a PCR 
machine. The eppendorf was centrifuged briefly to collect condensate, and 5 |il of Stop 
Reagent was added.
Labelled DNA was separated from remaining free biotin by precipitation. To 50 |il of
labelled DNA, 5 p.1 of 3 M sodium acetate, pH 5.2, and 100 jjI of absolute ethanol were
added. The mixture was incubated for 1 h at -20°C, and was then centrifuged for 10 minutes 
at 13,000 rpm.
The liquid was carefully drawn off using a pipette and 200 (J.1 of 70% (v/v) ethanol were 
added and aspirated to wash the pellet. The precipitated DNA was resuspended in 200 p.1 of 
ultrapure water.
2.13 Agarose gel eletrophoresis
The purity of extracted DNA and the action of topoisomerase II and novobiocin were 
assessed by agarose gel electrophoresis.
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Agarose was dissolved, with heating, at a concentration of 1% (w/v) in lx TAE buffer, 
containing 40 mM Tris, 20 mM acetic acid and 1 mM EDTA. Ethidium bromide was added 
a final concentration of 0.5 |j,g/ml. The solution was poured into a mini-gel plate, with the 
comb inserted, and allowed to solidify. 5 pi of sample DNA was added to 13 [¿1 of ultrapure 
water and 2 j.il of gel loading buffer (containing 0.25% (w/v) bromophenol blue and 40% 
(w/v) sucrose). The gel was covered with lx TAE buffer, and 20 j j .1 of each sample was 
loaded, together with 20 pi of pre-stained lambda phage DNA markers. The gel was 
electrophoresed at a voltage of 80 mV, and photographed under UV light.
2.14 Southern blots
Biotin-labelled DNA was detected by Southern blotting after transfer of neucleic acids from 
agarose gels to nitrocellulose membranes by capillary action.
The agarose gel was removed from the plate and the DNA was denatured by soaking in 1.5 
M NaCl / 0.5 M NaOH, for 45 minutes. This step, and all subsequent incubation and 
washing steps, were carried out at room temperature on a rotary platform. The gel was 
rinsed in ultrapure water, and then neutralised by soaking in 1 M Tris, pH 7.4, containing
1.5 M NaCl, for 30 minutes. A basin was filled with 20x SSC (3 M NaCl, 0.3 M sodium 
citrate, pH 7.0), and a strip of filter paper was draped across a glass plate suspended above 
the basin, with each end of the paper immersed in the buffer. The gel was then inverted and 
placed on top of the filter paper. A piece of nitrocellulose was cut to the size of the gel, and 
dipped in ultrapure water. The nitrocellulose was then soaked in 20x SSC for 5 minutes. 
The gel was surrounded with Parafilm, and the wet nitrocellulose membrane was placed on 
top. Two pieces of filter paper the same size as the gel were soaked in 20x SSC and placed 
on top of the nitrocellulose membrane. A stack of filter papers about 8 cm high was placed 
on top of this and weighed down with a 500 g weight. The capillary transfer of DNA was 
allowed to proceed overnight.
The nitrocellulose membrane was then removed and incubated for 1 h in a 5% (w/v) 
solution of dried milk powder in PBS. It was then washed 3 times (10 minutes each) in 
phosphate-free wash buffer (0.15 M NaCl, 0.05 M Tris, pH 7.5). A 1/4,000 dilution of 
avidin-alkaline phosphatase conjugate was prepared in wash buffer containing 5% (w/v) 
milk powder.
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The nitrocellulose membrane was incubated in 20 ml of conjugate solution for 1 hour, and 
then washed 3 times in wash buffer. Substrate buffer was prepared, containing 100 mM 
Tris/HCl, pH 9.5,100 mM NaCl and 5 mM magnesium chloride. 66 (al of BCIP (5-bromo- 
4-chloro-3-indoyl phosphate) and 33 |al of NBT (nitro blue tetrazolium) were added to 10 
ml of substrate buffer, and the nitrocellulose membrane was incubated in this solution at 
37°C until colour developed.
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CHAPTER 3
PRODUCTION AND CHARACTERISATION OF 
ANTIBODIES TO COUMARIN COMPOUNDS
3.1 In tro d u c tio n
This chapter describes the production and characterisation of a variety of different types of 
antibody using protein conjugates of coumarin compounds. Polyclonal antiserum to 7- 
hydroxycoumarin was raised in rabbits and purified by means of ammonium sulphate 
precipitation and protein G affinity chromatography. The purity of the antibody was tested 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The working 
dilution of this antibody in a competitive ELISA for 7-hydroxycoumarin was determined, 
and the degree of cross-reactivity of the antibody for a variety of coumarin compounds was 
assessed.
Somatic cell fusion was used to generate monoclonal antibodies, using spleen cells from 
mice immunised with 7-hydroxycoumarin-BSA. Cell culture supernatants were screened by 
ELISA, and, after cloning by limiting dilution, the antibodies produced were found to bind 
to the drug-protein conjugate, but not to free 7-hydroxycoumarin. A panel of 9 monoclonal 
antibodies to 7-hydroxycoumarin-BSA were affinity ranked using the BIAcore.
Three genetically-engineered single chain Fv (scFv) fragments against coumarin-BSA were 
affinity ranked using the BIAcore, and an observed affinity constant for the interaction of 
one of the antibodies with the conjugate was derived using BIAcore kinetic software. 
BIAcore was also used to pan a library of phage-displayed antibodies for anti-7- 
hydroxycoumarin antibodies. Although no binding signals could be obtained during the 
panning process, phage counts carried out on the eluate showed that specific elution had 
taken place.
3.2 The im m une system
The vertebrate immune system consists of a range of separate but inter-related cells and 
molecules, all concerned with protecting the parent organism against infectious agents 
(Roitt, 1994; Kuby, 1997). Both innate and acquired immunity exist.
The innate immune system consists of a series of physical and physiological barriers. The 
skin and mucous membranes provide the body's first line of defence against infection. In 
addition, physiological factors such as pH, temperature and the presence of degradative 
substances such as lysozyme also act to protect the body from pathogens. Foreign material 
is also broken down non-specifically by two processes known as endocytosis and
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phagocytosis. Endocytosis involves the breakdown of extracellular macromolecules, 
whereas particulate matter is broken down by phagocytosis. In both cases, the foreign 
matter is internalised by cells, and digested by enzymes prior to elimination. Endocytosis 
can be performed by almost any cell type, but only certain cells, such as monocytes and 
macrophages, are capable of phagocytosis. The inflammation generated in response to 
tissue damage also contributes to innate immunity, facilitating the emigration of phagocytes 
and the lysis of pathogenic microorganisms.
Unlike the processes involved in innate immunity, the acquired immune system is directed 
against specific molecules, and possesses immunological memory. Two different types of 
response, cellular and humoral, are generated when components of the acquired immune 
system encounter a foreign (or "non-self') substance.
The humoral immune response is mediated by antibodies, the specialised binding proteins 
produced by B lymphocytes. Each B lymphocyte expresses approximately 105 antibody 
molecules on its surface. The substance to which an antibody binds is known as an antigen. 
When a B cell expressing a particular antibody is activated by the binding of antigen, it 
proliferates, leading to the production of large amounts of specific antibody. This process is 
known as clonal selection. The selected B cells also differentiate into two cell types. 
Effector B cells (known as "plasma cells"), secrete large amounts of soluble antibody, and 
have a half-life of only a few days. Memory B cells, on the other hand, express membrane- 
bound antibody and have a longer life-span. Memory B cells are responsible for the rapid 
and strong antibody response to secondary infections, and are involved in the use of 
vaccines.
Antibodies can trigger the destruction of large infectious agents by binding to discrete sites 
on their surface. Smaller pathogens such as viruses and toxins can also be neutralised by the 
binding of antibody. The distinct chemical group on the surface of an antigen which is 
recognised by an antibody is called an epitope, and the immune system is capable of 
producing several million individual antibodies, each of which binds to a different epitope. 
One of the main characteristics of antibodies is their high degree of specificity. Antibodies 
can distinguish between proteins which differ in composition by only a single amino acid 
residue.
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The cellular immune response involves the production of T lymphocytes. Like B 
lymphocytes, T cells also have membrane-bound antigen-recognition molecules. While B 
cells can recognise antigen in solution, however, T cells can identify antigen only if  it is 
associated with a cell membrane protein of the major histocompatibility complex (MHC) 
group. When a T lymphocyte encounters specific antigen associated with an MHC 
molecule on the surface of another cell, it also undergoes clonal selection, and differentiates 
into memory and effector cells.
There are two categories of T lymphocyte, T helper (Tjj) and T cytotoxic (Tc) cells. TH cells 
recognise antigen associated with MHC II proteins, and are activated to produce cytokines. 
These are growth factors which are necessary for the production of B cells, T cells and 
macrophages. There are two subsets of Tn cells, which are differentiated by the particular 
cytokines they produce. TH1 cells, among whose secretary products are interferon gamma 
(IFN-y) and tumour necrosis factor beta (TNF-p), are responsible for cell-mediated 
functions, such as the activation of cytotoxic T lymphocytes. TH2 cells secrete mainly 
interleukins, and are involved in B-cell activation.
Tc cells bind to antigen associated with MHC I molecules, which causes activation to 
cytotoxic T lymphocytes (CTLs). These cells exert a cytotoxic effect on cells of the body 
which display antigen on their surface, such as virally-infected or tumour cells.
The generation of the humoral immune response, then, is dependent upon the production of 
cytokines, which is in turn dependent upon the activation of TH cells. A type of cell known 
as an antigen presenting cell (APC) is responsible for this process. These cells must express 
class II MHC proteins on their surface, as well as being able to deliver a signal which 
stimulates the activation of TH cells. B cells, macrophages and dendritic cells can all 
function as APCs. APCs internalise antigen by phagocytosis or endocytosis. Degraded 
antigen components then bind to MHC II molecules within the cell, and are exported to the 
cell surface. TH cells bind to the joint antigen fragment-MHC II complex, and a co­
stimulatory signal from the APC then activates the TH cell, causing cytokines to be 
produced. The sequence of events leading to the production of soluble antibody is illustrated 
in Figure 3.1.
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F igure  3.1 The generation of the humoral immune response. Antigen presenting cells 
internalise and degrade antigen. Antigen fragments are then presented on the surface of 
cells together with class II major histocompatability complex (MHC) molecules. T helper 
(Th) cells bind to the antigen-MHC II complex, and become activated to produce 
cytokines. B cells with specific antigen receptors on their surface bind to antigen in 
solution, and the proliferation of these B cells is stimulated by the presence of cytokines. 
This causes differentiation into plasma cells, and the production of specific soluble 
antibody.
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3.2.1 Im m unogenicity
The ability of a particular molecule to provoke an immune response is known as 
immunogenicity, and is dependent upon a variety of factors such as foreignness, molecular 
weight and chemical composition.
During the development of an embryo, any B cells expressing antibody against self 
molecules are killed off, and molecules recognised by the remaining antibody population are 
considered to be foreign. The greater the genetic distance between the source species of a 
molecule and the species of the host, the greater will be the immune response it generates. 
For example, bovine serum albumin (BSA) does not result in antibody production in cows, 
but is strongly immunogenic in sheep.
Substances with a molecular weight of approximately 100,000 Da are the best immunogens, 
while molecules with a molecular mass of less than 5,000 Da usually do not cause antibody 
production. Small molecules of this type are known as haptens. Haptens -  including very 
low molecular weight substances such as drugs and toxins - while themselves non- 
immunogenic, are able to combine with antibodies. By coupling haptens to a large carrier 
molecule and immunising with the hapten-carrier conjugate, specific anti-hapten antibodies 
can be produced. Carrier molecules are generally highly immunogenic proteins.
The greater the chemical complexity of a substance, the more immunogenic it will be. 
Synthetic polymers consisting of a single amino acid generally do not give rise to an 
immune response, whereas those containing a variety of amino acids are much more 
effective immunogens. The inclusion of amino acids with aromatic side-chains increases 
the immunogenicity still more (Kuby, 1997).
For proteinaceous immunogens, the different types of structural organisation also play a role 
in immunogenicity. Proteins possess four different levels of structure. The linear amino 
acid sequence of the protein is referred to as the primary structure. This polypeptide chain is 
folded into regular arrangements such as a-helices and P-pleated sheets, giving rise to 
secondary structure. Tertiary structure is the overall conformation of the protein, caused by 
folding of the areas between secondary structures, and resulting in the presence of individual 
domains with separate functional properties. Proteins which are polymeric in nature are said 
to possess quaternary structure. All four levels of structural arrangement contribute to a 
protein’s immunogenicity.
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The ease with which a molecule can be processed and presented by APCs is of critical 
importance to its immunogenicity. Large insoluble molecules, which are rapidly 
phagocytosed, tend to be better immunogens than small insoluble molecules.
The immune responsiveness of the host animal is also of importance. Immune 
responsiveness is genetically controlled by genes coding for the MHC molecules. The use 
of inbred animal strains, which are produced by inbreeding of brother and sister littermates, 
and are genetically identical, removes any variations in immune responsiveness between 
animals. One example of an inbred strain is the BALB/c mouse.
The dosage and route of immunisation also affect the immune response. Very low doses of 
immunogen will fail to activate sufficient numbers of lymphoctyes, while high doses result 
in lymphocytes entering an unresponsive state.
Immunogens can be administered by a variety of routes, the choice of which can alter the 
type of immune response given. For example, subcutaneous injection causes the 
administered substance to gather in local lymph nodes, whereas intravenous injection carries 
the immunogen straight to the spleen.
The reponse to an immunogen can be enhanced by administering it along with an adjuvant. 
Adjuvants are substances which non-specifically stimulate the immune system. One of the 
most widely-used of these agents is Freund's Complete Adjuvant, which consists of mineral 
oil, emulsifying agent and heat-killed Mycobacterium tuberculosis. When the immunogen 
is mixed with the adjuvant and injected, the emulsifying agent causes the oil to form into 
small droplets, which results in the immunogen being released slowly from the injection 
site. The presence of mycobacteria activates macrophages, leading to the stimulation of TH 
cells, and the adjuvant also provokes an inflammatory response. The less pathogenic 
Freund's Incomplete Adjuvant, which does not contain mycobacteria, is frequently used for 
second and subsequent injections - a process known as "boosting". The amount of specific 
antibody in the serum of an immunised animal is known as the titre, and boosting is 
repeated until a sufficiently high titre is reached.
3.2.2 A n tibody  structure
There are a range of different types of antibody, with varying functions in vivo. Those most 
commonly produced and used for analytical applications have been either entire or partial
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antibodies of the subclass immunoglobulin G (IgG). The structure of a typical IgG 
molecule is shown in Figure 3.2. The antibody is composed of four polypeptide chains - 
two heavy chains (H) and two light chains (L) - held together by a number of inter- and 
intra-chain disulphide bonds. The light chains weigh about 25 kDa, and the heavy chains 
approximately 50 kDa, giving the entire IgG molecule a relative molecular mass of 150-160 
kDa. The H and L chains are further subdivided into domains on the basis of the variability 
of their amino acid composition. Each L chain contains one variable (VL) and one constant 
(CL) domain, while the H chain consists of a single variable domain (Vu) and three constant 
domains (CH1, CH2 and CH3). As shown in the figure, the variable regions of the light and 
heavy chains associate with each other, as do the CL and CH1 regions. The CH2 and CH3 
domains of each heavy chain also pair with those on the other heavy chain. Between each 
CH1 and CH2 domain lies the hinge region, which introduces a degree of flexibility for the 
two "arms" of the molecule.
While the constant regions of the molecule are responsible for effector functions and 
complement binding, it is the VH and VL domains of the antibody which are involved in the 
specific recognition of antigen. Within each of these domains, which exhibit high 
variability in amino acid sequence from one molecule to the next, are three discrete 
"hypervariable" regions. The combined hypervariable loops from a pair of VH and VL 
domains make up the six complementarity determining regions (CDRs), which are situated 
at the end of each antibody arm and form the antigen binding site. The CDRs comprise 15- 
20% of the variable domain (Kuby, 1997), and the remaining areas - which exhibit much 
lower variability - are known as “framework regions”. The variable regions of heavy and 
light chains are coded for by several hundred genes, which genetic diversity, together with 
somatic mutation and the combining of different light and heavy chains, allows for the 
production by the immune system of more than 108 different antibody specificities.
The IgG molecule can be broken down into various fragments by means of enzymatic 
degradation. These fragments, together with those produced by means of genetic 
engineering, are shown in Figure 3.3. Treatment with pepsin cleaves the two heavy chains 
below the intrachain disulphide bonds, resulting in the formation of an F(ab')2 fragment, 
which consists of the two light chains joined together by the hinge region.
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F igure 3.2 The structure of an immunoglobulin G molecule. The molecule consists of 
two heavy and two light chains, which are held together by both inter- and intra-chain 
disulphide bonds. The antigen binding sites are located at the end of the "arms" of the 
structure, and molecular recognition involves both the complementarity determining 
regions (CDRs) and the framework regions (FRs).
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F igure  3.3 Antibody fragments. F(ab')2 and Fc fragments are obtained from papain 
digestion of IgG, and Fab fragments are generated by treating with pepsin. Other 
fragments have been produced by antibody engineering. These include the antigen- 
binding fragment (Fab); Fd fragment -  consisting of the heavy-or light-chain moiety of a 
single Fab; variable fragment (Fv); single chain variable fragments (scFv); and individual 
complementarity determining region (CDR).
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The action of papain cleaves the molecule above the disulphide bridge, giving the two Fab 
fragments, which bind antigen, and the Fc fragment, which has effector functions.
While IgG is the predominant type of antibody in circulation, there are four other classes of 
immunoglobulin, all of which basically consist of two identical light and heavy chains 
joined by disulphide bridges, although some are polymeric in structure. IgM is a pentameric 
protein, and is produced in response to primary infections. IgA may be present as a 
monomer or a dimer, and is the predominant antibody in salivary and mucous secretions. 
IgD is a membrane component of many B lymphocytes, and is thought to be involved with 
lymphocyte differentiation. IgE is present in only trace amounts in serum, and plays a role 
in immunity against parasites, in addition to being implicated in many hypersensitivity 
conditions such as hay-fever.
The IgG class of immunoglobulins is further subdivided into four subclasses or isotypes - 
called IgG,, IgG2, IgG3, IgG4 - based on the type of heavy chain which is present.
3.3 A n tibody-antigen b ind ing
As stated above, the variable regions of the antibody molecule are involved in the specific 
recognition of antigen, and antibody-antigen binding occurs as a result of contacts between 
the surfaces of both interactants. X-ray crystallographic analysis of antibody molecules has 
made possible the visualisation of the shape and size of antigen-binding sites. The antigen- 
binding sites of antibodies against small molecules, including haptens, appear to form deep 
concave pockets (Garcia et al., 1992). Protein antigens, on the other hand, bind to specific 
antibody via flat undulating areas on the antibody surface (Amit et al., 1986), and the two 
surfaces in this type of interaction have matching depressions and protrusions. Hanin et al. 
(1997) demonstrated complementarity of the hydrophobic or hydrophilic nature of the 
individual amino acid residues making contact between CDRs on a monoclonal antibody 
and a neuropeptide antigen, and used BIAcore to show that modification of this 
“hydropathic profile” resulted in dramatic reduction in binding.
Wilson and Stanfield (1995) studied the binding of Fab fragments to a range of different 
antigens, and reported that for small antigens such as haptens, approximately 60% of the 
contact area is “buried” within the antibody binding site, whereas a maximum of 15% of the 
contact area for large protein antigens was buried. In the same study, it was reported that at
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least 4 of the 6 CDRs make contact with the epitope, and that more heavy chain than light 
chain residues are involved. Laune et al. (1997) demonstrated that residues from the 
framework regions also play a role in antigen binding. The individual contributions of the 
heavy and light chain variable regions to binding were investigated by Noel et al. (1996) 
using BIAcore. They reported that the heavy chain of a murine antibody to human 
thyroglobulin was able to bind antigen in the absence of the light chain, but that the reverse 
was not the case.
With protein antigens, only those amino acid residues on the surface of the protein are 
accessible to the antibody. Due to the nature of the biological environment, these amino 
acids are predominantly hydrophilic in nature. In the average interaction between an 
antibody and a protein antigen, between 15 to 22 amino acids on the antigen make contact 
with the antibody (Amit et al., 1986). The amino acids which make up the epitope may be 
either contiguous - i.e. run in sequence along the polypeptide chain - or non-sequential. 
Non-sequential epitopes consist of amino acids which, although far apart in terms of 
primary structure, are brought together by the tertiary structure of the antigen. In addition, 
protein epitopes are generally situated on the most mobile regions of the structure, allowing 
greater flexibility for combining with binding sites on antibodies. Holmes et al. (1998) 
demonstrated that CDRs could exhibit a similar flexibility, in that binding of a synthetic 
antibody to its antigen could reverse adverse conformations introduced by genetic 
engineering.
3.3.1 A n tibody  a ffin ity
The strength of the bond formed by an antibody and its specific antigen is determined by a 
combination of different physical forces, the same type of weak non-covalent forces which 
govern other basic biochemical interactions such as DNA replication and enzyme-substrate 
binding. These forces are hydrophobic interactions, electrostatic binding, van der Waals 
forces, and hydrogen bonds (Tijssen, 1985).
Hydrophobic interactions occur when the conjunction of non-polar groups in a binding site 
repulses water molecules from a binding site. Electrostatic binding occurs between 
oppositely charged groups on the two interactants, and its effect is greatly enhanced by the 
removal of water molecules as a result of hydrophobic interactions. Van der Waals forces
81
are a result of attraction between the electron clouds of adjacent non-polar groups on the 
binding partners. Hydrogen bonds are formed when hydrogen atoms are shared between 
two other atoms, and are stronger than van der Waals forces.
The individual bond energies of these weak non-covalent interactions are negligible -  
especially in an aqueous environment - and their effect is significant only when they occur 
in large numbers. In addition, non-covalent interactions are only effective over a small 
distance, making the goodness of the fit between the epitope and the binding site on the 
antibody the defining factor for the strength of the bond.
The sum of the attractive and repulsive forces for a single antibody-antigen bond is known 
as the antibody affinity, and may be described in terms of reaction kinetics. For an antibody 
(Ab) and an antigen (Ag) at equilibrium, the formation of antibody-antigen complex (Ab- 
AG) can be expressed as:
K
E quation 3.3.1 Ab+Ag^AbAg
kd
where ka and kd are the association and dissociation rate constants, respectively. The affinity 
of the antibody for the antigen is given by the equilibrium association constant (K):
Equation 3.3.2 K =  k '  -  [A b A g l
k d [Ab][Ag]
The affinity of an antibody may also be quoted as the equilibrium dissociation constant, KD, 
which is the reciprocal of the K value.
3.3.2 Im p lica tions o f an tibody a ffin ity  fo r im m unosensor design
Optimisation of regeneration conditions is a necessary, but frequently problematic and time- 
consuming, aspect of immunosensor assay development. Some knowledge of the nature of 
the binding forces between the antibody and the antigen can considerably speed up the 
process, although the reverse is usually the case, with insight into the type of attractive
82
forces which predominate being gained as the optimal regeneration conditions are 
discovered.
Antibody-antigen bonds which are significantly electrostatic in nature are generally easily 
broken by the use of extremes of pH or ionic strength. Chaotropic reagents disrupt the steric 
complementarity of the binding sites, while the use of organic solvents interferes with 
hydrophobic interactions. Van der Waals forces can be affected by contact with low surface 
tension organic acids. For interactions in which the main attractive forces are exothermic 
hydrogen bonds (“cold antibodies”), increased temperatures may be used for regeneration. 
Zeder-Lutz et al. (1997) reported that the affinity of a Fab fragment for lysozyme, as 
measured with BIAcore, decreased with increasing temperature.
3.4 A n tib o d y  production
3.4.1 P roduction o f h ap ten-carrie r conj ugates
As discussed in section 3.2.1, haptens are not themselves capable of generating an immune 
response, and must first be linked to a carrier molecule. The most frequently used carriers 
are highly immunogenic proteins, but lipid bilayers, polymers (e.g. dextran), and synthetic 
organic molecules have also been used (Hermanson, 1996). Carriers must be inherently 
immunogenic, possess suitable functional groups for covalent linkage, and be non-toxic in 
vivo. Haptens may be coupled to carriers via existing reactive groups, while some 
molecules may require initial derivatisation to introduce such groups. The use of spacer 
molecules to distance the hapten from the surface of the protein may be beneficial (Erlanger, 
1980).
Hapten-protein conjugates are also used at the screening stage of antibody production. 
When screening for the presence of specific antibody it is necessary to use a conjugate 
containing a different protein moiety than the immunogen, to minimise false positive 
results. Danilova (1994) recommended that, when dealing with very small haptens, the 
conjugate used for screening should possess a different carrier molecule and coupling 
chemistry than that used for immunisation. Carriers for use in screening must have good 
solubility, even when derivatised. This is not a necessity for immunogens, however. As 
discussed in section 3.2.1, precipitated molecules often produce good immune responses.
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For the work presented in this chapter, three different proteins - BSA, ovalbumin and 
thyroglobulin - were conjugated to drugs, both for screening and immunisation purposes. 
Conjugation was carried out by either diazonium conjugation and EDC-mediated NHS- 
esterification.
Bovine serum albumin (BSA) is a highly soluble protein with a molecular weight of 67 
kDa, which has a variety of available functional groups for derivitisation. Ovalbumin is the 
major protein present in hen egg whites, and has a molecular weight of 43 kDa. 
Thyroglobulin is a multisubunit prohormone protein produced by the thyroid gland, with a 
molecular weight of 670 kDa.
Many aromatic ring systems contain active hydrogens which can easily be displaced by 
attacking electrophilic groups. Diazonium groups are particularly reactive with these active 
hydrogens, and are a useful means of attachment for molecules with few available 
functional groups (Hermanson, 1996). Amino groups on phenolic compounds can be 
converted to diazonium groups by reaction with sodium nitrite in acidic conditions. The 
diazonium group reacts rapidly with the aromatic ring of tyrosine and histidine residues on 
protein molecules. Egan (1993) and Bogan (1996) used this procedure to convert 3-amino- 
7-hydroxycoumarin to the diazonium derivative before conjugation to protein, as shown in 
Figure 3.4. The conjugates produced were used in immunisation and screening steps.
The formation of amide bonds between amino and carboxyl groups can be effected by the 
combined use of l-ethyl-3-(3-dimethylaminopropyl) carbodiimide - EDC - and N- 
hydroxysuccinimide, or NHS. EDC reacts with carboxyl groups to form highly reactive O- 
acylisourea intermediates, and the addition of NHS leads to the production of more stable 
esters. Reaction with amine groups on the other compound to be conjugated results in the 
formation of amide bonds (Staros et al., 1986). The reaction scheme for the production of 
protein conjugates of 7-hydroxycoumarin, with initial derivatisation of 7-hydroxycoumarin-
4-acetic acid (John Quinn, DCU, Personal communication), is given in Figure 3.5. 
Coupling occurs predominantly at the s-amine group of lysine residues on the protein.
Other types of coupling chemistry for hapten-carrier conjugates are also widely used. These 
include the use of heterobifunctional crosslinkers, such as NHS ester-maleimide and the 
homobifunctional crosslinker glutaraldehyde, which reacts with primary amine groups 
(Hermanson, 1996).
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F igure  3.4 Reaction scheme for the production of a diazonium-coupled 7- 
hydroxycoumarin-protein conjugate. 3-amino-7-hydroxycoumarin is first treated with 
sodium nitrate to form the diazonium derivative, which is then reacted with protein. 
Conjugation occurs mainly at tyrosine and histidine residues.
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F igure  3.5 Conjugation of 7-hydroxycoumarin to proteins by EDC-mediated NHS 
esterification. Treatment o f 7-hydroxycoumarin-4-acetic acid with EDC results in 
derivatisation at the carbonyl group and formation of an active o-acylisourea intermediate. 
Reaction with NHS causes NHS esterification, and addition of protein leads to the 
formation of amide bonds. The 8-amino groups of lysine are the predominant site of 
conjugation.
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3.4.2 Polyclonal antisera
The serum produced by any host animal in response to immunisation is known as a 
polyclonal antiserum. The blood of the host animal will contain a heterogeneous mixture of 
antibodies directed against different epitopes on the immunogen, and binding with a variety 
of affinities. When producing a polyclonal antiserum, the host animal is generally chosen 
on the basis of ease of handling and the quantity of serum obtainable. Rabbits, sheep and 
goats are among the species most commonly used.
The concept of antibody affinity cannot be applied to polyclonal antisera, due to the 
heterogeneity of their composition. Instead, the term "avidity" is used to describe an 
average affinity value for the mixture of antibodies in a polyclonal antiserum. The binding 
of polyclonal antibodies to an antigen with several epitopes is often many times stronger 
than that of a single antibody to a monovalent antigen, as a result of the formation of 
multiple antibody-antigen bridges between molecules.
While individual antibody molecules exhibit high specificity of binding, the presence of 
similar epitopes on different (frequently related) molecules may result in antibodies binding 
to antigens other than those against which they were raised. Due to their mixed population, 
this effect - known as "cross-reactivity" - is more prevalent among polyclonal antibodies; it 
may also, however, be encountered when dealing with homogeneous antibody preparations. 
In this and subsequent chapters, the term cross-reactivity will be used to denote binding of 
antibodies to shared or similar antigenic determinants on different molecules. The related 
phrase of "non-specific binding" is taken to refer to any other extraneous interaction which 
takes place (usually between proteins) in a biological matrix, generally as a result of 
electrostatic attraction.
From a practical aspect, the production of polyclonal antibodies is a relatively inexpensive 
and rapid process. Consistency between batches of antisera is impossible to guarantee, 
however, and even with large molecular weight immunogens, a maximum of 30% of the 
antibodies obtained will be of the desired specificity (Catty, 1988).
3.4.3 M onoclonal antibodies
In order to produce a homogeneous antibody preparation - or monoclonal antibody - it is 
necessary to isolate and propagate one individual B cell clone. B lymphocytes, however,
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can be cultured in vitro for only a short time. The production of monoclonal antibodies was 
pioneered by Kohler and Milstein (1975), when they immortalised antibody-producing cells 
by fusing them with a continuously growing cell line.
Monoclonal antibody production by somatic cell fusion requires initial immunisation of a 
host animal with the molecule of interest. When the titre of antibodies in the blood has 
reached a satisfactory level, the animal - usually a mouse or rat - is given a final intravenous 
injection of the immunogen (without adjuvant). This results in the presence in the spleen of 
a large number of specific B lymphocytes when the animal is sacrificed three or four days 
subsequently (Campbell, 1986).
The other fusion partner in the process is a mouse myeloma cell line. Myeloma cells are 
tumorigenic B lymphocytes which can be readily cultivated in vitro, and those used for 
monoclonal antibody production should not themselves secrete any antibody. They are also 
deficient in an enzyme called hypoxanthine guanidine phosphoribosyl transferase (HGPRT). 
The final number of fused cells will be low, which requires that selective media be used to 
promote their growth. HGPRT cells cannot utilise the salvage pathway of nucleic acid 
synthesis, and when cultured in medium containing hypoxanthine, aminopterin and 
thymidine (HAT medium) - which blocks the de novo synthesis of nucleic acid production - 
only fused cells will proliferate.
Splenocytes from the immunised animal are fused with myeloma cells by the addition of 
polyethylene glycol (PEG), which promotes membrane bridging and communication. 
Nuclear fusion will occur in a certain proportion of the fused cells, and a percentage of these 
cells will undergo mitosis and chromosome mixing (Freshney, 1983). The resulting cells - 
which possess the immortality of the myeloma line and the antibody production capability 
of the splenocytes - are called "hybridomas".
The cell mixture, which will contain splenocytes, myelomas and hybridomas, is divided into 
aliquots and cultured in selective HAT medium in multi-well cell culture clusters. After a 
number of weeks, by which time only the hybridomas should survive. The culture 
supernatants are assayed for the presence of specific antibody and eventually hybridomas 
derived from a single cell are produced.. This can be achieved by a process known as 
cloning by limiting dilution, in which the contents of positive wells are divided and 
subdivided a number of times (Goding, 1996). The predominant protein in the culture
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supernatant from these cells will be monoclonal antibody of the required specificity. As the 
average amount of antibody in supernatant from conventional cell culture flasks is only 
between 10 and 100 mg/ml (Epstein and Epstein, 1986), the generation of ascites fluid has 
traditionally been used to produce large amounts of antibody, When hybridoma cells are 
injected into the peritoneal cavity of a mouse or rat they rapidly proliferate, and the resulting 
ascites fluid which forms can contain up to 1000 times as much specific antibody as spent 
cell culture medium (Galfre and Milstein, 1981). The high yields from this method, 
however, are accompanied by the presence of considerable amounts of contaminating 
protein. Concern has also been widely expressed for the welfare of animals used to produce 
ascites fluid (Marx et al., 1997). These factors have lead to the development of high cell 
density bioreactors which allow the in vitro production of large quantities of high purity 
antibody (Evans and Miller, 1988).
Although the description above deals with mouse and rat antibodies, it is possible for human 
monoclonal antibodies to be produced in a similar fashion. Routine immunisation of 
humans is not, of course, possible. Nor is the use of the spleen as the source of 
lymphocytes; instead, B cells are generally taken from the tonsils or other lymphoid tissues. 
An alternative approach is to use the technique of in vitro immunisation. With this 
procedure, the antigen of interest is added to a mixture containing unsensitised B 
lymphocytes, together with macrophages, T helper cells, and other stimulatory and growth 
factors required to carry out the immune response (Carroll et al., 1989).
Whatever the method used to generate specific B cells, the lack of availability of non­
secreting human myeloma cell lines means that human lymphocytes are fused with mouse 
myelomas, resulting in the production of hybridomas which are frequently unstable due to 
chromosome loss.
A schematic representation of the steps involved in producing a murine monoclonal 
antibody is given in Figure 3.6. The inherent specificity of monoclonal antibodies can 
enhance the sensitivity of many immunoassays. However, the high affinities of these 
antibodies may render them unsuitable for use in regenerable immunosensor formats (see 
Chapter 5). The generation of monoclonal antibodies is also a much more expensive and 
labour-intensive process than that required to produce polyclonal antisera.
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F igure  3.6 Flow diagram showing the main steps in the production of a murine 
monoclonal antibody. Spleen cells from an immunised mouse are fused with non­
secreting myeloma cells and cultured in selective HAT medium. Cells producing specific 
antibody are cloned to ensure homogeneity, and monoclonal antibody is purified from 
ascitic fluid or culture medium.
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3.4.4 A n tibody  engineering
The continuing improvement in both the efficiency and the ease of use of recombinant DNA 
technology has meant that it is now possible to produce specific antibody by means of 
genetic engineering. The genes for antibody heavy and light chains can be isolated from 
cells of the immune system and inserted into a vector. A vector is a means of transferring 
genetic information into a host organism ("transfecting"), which then produces the desired 
protein. It is generally unpractical to incorporate entire antibody genes into a vector, and 
usually only those fragments necessary for antigen binding are used.
Plasmids are naturally-occurring closed circles of DNA which have been widely used as 
vectors in the field of antibody engineering. They may be used to transfect a range of 
different hosts. Better et al. (1988) utilised a plasmid vector to produce a Fab fragment 
against human carcinoma which was secreted by E. coli. Yeast was used by Horwitz et al. 
(1988) as the host organism for the production of a Fab fragment, and functional antibodies 
were expressed in plants by Hiatt et al. (1989).
A more recent development in the genetic engineering of antibodies is that of phage display 
technology. A bacteriophage, or phage, is a virus which infects bacteria, and can thus be 
used as a vector. However, by coupling inserted antibody genes to one of two phage coat 
protein genes, the antibody fragment can be displayed on the surface of the phage particle 
(McCafferty et al., 1990). This means that phage bearing specific fragments can be selected 
on the basis of affinity, and transfected into bacterial cells. This selection is achieved by 
adding a mixture of phage to antigen immobilised on a solid support. Phage particles 
expressing unspecific antibody fragments, or fragments with low affinity, are washed away, 
and binders are eluted. This process is known as "panning". Panning can be repeated 
several times, and each step should result in an enrichment of the culture supernatant. When 
the required specificity and affinity have been obtained, the phage particles are transfected 
into a different strain of E. coli which causes the antibody fragment to be expressed as a 
soluble protein, and secreted into either the cytoplasm or the growth medium. A flow chart 
showing the main steps involved in producing antibody fragments from a phage display 
library is given in Figure 3.7.
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F igure  3.7 Flow diagram showing the main steps in the production of antibody 
fragments from a combinatorial phage display library.
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The entire repertoire of antibodies expressed on the surface of all the phage particles prior to 
panning is known as a combinatorial phage display library. One way of producing such a 
library is to immunise an animal, remove lymphoid cells, extract DNA coding for antibody 
and insert this into phage. In such a system, large amounts of the antibody being expressed 
should be of the desired specificity. A procedure of this type was employed by Clackson et 
al. (1991) to generate antibody fragments directed against the hapten phenyloxazolone from 
immunised mice. Amersdorfer et al. (1997) also used the spleens of immunised mice to 
generate antibodies to botulinum neurotoxin type A, which may have therapeutic 
applications for neutralisation of the toxin.
However, the necessity for immunisation means that this approach comes no closer to 
solving the problems involved with human monoclonal antibody production. An alternative 
technique is to use lymphoid tissue from an unimmunised individual to construct what is 
known as a "naïve" library. Due to the genetic hypervariability discussed in section 3.2, 
such a library will contain antibodies to all possible antigens, and fragments of the required 
specificity can be isolated by repeated panning and enrichment steps. Marks et al. (1991) 
used a naïve phage display library to produce antibody fragments specific to turkey egg- 
white lysozyme. Dorsam et al. (1997) produced IgM fragments against a range of steroids 
including digoxin and progesterone from a naïve human library.
Antibody engineering has made possible the production of antibody fragments smaller than 
those produced by enzymatic degradation. These are shown in Figure 3.1. The variable 
fragment, Fv, is composed of the VH and VL domains. The lack of a disulphide linkage 
makes the Fv fragment inherently unstable, however, and methods to covalently join the 
two chains together, forming a single chain Fv (scFv), have been developed. An scFv 
directed against a human tumour marker has been produced by Savage et al. (1993).
An Fd fragment - consisting of either the VL and CL or VH and CH1 domains joined together 
- has also been generated, as has a single CDR region. The production of CDR regions is of 
great importance in the so-called "humanisation" of antibodies, and Riechmann et al. (1988) 
have created humanized antibodies in which only the CDR regions are of mouse origin. 
Hybrid molecules such as bifunctional antibodies have also been produced by antibody 
engineering. Bifunctional antibodies are bivalent antigen-binding molecules, in which the 
two arms of the antibody are specific for two different antigens. Their production and
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applications have been reviewed by Nolan and O'Kennedy (1992). Bifunctional antibodies 
were first produced for use in cancer chemotherapy by targeting tumour cells and providing 
close contact with the chemotherapeutic agent (Raso and Griffin, 1981). They may also be 
used to obviate the need for antibody labelling in immunoassays (Reinartz et al., 1996). 
The chemical means used to conjugate labels such as enzymes and fluorophores may 
damage the biological efficiency of the immunological component. If the label is bound by 
one arm of the bifunctional antibody, however, there is no necessity for chemical 
modification of the structure. Both biological and chemical methods for the production of 
bifunctional antibodies have been developed. Biological production is based on fusing two 
hybridomas of different specificities (Reading, 1981), or fusing a hybridoma specific for one 
antigen with splenocytes from an animal immunised with a second antigen (Milstein and 
Cuello, 1984). Chemical methods of bifunctional antibody production basically involve 
cleaving two antibodies and joining Fab fragments of differing specificities, or preparing 
heteroconjugates, which consist of two separate monoclonal antibodies that have been 
chemically crosslinked.
Holliger et al. (1993) engineered a hybrid molecule consisting of the VH and VL domains of 
one antibody covalently linked to the VH and VL domains of another. This novel 
bifimctional antibody fragment was named a "diabody". Atwell et al. (1996) generated a 
stable bispecific scFv dimer with reactivity for glycophorin and N9 neuraminidase. This 
dimeric protein was formed by non-covalent association of the two variable domains, and 
was designated a bisFv. Using a different approach to the production of a bifunctional 
antibody fragments, Pearce et al. (1997) created an scFv-streptavidin fusion, with specificity 
for neuraminidase, by genetic methods. This was linked to a biotinylated anti-ferritin Fab’ 
to form a bispecific molecule. Iliades et al. (1997) reported that scFv fragments which were 
produced by directly linking VH and VL domains formed into stable trimers, called 
“triabodies”.
3.5 A n tib o d y  p u rifica tio n
The purification of antibodies from serum, culture supernatant, bacterial cell lysate or ascites 
fluid is often a necessity. The extent of purification required depends upon the final
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application, and ranges from the removal of any non-immunoglobulin material to the 
isolation of specific antibody to a particular antigen.
Ammonium sulphate precipitation is frequently employed as a preliminary crude 
purification step. This procedure separates proteins on the basis of their solubility. 
Addition of saturated ammonium sulphate to an antibody-containing solution increases the 
number of hydrophobic interactions between the proteins, and results in precipitation of the 
immunoglobulin fraction, among other proteins. Approximately 50% of the extraneous 
protein can be removed by this treatment.
Further purification of the IgG fraction of the sample can be achieved by chromatographic 
methods. Ion-exchange chromatography may be used to purify antibodies. As antibodies 
are more basic than other serum proteins, they can be separated by using anion exchangers 
such as DEAE-cellulose (English, 1994).
Column chromatography with protein A or protein G may also be used to isolate IgG. 
Protein A is a 42 kDa polypeptide produced by Staphlococcus aureus. The protein has 4 
binding sites for the Fc region of IgG, two of which may be occupied at any time. The 
binding sites for protein A are located on the CH1 and CH2 domains. Protein G is a 30 kDa 
protein which is found in the cell walls of P-haemolytic streptococci. This protein also 
binds strongly to mouse and rabbit IgG, with a higher affinity for some isotypes (most 
notably IgG,) than protein A. Proteins A and G can be immobilised on a solid matrix, such 
as Sepharose gel, and poured into a column (Surolia e t a t, 1982). When the sample is 
added, any IgG present will bind to the column, and can subsequently be eluted by changes 
of pH or ionic strength (Hudson and Hay, 1980). Antibodies can also be purified on the 
basis of size, using HPLC (Carty and O'Kennedy, 1988).
Specific antibodies may also be isolated by affinity column chromatography, where the 
antigen is immobilised on a solid support. One such method has been described for the 
purification of specific anti-7-hydroxycoumarin antibodies from rabbit serum (H. Reinartz, 
Personal communication). In this procedure, 7-hydroxycoumarin-4-acetic acid was coupled 
to EAH sepharose by EDC/NHS esterification and poured into a column. Serum from an 
immunised rabbit was passed down the column, and specific antibodies were eluted with 50 
mM phosphate buffer containing 0.5 M NaCl, pH 11.0. A yield of 4% for specific anti-7- 
hydroxycoumarin was reported.
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3.6 The ro le  o f B IA core  in  the analysis o f an tibody p roduction
In recent years, BIA technology has become a widely-used tool in the production and 
characterisation of antibodies. Screening for specific monoclonal antibodies in cell culture 
supernatants is traditionally carried out by ELISA. In addition to being a laborious and 
time-consuming procedure, ELISA is an equilibrium system, and binders with high 
dissociation constants (i.e. low to moderate affinity) may be lost. The ease of automation, 
ability to analyse crude samples, and high sample throughput of BIA instrumentation would 
seem to make it ideally suited for such a task.
BIAcore has been utilised to screen for antibody fragments produced by genetic means. 
Soluble Fab fragments produced using a recombinatorial phage display library (established 
from in vitro immunised lymphocytes) were screened on BIAcore by Duenas et al. (1996). 
Binders were selected on the basis of their rates of dissociation from the immobilised 
antigen.
The use of BIAcore to pan an entire phage display library has been investigated by 
Malmborg and Borrebaeck (1995). They devised a model system in which a mixture 
containing 10% specific and 90% non-specific phage-displayed antibody fragments were 
injected over an immobilised antigen. Bound phage particles were eluted from the chip, and 
the eluate was collected and re-analysed, and exhibited a 5-fold increase in specific phage. 
Duenas et al. (1996) also used BIAcore to screen a phage display library generated from 
immunised lymphocytes, and demonstrated that soluble Fab fragments derived from phage 
collected during the later stages of elution had lower dissociation rates than those which 
were more readily eluted.
BIAcore can also be used to characterise antibodies, with respect to their specificity, 
subclass and concentration. One valuable application is that of pairwise epitope mapping of 
a panel of antibodies. In this procedure, a capture molecule is immobilised at the sensor 
surface and the first antibody is bound. The antigen is then added, followed by a second 
antibody. If the two antibodies are specific for the same epitope, then the second antibody 
will not bind. By analysing all the possible pairs of antibodies in this way, an epitope map 
of the antigen can be constructed. Fagerstam et al. (1990) used this procedure to study the 
binding of 29 murine monoclonal antibodies to recombinant HIV-1 proteins. Allauzen et al.
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(1995) also investigated the binding of a panel of 7 monoclonal antibodies to insulin by this 
method.
Yu et al. (1998) utilised BlAcore to characterise the binding behaviour of hybrid 
biomolecules consisting of the Fab’ fragment of a rat monoclonal antibody linked to the 
cardiac protein Troponin I.
Johne et al. (1993) used BlAcore to isotype antibodies to human heart myoglobin, and 
found the results to be comparable to those obtained from commercial isotyping kits.
By ensuring that conditions of mass transport limitation prevail (see section 3.7), the 
concentration of scFv, Fab, diabody and whole antibody in crude samples can be determined 
(Abraham et al., 1995; Kazemier et a l, 1996). Schier and Marks (1996) employed mass 
transport limitated analysis of this type to measure the percentage of specific phage present 
in bacterial cell lysate, and used the results to determine the antigen concentration for the 
next round of panning.
3.7 B lA co re  fo r m easuring an tibody a ffin itie s
The concept of antibody affinity has been discussed in section 3.3. The real-time aspect of 
biospecific interaction analysis makes it a useful tool for the estimation of affinity constants 
and association and dissociation rates, based on the assumption that the antibody-antigen 
interaction obeys pseudo-first order reaction kinetics (Karlsson et al., 1991).
From equation 3.3.2, the rate of production of analyte-ligand complex can be expressed as:
Equation 3.7.1 d[AB]/dt = k a [A][B] -  k d [AB]
where [A], [B] and [AB] are the concentrations of analyte, ligand and analyte-ligand 
complex, respectively, k¡ is the association rate constant, and kd is the dissociation rate 
constant. In BlAcore investigations, the ligand is immobilised on the surface of the sensor 
chip, so the concentration of AB is identical to the concentration of bound analyte, which is 
proportional to the observed response, R:
Equation 3.7.2 dR/dt = k a[A][B] -  k dR
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The concentration of free ligand - [B] - is the difference between total and bound ligand. 
The total amount of ligand on the chip surface is determined indirectly as it becomes 
saturated with analyte. In other words, the maximum response due to antibody binding - 
Rmax - will be proportional to the total ligand concentration, and ( R ^  - R) will be 
proportional to the free ligand concentration:
Equation 3.7.3 dR/dt = k a [A](Rmax -  R) -  k dR
As the analyte is supplied to the surface in continuous flow, the concentration of free analyte 
- [A] - can be considered to be constant, and identical to that of the original free analyte 
concentration. The rate equation can therefore be rewritten as:
E quation 3.7.4 dR/dt = k aC(Rmax -  R) -  k dR
Where C is the concentration of injected analyte in moles. The equation can be rearranged 
as follows:
Equation 3.7.5 dR/dt = k aCRmax - ( k aC + k d)R
This implies a linear relationship between the derivative of the binding curve, and the 
observed response. In theory, then, the rate constant can be obtained by plotting dR/dt 
against R.
In order to calculate the rate constants in this way, however, it is necessary to know the 
value of Rmax - the response obtained when the immobilised ligand is saturated with analyte. 
This practical terms, this requires very high levels of analyte: injecting 10 times the amount 
needed to give 50% saturation will result in only 91%  saturation. In addition the time taken 
to reach equilibrium may be very long. The necessity of determining the R ^  value
experimentally can be avoided if the slopes of plots of dR/dt against R (i.e. kaC + kd) over a
range of concentrations are plotted against concentration. This results in a line with the 
equation:
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Equation 3.7.6 slope (dR/dt vs R) = k aC + k d
which has a slope of ka and an intercept on the abscissa of kd.
Once the sample plug has passed over the chip surface and is replaced by running buffer, the 
change in response is due solely to the dissociation constant, provided that no significant re­
binding of dissociated analyte to the surface occurs:
Equation 3.7.7 dR/dt = - k d R
Analyte re-binding can be minimised by the use of faster flow rates. Integrating equation
3 .7 .7  with respect to time gives:
E quation 3.7.8 In —— = k d ( tn — t , )
R tn
where Ru is the response at an arbitrarily chosen time 1, and is the response at later time 
n. If the log of decrease in response is plotted against time, the slope of this line will be kd.
Since the value of dR/dt at equilibrium is zero, by introducing the affinity constant (K = 
k/kj) the equation can be rearranged as follows:
Equation 3.7.9 R/C = KRmax -  KR
Therefore, by plotting R/C against R for a range of concentrations at equilibrium, a line with 
a slope of K and an intercept on the abscissa of KRnrax can be obtained.
Some practical considerations must be taken into account in order that BIAcore kinetic and 
affinity experiments produce accurate data. The fundamental factor governing the 
association and dissociation of antibody and antigen is the mass transport of analyte across a 
stationary layer of solution at the surface of a flow cell. Diffusion across this layer is
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dependent upon the concentration gradient and the thickness o f the layer, the latter 
depending upon the flow rate. In order for correct calculation of kinetic parameters, any 
mass transport limitation must be overcome, so that the rate of binding is controlled only by 
the association and dissociation constants. The flow rate used in kinetic determinations 
should be high enough to remove mass transport effects, but low enough to reduce sample 
wastage.
Perhaps the most important point to address in experimental design is which of the two 
interactants to immobilise. In general, this should be the component which is more stable to 
regeneration. Ideally the more precious sample should be immobilised in order to minimise 
its consumption. When performing kinetic analyses it is necessary to use a range of analyte 
concentrations. In an antibody-antigen system, the absolute concentration of antigen is 
often much easier to determine than that of the antibody preparation, making it preferable to 
immobilise antibody. This approach is not, however, practicable where the antigen in 
question is of low molecular weight.
The amount of ligand immobilised should be sufficiently high to allow measurement of a 
reasonable range of responses, while remaining low enough to avoid steric hindrance and 
mass transport limitation. Generally speaking, an Rmax value of 300-2000 RU will satisfy 
these requirements. The amount of ligand to be immobilised in order to obtain an Rmax value 
in this range can be calculated using the following equation:
1 MW
Equation 3.7.10 R L = (300 -  2000) x -  x
where RL is the number of response units of immobilised ligand, s is the number of analyte 
molecules which can bind each ligand molecule, MWL is the molecular weight of the ligand, 
and MWa is the molecular weight of the analyte.
The concentration of analyte to be used should be sufficiently high to avoid mass transport 
limitations, yet low enough to give a signal in a satisfactory time for derivative readings to 
be taken.
Recently, some researchers have reported significant deviations from the pseudo first-order 
kinetic behaviour assumed for the interactants in the above model. O’Shanessy and Winzor
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(1996) concluded that these differences were due to the heterogeneity of the immobilised 
ligand sites, and suggested that the net observed rate constant might be used to calculate 
more accurate ka and kd values. Nieba et al. (1996) reported the use of a competitive method 
for measuring affinity constants which exhibited considerable differences from values 
calculated using binding kinetics.
Results
3.8 P roduction and characterisation o f po lyclona l an ti-7 -
hydroxycoum arin
Polyclonal antibodies to 7-hydroxycoumarin were produced, purified by saturated 
ammonium sulphate precipitation and protein G affinity chromatography. The purity of the 
antibody was investigated by SDS-PAGE, and the working dilution of antibody in a 
competitive ELISA for 7-hydroxycoumarin was assessed. The coating and blocking of 
chemically-activated microtitre plates with 7-hydroxycoumarin was optimised, and these 
plates were used in an enzyme-linked immunosorbent assay (ELISA) to examine the degree 
of cross-reactivity of the antibody preparation with a range of related coumarin derivatives.
3.8.1 E stim ation o f titre
New Zealand White rabbits were immunised with a diazo-coupled thyroglobulin conjugate 
of 7-hydroxycoumarin as described in section 2.2.2. The rabbits were injected 
subcutaneously with a solution of the conjugate in Freund's adjuvant. Blood was drawn 
periodically to estimate the titre of specific antibody. The titre was assessed by ELISA, as 
outlined in section 2.7.1. 96-well microtitre plates were coated with 7-hydroxycoumarin- 
BSA and blocked with 1% (w/v) BSA. Dilutions of rabbit serum (see section 2.3.1) from 
1/200 to 1/50000 were prepared. Control serum from an unimmunised rabbit was diluted in 
the same way, and both sets of samples were added to the plate, followed by labelled anti­
rabbit antibody and chromogenic substrate. The titre was taken to be the highest dilution of 
immunised serum which gave a signal greater than the corresponding dilution of control 
serum. The final titre of serum was greater than 1/50000, and an overlay plot of the results 
for immunised and control serum is shown in Figure 3.8.
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F igure  3.8 Overlay plot showing the titres for immunised and non-immunised (control) 
rabbit serum. Serial dilutions of both were added to wells coated with 7- 
hydroxycoumarin. At a dilution of 1/50000, serum from the immunised animal still gives 
a higher reponse than the control serum.
1/dilution factor
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3.8.2 Purification of polyclonal antiserum
The serum was initially partially purified by saturated ammonium sulphate precipitation, as 
described in section 2.4.1. The precipitate was then further purified by protein G affinity 
chromatography as in section 2.4.2. IgG in the sample bound to the protein G on the 
column, and was then eluted, after washing, by addition of glycine buffer. The presence of 
antibody in collected fractions was determined by monitoring the absorbance at 280nm. A 
typical elution profile for anti-7-hydroxycoumarin from the protein G column is shown in 
Figure 3.9.
Fractions containing antibody were pooled and dialysed, and the concentration of IgG was 
determined by BCA assay as described in section 2.5. The average protein concentration of 
pooled fractions was 4-5 mg/ml.
3.8.3 Characterisation of purified antibody by SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique 
which separates proteins on the basis of molecular weight. The purity of the polyclonal 
antibody preparation was assessed by SDS-PAGE as described in section 2.6. The antibody 
was electrophoresed under reducing conditions, along with a series of molecular weight 
markers, on a gel containing 5% (w/v) acrylamide. The results are shown in Figure 3.10. 
Boiling together with mercaptoethanol causes the polypeptide chains of the 
immunoglobulin to separate, and the two main sample bands on the electropherogram - one 
between the 45 kD and 66 kD markers, and the other below the 29 kD marker - correspond 
to the 50 kD heavy chain and the 25 kD light chain of IgG. The "spreading" seen for the 
second band is probably due to a combination of high protein concentration and excessive 
voltage.
3.8.4 Working dilution of antibody in a competitive ELISA for 7- 
hydroxycoumarin
Egan and O'Kennedy (1993b) described the use of polyclonal anti-7-hydroxycoumarin in a 
competitive ELISA for the free drug (see Chapter 4). The working dilution of this antibody 
in such an immunoassay format was assessed as described in section 2.7.2.
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F igu re  3.9 A typical elution profile for polyclonal anti-7-hydroxycoumarin from a 1 ml 
protein G affinity column. Crude sample was passed down the column, followed by 20 
column volumes of wash buffer. Bound antibody was then eluted with 0.1 M glycine, pH 
2.5, 1 ml fractions were collected, and the protein content was measured by absorbance at 
280 nm. The majority of IgG is eluted in the first 3 fractions.
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Figure 3.10 SDS-PAGE of purified polyclonal anti-7-hydroxycoumarin. Rabbit 
antiserum which had been purified by saturated ammonium sulphate precipitation and 
protein G affinity chromotagraphy was electrophoresed under reducing conditions. 
Markers containing carbonic anhydrase (29 kDa), ovalbumin (45 kDa), BSA (66 kDa), 
phosphorylase B (97.4 kDa), (3-galactosidase (116 kDa) and myosin (205 kDa) were also 
run. The sample has one band between the 45 kDa and 66 kDa markers, and one below 
that for the 29 kDa marker, consistent with the presence of the 50 kDa heavy chain and 25 
kDa light chain of IgG. The “spreading” seen for the 25 kDa sample band is probably 
due to a combination of high protein concentration and high voltage.
MARKERS SAMPLE MARKERS
1 1  H  H
50 kDa 
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Wells of a microtitre plate were coated with 7-hydroxycoumarin-BSA, and blocked with 1% 
(w/v) BSA. Dilutions of purified rabbit anti-7-hydroxycoumarin from 1/50 to 1/2000 were 
prepared, as well as a range of standard solutions of 7-hydroxycoumarin. Equal volumes of 
appropriate standard and antibody solution were added to the wells. After incubation, 
enzyme-labelled anti-rabbit IgG was added, followed by a chromogenic substrate. An 
overlay plot of the results for the different antibody dilutions is shown in Figure 3.11. An 
antibody dilution of 1/200 performs well in the assay, giving a standard curve with an r2 
value of 0.98 and a measuring range of 2.5 - 40 (xg/ml of 7-hydroxycoumarin, as shown in 
Figure 3.12.
3.8.5 Cross-reactivity of polyclonal anti-7-hydroxycoumarin
The coating and blocking of Covalink plates (NUNC) with 7-hydroxycoumarin-4-acetic 
acid was first optimised. These microtitre plates were then used to assess the cross­
reactivity of purified polyclonal antibody with a range of coumarin derivatives.
3.8.5.1 Optimisation of coating and blocking for Covalink plates
The polystyrene surface of Covalink microtitre plates is derivatised with amino groups, 
allowing the direct covalent attachment of molecules via a range of chemistries. NHS 
esterification was used to link 7-hydroxycoumarin-4-acetic acid to the plates as described in 
section 2.7.3. Plates were coated with a 1 mg/ml solution of 7-hydroxycoumarin-4-acetic 
acid and blocked with a range of different reagents: 1% (w/v) gelatin, 5% (w/v) milk 
powder, 2% (w/v) ovalbumin, and 5% (v/v) foetal calf serum (FCS). Antibody was added 
to these wells, and to uncoated wells which had been blocked using the same reagents. 
Labelled anti-rabbit antibody and chromogenic substrate were then added, and the 
absorbance of wells at 280 nm was measured. 5% (v/v) FCS was found to give the best 
reduction in background reading.
Wells of covalink plates were then coated with a range of different concentrations of 7- 
hydroxycoumarin-4-acetic acid: 1, 2, 3, 4, and 5 mg/ml. These wells were then blocked 
with 5% (v/v) FCS. A range of dilutions of purified anti-7-hydroxycoumarin from 1/50 to 
1/1600 were prepared, and 100  (il/well of appropriate dilutions were added to the plate.
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F igu re  3.11 An overlay plot for the assessment of the working dilution of purifed anti-7- 
hydroxycoumarin in a competitive ELISA for 7-hydroxycoumarin. Antibody at various 
dilutions was mixed with standard 7-hydroxycoumarin solutions in the wells of microtitre 
plates coated with 7-hydroxycoumarin. The absorbance of wells at 405 nm is inversely 
proportional to the amount of drug present. Results are the averages of duplicate 
analyses.
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F igu re  3.12 Standard curve for 7-hydroxycoumarin in a competitive ELISA format using 
a 1/200 dilution of purified polyclonal antibody. The absorbance at 405 nm is inversely 
proportional to the amount of 7-hydroxycoumarin present. The results shown are the 
average of five replicate analyses, and all coefficients of variation were below 2.5%. The 
assay has a measuring range of 2.5-40 (ig/ml and an r2 value of 0.98.
0.14
0 .1 3
0.12
E
c
in
O  0.11 
(An
<
0.1
0 .09
1 10 100 
Log of 7-OHC conc (ug/ml)
0.08
=  0.98
108
Following addition of labelled anti-species antibody and chromogenic substrate, the 
absorbance of wells at 280 nm was measured. The results of this experiment are shown in 
Figure 3.13. It can be seen that the response at all antibody dilutions increases up to a 
coating concentration of 5 mg/ml.
At higher concentrations, 7-hydroxycoumarin-4-acetic acid is insoluble. Coating with 5 
mg/ml of 7-hydroxycoumarin-4-acetic acid and blocking with 5% (v/v) FCS were thus 
taken to be the optimal conditions.
3.8.5.2 Assessment of antibody cross-reactivity by ELISA
The degree of cross-reactivity of purified polyclonal anti-7-hydroxycoumarin was 
determined by competitive ELISA as described in section 2.7.3.1. Wells of a Covalink 
microtitre plate were coated with 7-hydroxycoumarin-4-acetic acid and blocked with FCS. 
Solutions containing from 0 - 5 0  (ig/ml of 7-hydroxycoumarin, warfarin, coumarin, 4- 
hydroxycoumarin, 7-hydroxywarfarin, and 7-hydroxycoumarin-4-acetic acid were prepared. 
50 (J.1 of appropriate solutions were added to wells of the microtitre plate, together with an 
equal volume of polyclonal antibody.
The absorbance reading for the wells containing 50 (J,g/ml of 7-hydroxycoumarin 
represented 100% inhibition of antibody binding The degree of cross-reactivity of the 
antibody was calculated from the percentage inhibition produced by 50 (j.g/ml of each of the 
compounds tested, and is shown in Table 3.1. It can be seen that the antibody exhibits low 
cross-reactivity with warfarin and coumarin, moderate cross-reactivity with 4- 
hydroxycoumarin and 7-hydroxywarfarin, and is highly cross-reactive with free 7- 
hydroxycoumarin-4-acetic acid, 50 fag/ml of which results in 86% inhibition.
3.9 Production and characterisation of monoclonal antibodies
BALB/c mice were immunised with a 7-hydroxycoumarin-protein conjugate and the titre of 
antibodies in serum was estimated by ELISA, using a range of immobilised substances. 
Spleen cells from immunised mice were fused with a myeloma cell line, and culture 
supernatants from the resultant hybridomas were screened for antibody production by 
BIAcore and ELISA, with an immobilised drug-protein conjugate.
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F igu re  3.13 The effect of covalently linking increasing amounts of 7-hydroxycoumarin- 
4-acetic acid to Covalink microtitre plates. 1,2,3,4 and 5 mg/ml solutions of the 
compound were used to coat plates, and doubling dilutions of purified polyclonal 
antibody were added to wells. The binding increases up to a coating concentration of 5 
mg/ml.
1/dilution factor
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Table 3.1 Cross-reactivity of purified polyclonal anti-7-hydroxycoumarin. The antibody 
was tested in a competitive ELISA format. 7-hydroxycoumarin-4-acetic acid was 
covalently linked to Covalink plates, and antibody was added along with various 
concentrations of coumarin compounds. The percentage inhibition caused by 50 (ig/ml of 
each compound was compared to the 100% inhibition of binding caused by 50 p-g/ml of 
7 -hydroxycoumarin.
Compound Percentage inhibition at 50 jig/ml
7-hydroxycoumarin 10 0 %
7-hydroxycoumarin-4-acetic acid 86%
7-hydroxywarfarin 40%
4-hydroxycoumarin 41%
Warfarin 13%
Coumarin 13%
Il l
Hybridomas from positive wells were scaled up and rescreened against both drug-protein 
conjugate and native protein. 3 surviving hybridoma populations which exhibited 
significantly greater binding to drug-protein conjugate than to unconjugated BSA were 
cloned by limiting dilution. 13 positive clones were isolated which, when tested in a 
competitive ELISA format, were found not to bind to free drug. The affinities of the panel 
of antibodies for drug-protein conjugate were ranked using BIAcore.
3.9.1 Estimation of titre
BALB/c mice were immunised with an EDC/NHS-coupled 7-hydroxycoumarin-ovalbumin 
conjugate as described in section 2.2.3. The mice were injected subcutaneously and 
intraperitoneally with a solution of the conjugate in Freund's adjuvant. Blood was taken and 
the titre of specific antibodies was estimated by ELISA as in section 2.7.4. 96-well 
microtitre plates were coated with BSA, ovalbumin, diazo-coupled 7-hydroxycoumarin- 
ovalbumin and EDC/NHS-coupled 7-hydroxycoumarin-ovalbumin. In addition, Covalink 
plates were coated using 7-hydroxycoumarin-4-acetic acid.
Dilutions of mouse serum (see section 2.3.2) from 1/200 to 1/12800 were prepared. Serum 
from an unimmunised mouse and purified polyclonal anti-7-hydroxycoumarin were also 
prepared at the same dilutions, for use as negative and positive controls, respectively. 
Dilutions of immunised serum, negative and positive controls were added to appropriate 
wells, followed by labelled anti-species antibody and chromogenic substrate. The test 
serum gave a high response on the ovalbumin-coated plate, but did not bind to the BSA 
surface. Both immunised and control serum gave a similarly low response on the Covalink 
plate. Figure 3.14 shows that neither immunised nor control serum gave a significant 
response to the diazo-coupled conjugate, whereas the positive control (purified polyclonal 
antibody) bound strongly. On wells coated with EDC/NHS-coupled drug-protein conjugate, 
however, serum from the immunised mouse gave an even higher response than the positive 
control, and had a titre of greater then 1/12800. This result is shown in Figure 3.15. The 
mouse was then injected intravenously 3/4 days before being sacrificed.
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F igu re  3.14 Overlay plot showing the lack of binding of mouse serum to wells coated 
with a diazonium-coupled 7-hydroxycoumarin-BSA conjugate. Serum from an 
immunised mouse (Mouse 1) and pre-immune serum (Neg control) gave similarly low 
responses, while positive control (polyclonal anti-7-hydroxycoumarin) bound strongly to 
the immobilised conjugate.
1/dilution factor
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F igu re  3.15 Overlay plot showing the titre of immunised mouse serum on wells coated 
with EDC/NHS-coupled 7-hydroxycoumarin-BSA conjugate. Serum from an immunised 
mouse (Mouse 1) gave a higher reponse than the positive control (polyclonal anti-7- 
hydroxycoumarin). The titre of the serum was greater than 1/12800.
1/dilution factor
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3.9.2 Somatic cell fusion
Spleen cells from the immunised BALB/c mouse were fused with SP2 myeloma cells as 
described in section 2.8.6. The SP2 cell line was first tested for the presence of mycoplasma 
(see section 2.8.4). Splenocytes were mixed with SP2s in a 10:1 ratio, and then fused by the 
addition of PEG. The fused cells were distributed into eight 48-well cell culture clusters 
containing HAT medium (including BriClone). The plates were visually inspected 12 days 
later, and approximately 85% of wells were found to contain colonies of hybridoma cells, 
while SP2 cells which had been cultured in HAT medium in a set of control wells were 
dead. The cells were fed by removal of supernatant and addition of a similar volume of 
HAT medium.
The removed supernatant was assayed for the production of specific antibody as described 
below. The hybridomas were monitored daily, and those which were producing antibody 
and had attained 50 - 70% confluence (covered 50 - 70% of the surface) were scaled up into 
cell clusters with larger surface areas as described in section 2.8.6. The cells were gradually 
weaned off hypoxanthine, thymidine, aminopterin, and BriClone.
3.9.3 Screening of cell culture supernatants
Hybridoma supernatants from 48-well masterplates were screened for specific antibody 
production as soon as 50% confluence had been reached. Initial screening by ELISA is 
described in section 2.7.5. Neat culture supernatants were added to wells of plates coated 
with 7-hydroxycoumarin-BSA, followed by labelled anti-mouse antibody and chromogenic 
substrate. Purified polyclonal anti-7-hydroxycoumarin was included in all assays as a 
positive control.
Of the 336 hybridoma-containing wells which were screened, 27 produced a positive result 
when screened by ELISA against 7-hydroxycoumarin-BSA. The same supernatants were 
assayed by BIAcore. 7-hydroxycoumarin-BSA was immobilised on the sensor chip as in 
section 2.9.2, and neat culture supernatants were injected over this surface. No binding 
signal was obtained for any of the supernatants tested.
Those 27 hybridomas which had given positive screening results with ELISA were scaled 
up to 24-well cell culture plates. Supernatants from all hybridomas were then rescreened by 
ELISA. Wells of microtitre plates were coated with 7-hydroxycoumarin-BSA and native
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BSA, and a sample of each culture supernatant was added to both wells. 12 of the positive 
hybridoma populations had ceased antibody secretion after scaling up, and the results for the 
other 15 supernatants from this round of screening are shown in Figure 3.16. It can be seen 
that of the 15 hybridomas tested, only 5 bound significantly more strongly (at least 2-fold 
greater) to 7-hydroxycoumarin-BSA than to BSA. Supernatants from the remaining wells 
were subsequently found also to bind to native thyroglobulin.
The 5 hybridomas which bound significantly to drug-protein conjugate were further scaled 
up to 12-well clusters, and supernatants were again screened by ELISA. At this stage, 2 of 
the hybridomas had ceased to secrete antibody. A summary of the results from ELISA 
screening of original hybridomas is given in Table 3.2.
3.9.4 Cloning by lim iting dilution
The remaining three positive hybridomas were cloned by limiting dilution as outlined in
section 2.8.7. Hybridomas were grown up in culture flasks and then added to wells of 96- 
well microtitre plates at 10 cells/well. When sufficient growth had occurred, the 
supernatants were again screened by ELISA against 7-hydroxycoumarin-BSA. 2 positive 
wells were identified, and the contents of these wells were gradually scaled up to 6-well 
plates, and then again cloned out into 96-well plates at 1 cell/well. Screening of these plates 
by ELISA yielded 13 positive clones, which were again scaled up.
3.9.5 Assessing reactivity of clones to free 7-hydroxycoumarin
The 13 clones isolated were assayed by ELISA for reactivity to free 7-hydroxycoumarin.
Microtitre plate wells were coated with 7-hydroxycoumarin-BSA as for screening. Culture 
supernatants from the cloned hybridomas were added to wells together with 7- 
hydroxycoumarin at a final concentration in the wells of 50 fig/ml. Controls in which 
supernatant was diluted by the same factor with PBS were also set up. The assay was then 
performed as normal. The results are given in Figure 3.17, and clearly show that the 
presence of free 7-hydroxycoumarin in the wells does not inhibit binding to immobilised 7- 
hydroxycoumarin-BSA. 50 |_ig/ml is one of the most concentrated standards in both the 
ELISA and BIAcore competitive assays for 7-hydroxycoumarin, in which purified 
polyclonal antibody is used.
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Figure 3.16 Supernatants from 15 hybridoma colonies screened against both 7- 
hydroxycoumarin-BSA and native BSA. Most of the antibodies produced reacted 
strongly with the unconjugated protein, but supernatants 2, 3, 8, 11 and 12 exhibited at 
least 2-fold higher binding to the drug-protein conjugate. 1/200 purified polyclonal anti-7- 
hydroxycoumarin was used as the positive control ("POS").
0 . 7
Supernatant number
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Table 3.2 Summary of results from the screening of hybridoma supernatants. 
Supernatants were tested against drug-protein conjugates and unconjugated protein.
Percentage of wells with hybridoma colonies 87.5%
Number of hybridoma supernatants screened 336
Number of supernatants positive for 7- 
hydroxycoumarin-BSA
27
Number of supernatants with significantly 
higher binding for drug-protein conjugate than 
native BSA
5
Number of positives cloned by lim iting dilution 3
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Figure 3.17 13 monoclonal antibodies tested in a competitive ELISA format. Wells of a 
microtitre plate were coated with 7-hydroxycoumarin-BSA, and antibody was added, with 
and without free 7-hydroxycoumarin. 1/200 purified polyclonal anti-7-hydroxycoumarin 
was used as the positive control ("POS"). The presence of free drug in wells containing 
antibody does not cause any appreciable inhibition. As the original stocks were shown 
not to bind significantly to native BSA, these results indicate that the antibodies produced 
are directed against a joint drug-protein epitope.
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The microgramme quantities of antibody present in culture supernatant would be saturated 
by the addition of such a high amount of 7-hydroxycoumarin. This demonstrates that the 
monoclonal antibodies produced do not recognise free drug.
3.9.6 A ffin ity ranking of monoclonal antibodies
Of the 13 clones which were produced, 4 did not survive the scaling process. The affinities 
of the remaining 9 monoclonal antibodies for 7-hydroxycoumarin-BSA were ranked using 
BIAcore. Neat supernatants were injected over an immobilised 7-hydroxycoumarin-BSA 
surface (see section 2.9.2), and the response generated by the binding of each antibody was 
recorded. The concentration of mouse IgG in each culture supernatant was calculated by 
the method of standard addition, as described in section 2.7.13.
The relative affinities of the antibodies for the antigen - expressed as the BIAcore response 
divided by the calculated immunoglobulin concentration - are illustrated in Figure 3.18. 
The results suggest that the clones numbered 3,4,5 and 6 might be identical. The same may 
be true for numbers 8 ,1 1  and 1 2 .
An example of a sensorgram obtained for the one of the hybridoma supernatants - clone 
number 3 - is given in Figure 3.19. This sensorgram is typical of those obtained for all 11 
clones. It can be seen that the bulk refractive index change due to the composition of the 
cell culture supernatant is considerable, and appears to mask an initial high rate of antibody 
binding, as no large increase in signal during the rest of the injection phase is present to 
account for the binding signal of 670 RU. The shape of this sensorgram, with its rapid 
association and dissociation phases, suggests that the antibodies may have only a weak 
overall affinity for 7-hydroxycoumarin-BSA.
3.10 BIAcore-based kinetic and affinity studies on scFv fragments against
a coumarin-BSA conjugate
A human semi-synthetic phage display library (Nissim et al., 1994) - a naïve library which 
had been subjected to random mutagenesis in order to increase genetic diversity - 
underwent three rounds of panning on microtitre plates against a coumarin-BSA conjugate. 
Three clones which displayed reactivity to coumarin-BSA and produced soluble antibody 
were isolated, and expressed from large-scale culture.
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Figure 3.18 Affinity ranking of a panel of 9 monoclonal antibodies on BIAcore. Neat 
hybridoma supernatants were injected over an immobilised 7-hydroxycoumarin-BSA 
surface, and the resultant binding signals were divided by the concentration of antibody in 
each supernatant.
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Figure 3.19 Sensorgram obtained for the binding of monoclonal antibody number 3 to 
immobilised 7-hydroxycoumarin-BSA. The initial bulk refractive index change appears 
to mask a fast association phase, which together with the rapid dissociation suggest an 
overall weak affinity constant for the antibody. The difference between the signal after 
injection and the initial baseline represents the amount of antibody bound.
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None of the three antibodies selected exhibited binding to free coumarin. Bacterial 
periplasmic lysates from all three were purified by column chromatography with 
immobilised coumarin-BSA. The three clones were designated a-C5, a-C13 and a-C14 
(“a-C” stands for “anti-coumarin”) The production and purification of antibodies was 
carried out by Anthony Killard, DCU. BIAcore was then used to affinity rank the purified 
scFvs and to calculate apparent affinity and rate constants for one of the antibody 
fragments.
Coumarin BSA conjugate was immobilised on a BIAcore sensor chip as in section 2.9.2. 
Native BSA was also immobilised on a separate flow cell. The three antibodies were 
passed over each surface at a concentration of 100 nM. 5 minute injections at a flow rate of 
20 fil/min were used. The non-specific interaction of a-C5 with the BSA surface is shown 
in Figure 3.20, and is characteristic of the response seen for the other two clones.
An overlay plot of the binding curves for the three clones to immobilised coumarin-BSA is 
given in Figure 3.21, and shows the affinity ranking of the three scFvs to be in the order a- 
C13 > a-C5 > a-C14.
For the kinetic analysis of a-C5, purified scFv at concentrations of 10, 25, 50, 75 and 100 
nM were injected over the immobilised coumarin-BSA surface. BIAevaluation software 
was used to derive the rate constants for the interaction, as described in section 3.7. The 
linear portion of the dissociation phases at all antibody concentrations was selected from a 
plot of ln(tl/t0) against time, and these data were fitted to a simple dissociation model 
(AB-»A+B). The k<j value obtained from this plot was used to calculate ka values, 
following selection of linear portions from the association phase of the sensorgrams. 
Average calculated ka and k<j values were 1 x 105 and 5 x 10^, respectively, giving an 
overall affinity constant, for the interaction of 1 x 10'9 M. However, as shown in Figure 
3.22, there is a significant divergence between the calculated dissociation curve and the 
observed BIAcore data. This indicates that the data do not fit the simple dissociation 
model, and that the interaction deviates from pseudo-first order reaction kinetics.
3.11 BIAcore panning of a phage display library
A naïve phage display library (Nissim et al., 1994) was panned using BIAcore. 7- 
hydroxycoumarin-BSA was immobilised on the sensor chip as described in section 2.9.2.
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F igu re  3.20 Overlay plot showing the degree of non-specific binding o f monoclonal 
scFv antibody a-C5 to an immobilised BSA surface as determined by BIAcore studies. 
100 (il of scFv antibody at a concentration of lOOmM was passed over both BSA and 
coumarin-BSA surfaces. 40 RU of non-specific binding to BSA occurred, and similar 
results were obtained for the other two scFvs tested.
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F igu re  3.21 Affinity ranking of three scFv fragments against coumarin-BSA, Coumarin- 
BSA was immobilised on the BIAcore and purified scFvs at a concentration of lOOmM 
were passed over this surface. The relative affinities of the antibodies are in the order a- 
C13 >a-C5 > a-C14.
Time (s)
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F igu re  3.22 Dissociation plot for scFv antibodu a-C5 from BIAevaluation software. 
The bad fit between the calculated dissociation curve and the BIAcore data indicates a 
deviation from pseudo-first order reaction kinetics
Time (s)
126
Neat bacterial cell lysate containing 5.5 x 109 phage particles/ml was injected over the 
sensor surface for 5 minutes at a flow rate of 10 |al/min. No binding signal was generated 
as a result of this injection. The flow rate was increased to 100 (xl/min for 15 minutes, to 
wash the surface. A 20 minute injection of glycine buffer, pH 2.2, was then passed over 
the surface to remove any specifically bound phage. Samples of the eluate from the 
BIAcore flow cell were taken regularly throughout the experiment, and these samples were 
assayed for the presence of phage as described in section 2.10. E. coli cells were infected 
with the eluted samples, and plated out onto selective medium containing carbenicillin. 
Only infected cells grow on the medium, as the presence of phage confers carbenicillin 
resistance, and the amount of phage in the original sample is calculated from the number of 
colonies visible on the agar plates.
The results are shown in Figure 3.23, and demonstrate that, although the amount of specific 
phage in the cell lysate was not sufficiently large to generate a change in SPR angle, the 
sample collected after treatment with glycine buffer contained 10 0 -fold more phage than 
those collected during the washing phase. This indicates that specific elution of phage 
displayed antibodies was achieved. The final number of phage specifically eluted was 1.4 x 
104. This is 20,000-fold less than the original amount of 2.75 x 108 phage injected over the 
surface. As all of the phage in the eluted sample are specific for the immobilised conjugate 
surface, this represents a 20 ,000-fold enrichment step.
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Figure 3.23 Phage counts for samples taken during BIAcore analysis of bacterial cell 
lysates. Phage from a naive library were injected over an immobilised 7- 
hydroxycoumarin-BSA surface at 5.5xl09 phage particles per ml. Samples were taken 
during the injection, washing and elution phases, and analysed for the presence of phage. 
The eluted sample contained 7xl04 specific phage per ml. When compared to the counts 
for samples taken during the washing phase, this shows that specific elution took place.
Time (min)
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3.12 Discussion
The work presented in this chapter is concerned with antibodies produced - by 
immunisation, somatic cell fusion and genetic engineering - to small haptens. Together 
with reports from the literature, and other results generated in our laboratory, these findings 
highlight the problems encountered when dealing with small haptens and their protein 
conjugates. The limitations of solid-phase selection strategies - both microtitre plate and 
BIAcore-based - for antibodies to such molecules are discussed here. The importance of 
the choice of coupling chemistry and carrier protein for the production of drug-protein 
conjugates is also emphasised.
Polyclonal antibodies to 7-hydroxycoumarin were produced by immunising New Zealand 
White rabbits with a diazonium-coupled 7-hydroxycoumarin-thyroglobulin conjugate. 
Serum from immunised rabbits gave a good titre compared to control serum (Figure 3.8), 
and, following purification by ammonium sulphate precipitation and protein G affinity 
chromatography, the antibody preparation was shown to have a high degree of purity by 
SDS-PAGE (Figure 3.10).
The working dilution of this antibody in a competitive immunoassay for free 7- 
hydroxycoumarin was estimated. A dilution of 1/200 was found to perform with good 
reproducibility and linearity (Figure 3.12), and this value compares favourably to that 
quoted by Egan (1993) for another polyclonal antibody against 7-hydroxycoumarin in the 
same assay system.
The cross-reactivity of the polyclonal antibody was assessed by ELISA. Microtitre plates 
with active amine groups were used in order to minimise non-specific binding of antibodies 
to the carrier protein in drug-protein conjugates. The coating (by EDC/NHS coupling of 7- 
hydroxycoumarin-4-acetic acid) and blocking of these plates was first optimised, and the 
inhibition of antibody binding by a range of coumarin compounds was then investigated by 
competitive ELISA (Table 3.1). Little cross-reactivity with coumarin or warfarin was 
evident, but the antibody displayed moderate cross-reactivity to 4-hydroxycoumarin and 7- 
hydroxywarfarin, and high cross-reactivity to 7-hydroxycoumarin-4-acetic acid. The 
presence of a hydroxy group, whether at the 4- or 7- position, appears to be an absolute 
requirement for antibody binding. As 7-hydroxylation is the predominant metabolic fate of 
coumarin in man (Pelkonen et al., 1997) cross-reactivity with other simple hydroxylated 
forms of coumarin should not affect the use of this antibody preparation in analytical 
applications. The antibody was subsequently successfully employed in the development of
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a BIAcore-based immunoassay for free 7-hydroxycoumarin in human serum samples (see 
Chapter 4).
Prior to the production of monoclonal antibodies, BALB/c mice were injected with an 
EDC/NHS-coupled 7-hydroxycoumarin-ovalbumin conjugate. After several 
immunisations, the titre of specific antibodies in the mouse serum was assessed by ELISA, 
with a range of different immobilised interactants. Figure 3.15 shows that, on a microtitre 
plate coated with EDC/NHS-coupled 7-hydroxycoumarin-BSA, serum from the immunised 
mouse gives a higher response than that given by the positive control (purified polyclonal 
antibody), and had a titre of greater than 1/12800. The degree of similarity between 
ovalbumin and BSA can lead to misleading results if antibodies immunised with a 
conjugate of one protein are screened with a conjugate containing the other (Hermanson, 
1996). On control wells coated with native BSA, however, the serum from the immunised 
animal gave no significant response. This indicated that the response given by the serum in 
the 7-hydroxycoumarin-BSA wells was not simply due to cross-reactivity between anti­
ovalbumin antibodies and the BSA component of the immobilised conjugate.
While a good titre was obtained for the mouse serum using plates coated with EDC/NHS- 
coupled 7-hydroxycoumarin-BSA, no significant binding of serum components to wells 
coated with a diazonium-coupled BSA conjugate of 7-hydroxycoumarin was observed, 
although the positive control gave a good response (Figure 3.14). Similarly, control and 
immunised serum gave almost identically low responses on a plate to which 7- 
hydroxycoumarin had been covalently coupled. The final implications of these findings 
will be discussed in detail below, but at the screening stage it seemed probable that these 
differences in response could have been the result of proximity effects, differing orientation 
of drug molecules, or steric hindrance.
Splenocytes from the immunised animal were then fused with myeloma cells using PEG, 
and 87.5% of the wells of 48-well cell culture clusters were found to contain hybridomas, 
while unfused cells died in HAT medium. 336 cell supernatants were assayed by ELISA 
for antibody production, using microtitre plates coated with EDC/NHS-coupled 7- 
hydroxycoumarin-BSA. 27 positive results were obtained, but when the supernatants were 
subsequently assayed against both conjugated and unconjugated BSA, 22 of the antibodies 
had either ceased secretion or bound strongly to the native form of the protein (Figure 3.16). 
Further investigation of these supernatants showed that they also bound to thyroglobulin. 
The isolation of antibodies which bind non-specifically to protein, probably as a result of
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electrostatic interactions, is an inevitable consequence of screening with a hapten-protein 
conjugate. Breen (1987) found large numbers of such "sticky" immunoglobulins when 
screening for antibodies against human plasma apolipoproteins. The logistics of testing 
initial fusion supernatants, involving large numbers and small volumes of samples, mean 
that comparative screening against both conjugated and unconjugated protein is difficult to 
carry out until the apparent "positives" have been scaled up. Killard (1998) found that more 
complex screening strategies , such as competitive methods, were difficult to incorporate at 
earlier stages in the process, as optimisation of the assay conditions was not possible.
Of the five hybridoma colonies which produced antibodies that bound significantly more 
strongly to 7-hydroxycoumarin-BSA than to native BSA, two ceased secretion of antibody 
before they could be cloned. Such loss of antibody production is a frequently encountered 
problem, and can occur because of overgrowth of the antibody producing hybridomas by 
other cells in the well, or as a result of chromosome loss (McCullough and Spier, 1990).
The three hybridoma populations which were eventually cloned by limiting dilution grew 
slowly in the original 48-well plates, and were detected as positive two weeks after the start 
of the screening process. It is probable that hybridomas which are producing antibody 
naturally divide more slowly than non-secreting cells, because of their added metabolic 
burden (Reuveny and Lazar, 1989). In addition, the kinetics of antibody production may 
complicate the screening process. Most mouse monoclonal cell lines produce antibody at 
the beginning of the exponential growth phase and during the stationary and decline phases. 
However, some secrete antibody at the start of the exponential phase and during the decline 
phase only; while others only produce antibody during the exponential phase of growth 
(Merten et al., 1987). These differences in production kinetics, exacerbated by the presence 
in culture supernatants of proteases which can cleave antibody molecules (Schlaeger et al., 
1986), can make the timing of screening steps an important consideration.
Cloning of the three hybridoma populations by limiting dilution resulted in the production 
of a panel of eleven monoclonal antibodies. As these were derived from the contents of 
two wells initially subcloned at 10  cells/well it is unlikely, although not impossible, that 
they represented eleven different antibodies. The results from affinity ranking on BIAcore 
suggest that only 4 different antibodies are present.
When these antibodies were tested in a competitive ELISA format, none of them displayed 
any significant binding to free 7-hydroxycoumarin (see Figure 3.17). The results from 
previous rounds of screening show that no binding occurs to unconjugated BSA, indicating
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that the antibodies produced are interacting with a combined epitope on the drug-protein 
conjugate. In the light of these findings, the results from the initial titres of mouse serum 
take on a greater importance.
The serum from the immunised mouse was found to bind strongly to EDC/NHS-coupled 7- 
hydroxycoumarin-protein conjugate, but not to the same two components joined via a 
diazonium linkage. The drug molecule in the diazonium conjugate is joined closely to the 
protein (Figure 3.4), whereas the EDC/NHS conjugate contains a two-atom "spacer" 
between drug and protein, due to the use of 7-hydroxycoumarin-4-acetic acid (Figure 3.5). 
As there was no response for mouse serum on a Covalink plate onto which 7- 
hydroxycoumarin-4-acetic acid had been linked via EDC/NHS esterification, the antibodies 
produced by immunisation with an EDC/NHS conjugate appear to be binding to a joint 
epitope consisting of the drug molecule, the "bridge" region, and the protein. Although the 
animal was immunised with an ovalbumin conjugate and antibodies were screened with a 
BSA conjugate, the amino acid residues involved in conjugation are the same for both 
proteins.
Similar findings with regard to the screening of monoclonal antibodies against haptens were 
reported by Danilova (1994). In this study, a range of haptens were coupled to proteins for 
immunisation, and the effect of the coupling chemistry and carrier molecule used to screen 
by ELISA were investigated. In one experiment, the hormone thyroxine was joined to 
keyhole limpet haemocyanin (KLH) by glutaraldehyde, and mice were immunised with this 
conjugate. Hybridoma supernatants were screened by ELISA with an immobilised EDC- 
coupled thyroxine-BSA conjugate. Of six monoclonal antibodies produced from one 
fusion, three did not bind to free thyroxine, and one had only a weak affinity for the 
unconjugated hormone. Although the two conjugates used in this study contained different 
proteins and used different coupling chemistries, in both cases the hormone was linked to 
the protein via lysine groups.
Delcros et al. (1995) also investigated the screening of antibodies against small molecules 
using ligands immobilised by two different chemistries. The polyamines putrescine, 
spermidine and spermine are low molecular weight cations which are necessary for cell 
differentation and growth. Wells of microtitre plates were coated with gelatine, and 
polyamines were immobilised covalently by either reaction with EDC/NHS or 
glutaraldehyde cross-linking. A monoclonal antibody raised against an EDC/NHS-coupled 
spermine-thyroglobulin conjugate was assessed for binding to immoblised polyamines. In
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wells to which the polyamines had been linked via EDC/NHS esterification, antibody 
bound to spermine and spermidine to a similar degree, but very little binding to putrescine 
was observed. These findings were in agreement with the results of equilibrium analysis. 
In wells to which ligands had been coupled using glutaraldehyde, however, the antibody 
exhibited similar levels of binding to all three immobilised polyamines. These results were 
repeated when immunised mouse serum was tested on the same surfaces. The authors 
concluded that the affinities of antibodies for free and immobilised polyamines could not be 
compared, due to structural differences caused by the different immobilisation chemistries 
used. Such structural differences would be much less significant for larger antigens. 
Fasciglione et al. (1996) studied the generation of monoclonal antibodies to the 
hydrophobic haptens theophylline, heme, pyrrolequinoline quinone (PQQ) and the 
pentapeptide Leu-Trp-Gly-Phe-Ala. These haptens were coupled to gelatin, BSA, KLH 
and recombinant hepatitis B core antigen using EDC, and the resultant conjugates were 
used to immunise BALB/c mice. All of the monoclonal antibodies produced bound either 
to the hapten-carrier conjugate or to chemically-modified lysine groups on any carrier 
molecule. None of the antibodies bound to free hapten. The haptens were then coupled to 
highly hydrophilic carriers such as Sepharose and chemically modified poly-L-lysine. 
When these conjugates were used as immunogens, monoclonal antibodies to free hapten 
could be isolated. The authors postulated that the covalent binding of small hydrophobic 
haptens resulted in alterations to the tertiary structure of carrier proteins, causing the 
haptens to be “hidden” inside the protein, and limiting their interaction with the immune 
system. They suggested that this could be avoided by the use of highly hydrophilic carriers 
for hydrophobic haptens.
In order to produce the scFv fragments used in section 3.10, Killard (1998) used a 
diazonium-coupled coumarin-BSA conjugate to pan a naive phage display library, and 
selected three clones. These three antibodies were found not to bind to free coumarin, and 
the binding of the antibodies to drug-protein conjugates appeared to be independent of the 
particular protein used.
As discussed in section 3.4.6, the panning of phage display libraries using microtitre plates 
coated with protein conjugates is in many respects similar to the screening of hybridoma 
supernatants by ELISA. Phage are added to wells of the plate, and those expressing 
specific antibody are allowed to bind. The plate is then washed with a solution containing 
detergent and NaCl, and phage which remain bound are eluted and used to transfect
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bacteria, leading to an enrichment in the number of specific phage. The inability to 
generate antibodies to free coumarin in this fashion, together with the failure to produce 
antibodies to free 7-hydroxycoumarin by somatic cell fusion, may indicate an inherent 
problem with microtitre plate-based screening and selection strategies for antibodies to 
small haptens.
Danilova (1994) recommended that for low molecular weight haptens the conjugate used 
for screening should differ from the immunogen in terms of carrier protein, coupling 
chemistry and the amino acid residue at which conjugation occurs. Even such precautions, 
however, may not be sufficient to overcome some of the fundamental difficulties 
encountered when dealing with small haptens.
A procedure which used a 7-hydroxycoumarin affinity column to purify antibodies specific 
for 7-hydroxycoumarin from a polyclonal antiserum, resulted in a yield of approximately 
4% (H. Reinartz, Personal communication). This indicates that the 7-hydroxycoumarin 
molecule, even when conjugated to a carrier protein, is only weakly immunogenic - 
probably due to its low molecular weight and lack of numerous functional groups. Along 
with the results from antibody screening, this suggests that polyclonal antisera to small, 
weakly immunogenic molecules such as coumarin and 7-hydroxycoumarin function on the 
basis of avidity, and that individual antibodies are likely to have only weak affinities. If this 
assumption is correct, it is probable that the washing steps involved in both panning phage 
libraries and screening hybridoma supernatants actually remove those low affinity 
antibodies directed solely against the drug molecules. This type of solid phase selection 
strategy may thus be biased towards the selection of antibodies to combined hapten/bridge 
region/protein epitopes, which will have a higher affinity.
The use of an optical biosensor such as BIAcore has the potential to obviate the problems 
associated with microtitre-based screening procedures. In addition to the ability to detect 
the binding of low to moderate affinity antibodies in real-time, the use of automated 
BIAcore methods can reduce the time-consuming nature of screening multiple hybridoma 
supernatants by ELISA. However, as stated in section 3.9.3, the injection of neat culture 
supernatants from 48-well plates over an immobilised 7-hydroxycoumarin-BSA surface did 
not give any binding signals, although the same supernatants yielded some positive results 
when assayed by ELISA against the same conjugate. Equilibrium methods such as ELISA 
are more sensitive than BIAcore, and the low number and affinity of antibodies to 7- 
hydroxycoumarin present at the initial screening stage appear to be below the limit of
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detection. Not until cells had reached confluency in 12-well plates could a binding signal 
be obtained for the supernatant. There are no reports in the literature of BIAcore being used 
to screen neat hybridoma supernatants. Bynum et al. (1995) used immunoprécipitation as 
the primary selection method for antibodies against human milk fat globule (HMFG). 
Positive hybridomas were scaled up to 24-well plates and supernatants were then analysed 
by BIAcore. The average signal for the positive supernatants was only 180 RU. 
Unfortunately, then, BIAcore cannot be used - in this application - at the two stages of the 
screening process for which its sample throughput and automation seem ideally suited: 
initial screening and the screening of clones.
The sensorgram obtained for the binding of clone number 3 (Figure 3.19) suggests that 
even the antibodies generated against the combined conjugate epitope may have a weak 
overall affinity. The initial bulk refractive index change appears to mask a rapid association 
phase, and swift dissociation is evident after the end of the sample injection.
As the concentrations of the three purified scFv antibodies to coumarin were known, they 
could be directly affinity ranked using BIAcore (Figure 3.21). BIAcore kinetic software 
was also used to derive observed ka, kj and Ka values for one of the antibody fragments. 
However, the bad fit between the BIAcore data and the dissociation curve based on the 
simple dissociation model (Figure 3.22) indicates a deviation from pseudo-first-order 
kinetics. This could be ascribed to the significant interaction of the scFv with BSA (Figure 
3.18), but it is probable that the nature of the combined drug-protein epitope and the 
number of coumarin molecules on each conjugate molecule (approximately 12  moles of 
coumarin per mole of BSA) contribute to the complexity of the binding events. Such 
heterogeneity of immobilised ligand sites has been reported as the major cause of deviation 
from pseudo-first-order kinetics (O'Shannessy and Winzor, 1996). Bowles et al. (1997) 
found that the binding of monoclonal anti-paraquat antibodies to a paraquat analogue 
covalently immobilised on the BIAcore chip surface displayed marked deviations from 
psuedo-first-order kinetics.
The use of BIAcore to pan a naïve phage display library was also investigated. Bacterial 
cell lysate containing 2.75 x 108 phage particles was injected over an immobilised 7- 
hydroxycoumarin surface. As with the screening of hybridoma supernatants, the sensitivity 
of the instrument was not sufficient to detect binding of specific phage. The flow rate was 
increased, and running buffer passed over the surface, to remove any non-specifically 
bound phage. Glycine buffer was then injected to elute specific phage. Phage counts
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carried out on samples taken during injection, washing and elution phases, show that 
specific elution did take place, with a 10 0 -fold increase in the amount of phage compared to 
samples taken during the washing step. This compares favourably with the 5-fold increase 
in specific phage reported by Malmborg and Borrebaeck (1995) for their model system.
A total of 1.4 x 104 phage were recovered during the elution phase. As these were all 
specific for the immobilised conjugate, and the initial amount of phage injected was 
20,000-fold larger, this represents a 20,000-fold specific enrichment. The lack of an SPR 
signal during the injection is not surprising, considering the small number of specific phage 
present in a naïve library. Malmborg et al. (1996) reported that the binding of 1010 specific 
phage particles was necessary in order to cause a change in SPR angle. A sample from a 
naïve library containing such an amount of specific phage would be viscous in the extreme, 
and impossible to run on the BIAcore. However, by reinfecting bacteria with the eluted 
phage, and continuing this process for several rounds of panning, it seems possible that 
sufficient enrichment to produce a binding signal would eventually occur. Individual 
clones with low to moderate affinity could then be isolated.
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3.13 Summary
A polyclonal antibody to 7-hydroxycoumarin was produced by immunising a rabbit with a 
protein (BSA) conjugate of the drug. The antibody was purified and found to possess 
suitable specificity for use in ELISA techniques. The use of this antibody in a biosensor- 
based immunoassay for 7-hydroxycoumarin will be described in Chapter 4.
BALB/c mice were immunised with another 7-hydroxycoumarin-protein conjugate, and 
found to have a high specific antibody titre by ELISA. Somatic cell fusion using the spleen 
of an immunised mouse, however, failed to generate an antibody against the free drug. 
These results highlighted the limited immunogenicity of small haptens, and accentuated 
some of the problems with screening by ELISA. Although BIAcore was used successfully 
to affinity rank both whole antibodies and scFv fragments for joint drug-protein epitopes, 
the limit of sensitivity of the biosensor rendered it unsuitable for use in the early, labour- 
intensive, stages of screening. Affinity and kinetic constants for the interaction of scFv 
fragments with a drug-protein conjugate was derived using BIAcore, but the heterogeneity 
of the immobilised ligand caused significant deviation from pseudo-first-order kinetics.
The panning of phage display libraries using BIAcore was also investigated. Specific 
elution of phage from a naïve library was demonstrated, and the method may warrant 
further study.
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C H A P T E R  4
T H E  D E V E L O P M E N T  O F  A  B I A c o r e - B A S E D  I N H I B I T I V E  
I M M U N O A S S A Y  F O R  Q U A N T I T A T I V E  
D E T E R M I N A T I O N  O F  T O T A L  7 - H Y D R O X Y C O U M A R I N
I N  S E R U M
4.1 Introduction
This chapter describes the production of a quantitative method for the detection of free 7- 
hydroxycoumarin in human serum samples. Initially, a model immunoassay system for 
drug measurement in phosphate buffered saline (PBS) was set up using an immobilised 
drug-protein conjugate and polyclonal anti-7-hydroxycoumarin antibodies. Standard curves 
using human serum spiked with 7-hydroxycoumarin were then produced, and the molarity 
of enzyme buffer, incubation time of samples with enzyme, and methods for the removal of 
non-specific binding were optimised. The precision, accuracy, percentage recoveries and 
efficiency of regeneration of the assay were assessed, and found to be within suggested 
limits for BIAcore immunoassays.
4.2 Analysis of 7-hydroxycoumarin
Currently, a range of sophisticated techniques, ranging from chromatography and 
spectroscopy to immunoassay and electrochemical detection, exist for the quantitative 
detection of 7-hydroxycoumarin. Some of these methods are suitable for the measurement 
of total drug concentration in complex matrices, although deconjugation of the glucuronide 
conjugate and extensive sample clean-up in the form of solvent extraction are a prerequisite 
for many procedures.
Early methods of 7-hydroxycoumarin analysis included paper chromatography (Feigl et al., 
1955) and colorimetry (Ensminger, 1952), and were crude and generally qualitative in 
nature.
Thin layer chromatography (TLC) is an analytical technique typically involving a silica 
stationary phase onto which sample is applied, and an organic mobile phase which 
facilitates separation of sample components as they migrate along the solid support. The 
method of Indahl and Scheline (1971) allowed the qualitative analysis 7-hydroxycoumarin, 
which was detected by observing fluorescence at 254 nm. The use of TLC to quantitatively 
detect 7-hydroxycomarin in urine samples was reported by Cholerton et al. (1992). In this 
procedure, urine samples were treated with P-glucuronidase and extracted into chloroform, 
and drug levels were measured by fluorescence densitometry. The limit of detection for this 
method was 1 ng/ml.
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High-performance liquid chromatography (HPLC) is a separative technique based upon 
differences in polarity of the analytes. For 7-hydroxycoumarin analysis, reverse phase 
HPLC may be used. In this method, the stationary phase is generally a column containing a 
silica surface with hydrophobic chains of 8 or 18 carbon atoms (termed C8 or C18). The 
analyte is applied to the column in a more polar mobile phase, and binds to the column via 
hydrophobic interactions. Sample components are eluted in order of decreasing polarity, 
and quantitative measurement is usually carried out by measuring absorbance at a defined 
wavelength.
Moran et al. (1987) described a reverse-phase HPLC method for 7- hydroxycoumarin in 
urine, p-glucuronidase was added to urine samples, which were then freeze-dried and 
reconstituted prior to separation. The limit of quantification for this method was 500 ng/ml. 
Egan and O'Kennedy (1992) improved upon the above method by reducing the incubation 
times and amount of enzyme added. Instead of freeze-drying, samples were extracted into 
diethyl ether. The limit of detection of this method was also 500 ng/ml.
Sharifi et al. (1993b) used an extracted 7-hydroxycoumarin glucuronide from rabbit urine as 
a standard, removing the necessity for deconjugation, and allowing measurement of free and 
glucuronidated drug in urine and plasma samples, which were diluted with water and 
methanol prior to analysis. The limit of detection of this method was 0.3 ng/ml, for both 
metabolites.
Bogan and O'Kennedy (1996) reported a similar method for determination of 7- 
hydroxycoumarin and its glucuronide in serum, plasma and urine. No deconjugation step 
was necessary, and samples were treated with trichloroacetic acid before being applied to 
the column. The limit of detection of this method was 50 ng/ml for 7-hydroxycoumarin, 
and 200 ng/ml for its glucuronide.
In a study on 7-ethoxycoumarin O-deethylase activity, Evans and Relling (1992) measured 
7-hydroxycoumarin in reaction mixtures after extraction into chloroform and reconstitution 
with methanol-water. After elution, the drug was detected by fluorescence at 470 nm. A 
limit of quantification of 70 ng/ml was reported.
The in vitro metabolism of 7-hydroxycoumarin to 7-hydroxycoumarin glucuronide by 
uridine diphosphate glucuronyl transferase (UDPGT) was followed using reverse-phase 
HPLC by Killard et al. (1996). TCA was added to samples to precipitate large proteins, and
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a gradient elution method was used. The limit of detection of 7-hydroxycoumarin was 500 
ng/ml.
Gamache et al. (1993) used HPLC with coloumetric array detection to measure 7- 
hydroxycoumarin (and other derivatives) in juice beverages. They reported a limit of 
detection in the order of 1 ng/ml.
Capillary electrophoresis (CE) is a separative technique based on the movement of charged 
species in an applied electric field. Samples migrate through an electrolyte buffer in a 
narrow bore (20 -100  (am in diameter) fused silica capillary by a combination of 
electrophoretic mobility and electroosmotic flow (the characteristic movement of liquid in 
an electric field). The separated sample components are detected by means of UV 
spectroscopy.
Bogan et al. (1995) described a CE method for the quantitative determination of free and 
total 7-hydroxycoumarin in serum and urine samples. Samples were treated with p- 
glucuronidase to deconjugate 7-hydroxycoumarin glucuronide, although this step was found 
to interfere with the separation of internal standard (warfarin). Samples were prepared by 
extracting into diethyl ether and reconstituting with electrolyte buffer. 7-Hydroxycoumarin 
was detected at 2 10  nm and this method had a limit of detection of 1 (ag/ml.
The CE method of Bogan et al. (1996a) allowed the determination of both 7- 
hydroxycoumarin and its glucuronide in urine without the need for deconjugation or 
extraction steps. Detection was at 320 nm, and the reported limit of quantification for 7- 
hydroxycoumarin was 2 (ig/ml.
In comparative studies on the CYP2A6 activity of liver microsomal preparations, levels of 
7-hydroxycoumarin in neat unextracted enzyme reaction mixtures were measured by CE 
(Deasy et al., 1995; Bogan et al., 1996b). Absorbance was monitored at 214 nm, and the 
limit of detection was 1 |ag/ml.
Direct spectroscopic analyses, which exploit the characteristic absorbance and fluorescence 
of the compound, have also been reported for the detection of 7-hydroxycoumarin.
Tan et al. (1976) reported a spectrofluorimetric method for the determination of 7- 
hydroxycoumarin in whole blood. Samples were extracted first into ether and then into 
glycine buffer, and the fluorescence was measured at excitation and emission wavelengths 
of, respectively, 370 and 450 nm. In a further study (Ritschel et al., 1977), samples were
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treated with P-glucuronidase prior to estimation of total 7-hydroxycoumarin concentrations. 
The limit of detection in the above methods was 1 ng/ml. Direct fluorimetry using the 
above wavelengths has also been used to investigate the binding of 7-hydroxycoumarin to 
serum proteins and red blood cells (Ritschel et al., 1981). In a study on liver microsome 
preparations of eight different species, fluorimetry was used - following TCA precipitation - 
to determine coumarin 7-hydroxylase activity and its inhibition by antibodies specific for 
cytochrome P450 (Kaipainen et al., 1985).
Conway et al. (1984) described a novel method for monitoring the p-glucuronidation of 7- 
hydroxycoumarin, in which a fluorimeter was linked to microlight guides on the surface of 
liver samples by optical fibres. The decrease in content of 7-hydroxycoumarin was 
followed using excitation and emission wavelengths of 366 nm and 450 nm, respectively. 
Rautio et al. (1992) and Iscan et al. (1994) both reported the use of a spectrofluorimetric 
assay for detection of 7-hydroxycoumarin in urine. Samples were treated with P- 
glucuronidase and extracted into chloroform prior to analysis, and the method had a limit of 
detection of 5 nM. In a separate study, a similar method was used to investigate the effect 
of grapefruit juice on coumarin 7-hydroxylase activity (Merkel el al., 1994).
Egan and O'Kennedy (1993a) described a spectrofluorimetric microassay for measuring 7- 
hydroxycoumarin levels in urine and plasma. Both neat samples and samples extracted into 
diethyl ether were used, with similar results. The assay was performed in 96-well microtitre 
plates, and the limit of detection was 0.5 (j,g/ml.
In addition to spectrographic and separative techniques, immunoanalytical methods have 
also been used for the determination of 7-hydroxycoumarin.
Egan and O'Kennedy (1993b) reported an antigen-inhibition enzyme-linked immunosorbent 
assay (ELISA) for 7-hydroxycoumarin in urine. A protein conjugate of 7-hydroxycoumarin 
is coated onto microtitre plates, and urine samples are added to wells, along with polyclonal 
antibodies to 7-hydroxycoumarin. Free and immobilised drug compete for antibody binding 
sites, and, following the addition of a secondary labelled anti-species antibody, and colour 
development with a chromogenic substrate (oriAo-phenylenediamine), the increase in 
absorbance is inversely proportional to the concentration of 7-hydroxycoumarin. The 
immunoassay had a limit of detection of 0.5 |j,g/ml.
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Reinartz et al. (1996) described a one-step antigen-inhibition ELISA for 7- 
hydroxyconmarinin urine samples. A bispecific antibody, specific for both 7- 
hydroxycoumarin and alkaline phosphatase, was produced chemically. The dual activity of 
the antibody obviated the need for a secondary enzyme-labelled antibody. Microtitre plate 
wells were coated with 7-hyroxycoumarin-BSA, and urine samples or standards, bispecific 
antibody, and alkaline phosphatase were added. A chromogenic substrate for alkaline 
phosphatase (para-nitrophenol phosphate) was added, and absorbance at 414 nm was 
measured. The limit of detection of this method was 20 ng/ml for free 7-hydroxycoumarin. 
For determination of total drug, a deconjugation step was necessary. P-glucuronidase was 
added to samples, which were then diluted before analysis. For total 7-hydroxycoumarin 
detection, the limit of quantification was 30 ng/ml. When samples were extracted into 
diethyl ether and reconstituted with PBS, concentrations as low as 6 ng/ml could be 
detected.
Dempsey et al. (1993a) developed an electrochemical immunosensor for 7- 
hydroxycoumarin measurement. Polyclonal antibodies to the drug were immobilised on the 
surface of a glassy carbon electrode, behind a permeable cellulose dialysis membrane. 
Binding of drug to antibody results in a decrease in electroactivity, as detected by DC 
amperometry. The limit of detection of the sensor system was 10 (J.M.
Deasy et al. (1994) described an enzyme-linked competitive electrochemical immunosensor 
for detection of 7-hydroxycoumarin. 7-hydroxycoumarin-thyroglobulin was immobilised at 
the surface of a glassy carbon electrode. Antibodies to 7-hydroxycoumarin labelled with 
horseradish peroxidase (HRP) were mixed with standard solutions of the drug, and the 
electrode was added. Excess labelled antibody bound to the immobilised conjugate and, 
after washing and addition of substrate (hydrogen peroxide), the electroactivity of the HRP 
at the electrode surface was inversely proportional to the amount of 7-hyroxycoumarin in 
the original sample, and was determined by DC voltammetry. The limit of quantification 
for the sensor was 24 (J.M.
Lu et al. (1996) reported the use of a regenerable enzyme immunosensor for 7- 
hydroxycoumarin. The assay format was similar to that described by Deasy et al. (1994), 
except that potassium ferrocyanide (a mediator in the enzyme reaction) was present, and the 
sensor surface could be regenerated by washing with 10 mM HC1.
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Direct electroanalysis has also been utilised for the detection of 7-hydroxycoumarin. 
Dempsey et al. (1993b) used differential pulse voltammetry to measure total drug levels in 
urine, following treatment with P-glucuronidase, extraction, and reconstitution into 
methanol. Carrazon et al (1989) used a range of voltammetric techniques to detect 7- 
hydroxycoumarin in micelles and emulsions. Using differential pulse voltammetry with a 
rotating glassy carbon electrode they achieved a limit of detection of 0.28 pM.
To summarise, a wide variety of analytical approaches have been reported for the detection 
of 7-hydroxycoumarin. Chromatographic, spectroscopic, immunological, biosensor and 
electroanalytical techniques have all been used, and sample matrices have ranged from urine 
and plasma to fruit juices and foodstuffs. Table 4.1 lists the different methods of detection, 
and indicates whether deconjugation and extraction methods were used.
4.3 BIAcore and the measurement of low molecular weight analytes
For molecules of low molecular weight (less than 2000), the mass change caused by binding 
to the BIAcore sensor surface is too small to result in a change in SPR signal. When 
developing BIAcore-based assays for the quantitative determination of low molecular 
weight analytes such as drug molecules, then, it is necessary to use an indirect sensing 
method, of which there are two main types: inhibition and competitive.
Inhibition formats are analagous to the antigen-inhibition ELISA methods described in 
section 4.2. The analyte (or an analogue or protein conjugate) is immobilised on the sensor 
chip, and samples containing analyte are mixed with a high molecular weight interactant 
(for example, specific antibody). When the mixture is passed over the sensor chip, excess 
antibody binds to the immobilised surface, giving a change in relative response inversely 
proportional to the amount of analyte free in solution.
In competitive techniques the antibody (or other interactant) is immobilised on the sensor 
chip. Sample is mixed with a high molecular weight analogue, and the mixture passed over 
the antibody surface. The increase in SPR signal is due to the binding of the high 
molecular weight component, and, as with the inhibitive method, is inversely proportional 
to the amount of analyte in the sample.
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Table 4.1 Summary of reported methods of 7-hydroxycoumarin analysis.
M ethod Sample Matrix Enzyme
Added
Clean-up LOD Reference
TLC Urine Yes Extraction 1 ng/m1 Cholerton et al., 1992
HPLC Urine Yes Freeze-drying 0.5 ng/ml Moran et al., 1987
Urine Yes Extraction 0.5 ng/ml Egan and O'Kennedy, 1992
Urine No Dilution 0.3 ng/ml Sharifi el al., 1993 b
Urine No TCA 50 ng/ml Bogan and O'Kennedy, 1996
Enzyme Reaction 
Mixture
- Extraction 70 ng/ml Evans and Relling, 1992
Enzyme Reaction 
Mixture
■ TCA 0.5 ng/ml Killard et al., 1996
Juice Drinks - None 1 ng/ml Gamache et al., 1993
CE Serum, Urine Yes Extraction 1 ng/ml Bogan elal., 1995
Urine No None 2 ng/ml Bogan et al., 1993a
Enzyme Reaction 
Mixture
- None 1 ng/ml Deasy etal., 1995
Enzyme Reaction 
Mixture
- None 1 ng/ml Bogan et al., 1993b
Fluorimetry Whole Blood - Extraction 1 ng/ml Tan etal., 1976
Whole Blood Yes Extraction 1 ng/ml Ritschel et al., 1977
Microsome
Preparation
- TCA - Kaipainen el al., 1985
Liver Samples - None . Conway et al., 1984
Urine Yes Extraction 5 nM Rautio el al., 1992
Urine Yes Extraction 5nM Iscan etal., 1994
Urine Yes Extraction - Merkel et al., 1994
Urine, Plasma - None .5 ng/ml Egan and O’Kennedy, 1993a
ELISA Urine - None .5 ng/ml Egan and O Kennedy, 1993b
Urine Yes Dilution 30 ng/ml Reinartz et al., 1996
Immunosensor Buffer - - 10 nM Dempsey et al., 1993a
Buffer - - 24 nM Deasy etal., 1994
Buffer _ . - Lu et al., 1996
Voltammetry Urine Yes Extraction - Dempsey et al., 1993b
Micellar Preps - None 0.28 nM Carrazon et al., 1989
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Wagner et al. (1995) described the use of an inhibition technique to detect the pesticide 2,4- 
dichlorophenoxyacetic acid in tobacco extracts using the BIAlite instrument. A protein 
conjugate of the pesticide was immobilised on the sensor chip, and extracted tobacco 
samples were mixed with antibody and passed over this surface. Recoveries from spiked 
samples in the order of 90 - 95% were reported, with detection limits in the low ppm range 
using polyclonal antiserum, which were reduced to the ppb range with the use of 
monoclonal antibodies.
A BIAcore inhibition immunoassay for the determination of the antibiotics sulphametazine 
and enrofloxacin has been reported by Stemesjo et al. (1995), with limits of detection in the 
low ppb range.
Minunni and Mascini (1993) developed an indirect inhibition assay for the analysis of the 
pesticide atrazine in drinking water, which employed a monoclonal antibody for primary 
detection, and a polyclonal antibody for signal enhancement.
Vitamin levels in food were studied by Haines et al. (1995). They measured the 
concentration of biotin and folic acid in homogenized and clarified food extracts using 
monoclonal antibodies in an inhibition immunoassay format, and their reported results 
compared well to those obtained with standard microbiological assays.
Haines and Patel (1995) reported a BIAcore inhibition assay for the detection of the food 
borne pathogens Salmonella and Listeria. Polyclonal antibodies to bacterial cell wall 
antigens were added to cultures of food samples. The culture was filtered at 0.22 (j,m to 
remove all bacteria, and the filtrate passed over a BIAcore sensor chip bearing an 
immobilised anti-Fab antibody. Free antibody bound to the surface, giving a signal 
inversely proportional to the amount of bacteria in the original culture sample.
In a paper reporting a BIAcore method for the determination of antibody concentration, 
Wong et al. (1997) noted that few guidelines for the validation of BIAcore assays existed, 
although the system has been in use since 1990. They recommended the values of a range 
of parameters for the validation of quantitative BIAcore assays, including percentage 
recoveries, inter- and intra-day coefficients of variation, and baseline shift and rebinding 
after regeneration.
In light of the number of BIAcore inhibition immunoassays reported in the literature, this 
assay format was chosen for the development of a quantitative method for detection of 7-
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hydroxycoumarin in complex biological samples. A schematic diagram of the proposed 
system, with immobilised drug-protein conjugate and free polyclonal antibody, is given in 
Figure 4.1.
Results
4.4 Model system for 7-hydroxycoumarin measurement in PBS
To establish the basis for a method to quantitatively detect levels of 7-hydroxycoumarin in 
serum, a model system for the measurement of the drug in PBS was set up. The running 
buffer for all the following experiments was HBS, pH 7.4, as described in section 2.9, and a 
flow rate of 10  fil/min was used throughout.
The first step in the development of the assay was the immobilisation of a diazo-coupled 7- 
hydroxycoumarin-BSA conjugate. The immobilisation chemistry used was EDC-mediated 
N-hydroxysuccinimide esterification. The reaction scheme is shown in Figure 4.2. As 
discussed in section 2.9.1, this coupling method involves binding to the carboxymethylated 
surface via amine groups, and requires preconcentration of protein to the dextran layer by 
lowering the pH of solution to below the isoelectric point. A preconcentration study of 7- 
hydroxycoumarin-BSA was carried out as in section 2.9.1, with conjugate solutions in 10 
mM sodium acetate at varying pHs being injected over an underivatised chip. From the 
results (Figure 4.3), it can be seen that the optimum pH for immobilisation is 4.0. This is 
the lowest recommended pH for immobilisation on BIAcore sensor chips, as below this 
value protonation of carboxy groups causes collapse of the gel matrix and decreased 
mobility of attached biomoleules. A 2 mg/ml solution of 7-hydroxycoumarin-BSA in 10 
mM sodium acetate, pH 4.0, was immobilised as in section 2.9.2.
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Figure 4.1 Schematic representation of the BIAcore inhibitive immunoassay format for 
quantitative determination of 7-hydroxycoumarin. Standards and samples containing 7- 
hydroxycoumarin are premixed with antibody and injected over an immobilised 7- 
hydroxycoumarin-BSA surface. Excess antibody binds to the sensor surface, and the 
signals are recorded and a standard curve constructed.
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Figure 4.2 NHS/EDC coupling of proteins to the BIAcore sensor chip surface. Protein at 
a pH lower than its isolectric point is injected over the surface following EDC-mediated 
NHS derivatisation. Unreacted sites are capped with ethanolamine.
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F igu re  4.3 Overlay plot showing the preconcentration profile for 7-hydroxycoumarin- 
BSA. Conjugate at 100 p.g/ml in 10 mM sodium acetate at pH 6.0, 5.5, 5.0, 4.5, and 4.0 
was injected over an underivatised sensor chip surface, and the degree of electrostatic 
binding was monitored. The optimal pH for preconcentration is 4.0.
Time (Sec)
149
The chip surface was activated with a mixture of EDC and NHS, and the conjugate solution 
was injected over the activated surface - unreacted groups were then capped by injection of 
1M ethanolamine/HCl, pH 8.5. A typical sensorgram for immobilisation of 7- 
hydroxycoumarin-BSA is shown in Figure 4.4.
A number of standards of 7-hydroxycoumarin, ranging from 0.1 to 50 fig/ml, were prepared 
by diluting a stock solution of the drug (1 mg/ml in a mixture of 30% (v/v) ethanol : 70% 
(v/v) PBS) in PBS. Purified polyclonal antibody to 7-hydroxycoumarin (see Chapter 3), at a 
concentration of 0.7 mg/ml in PBS, was then mixed with an equal volume of standard. The 
mixture was incubated for 5 minutes at room temperature and then a 20 |_d aliquot was 
injected over a chip surface on which approximately 10,000 RU of 7-hydroxycoumarin- 
BSA had been immobilised. The surface was regenerated by injection of 10 fil of the 
following sequence of reagents: 5 mM NaOH, 20 mM HC1, and 5 mM NaOH.
After regeneration, the next standard-antibody mixture was injected. A typical sensorgram 
showing binding and regeneration for a single standard is shown in Figure 4.5. A 
calibration curve was produced by plotting the change in response for each standard (caused 
by the binding of excess antibody in each sample to the immobilised conjugate) against the 
concentration of 7-hydroxycoumarin (Figure 4.6). The standard curve for this model system 
is linear in the range 0.1 - 50 |ig/ml, with an r2 value of 0.99.
4.5 Development of serum-based assay
Having constructed a standard curve for 7-hydroxycoumarin in PBS and demonstrated the 
principle of the inhibitive immunoassay system, an analytical method for the determination 
of drug levels in human serum, incorporating a deconjugation step for 7-hydroxycoumarin 
glucuronide in samples, was optimised and validated.
4.5.1 Non-specific binding of polyclonal antibody to BSA
Binding of the polyclonal antibody to the BSA of the conjugate immobilised on the sensor 
chip would result in high background signals and have a damaging effect on the sensitivity 
of the assay. The extent of non-specific binding was assessed by immobilising similar 
amounts of 7-hydroxycoumarin-BSA and unconjugated BSA (10,000 and 13,000 RU 
respectively) on separate flow cells, as in section 2.9.3.
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F igure  4.4 Typical sensorgram from immobilisation of 7-hydroxycoumarin-BSA. (A) 
Sensor chip surface is derivatised with a mixture of EDC and NHS. (B ) Conjugate at 2 
mg/ml in lOmM sodium acetate, pH 4.0, is injected over this surface for 20 minutes (C ) 
Unreacted sites are capped by injection of ethanolamine.
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F igure  4.5 A typical sensorgram for one standard from the BIAcore 7-hydroxycoumarin 
immunoassay. (A) Standard containing free drug is mixed with antibody and injected 
over a 7-hydroxycoumarin-BSA surface; the binding signal is inversely proportional to 
the amount of drug in the sample mixture. The surface is then regenerated by one minute 
pulses of 5mM NaOH (B), 20mM HC1 (C), and 5mM NaOH (D).
Time (Sec)
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F igu re  4.6 Standard curve for 7-hydroxycoumarin from BIAcore immunoassay model 
system. A range of 7-hydroxycoumarin standards was prepared in PBS, mixed with 
polyclonal antibody, and injected over a 7-hydroxycoumarin-BSA surface. The standard 
curve is linear over the range 0 .1 -5 0  p,g/ml.
Log of 7-OHC conc (ug/ml)
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Polyclonal anti-7-hydroxycoumarin at a concentration of 0.25 mg/ml in PBS 
(approximating to the working dilution after mixing with sample) was passed over both 
surfaces (Figure 4.7). Binding of antibody to native BSA was shown to be negligible - 4 
RU compared to 235 RU for the conjugate surface - under these assay conditions.
4.5.2 Cross-reactivity of polyclonal antibody to 7-hydroxycoumarin
glucuronide
The specificity of polyclonal antibody is of critical importance for the performance of the 
immunoassay. Antibody (0.7 mg/ml in PBS) was mixed with 7-hydroxycoumarin at 50 
|ig/ml in human serum, 7-hydroxycoumarin glucuronide at 40 (ig/ml in human serum, and 
control serum. These three samples were then injected over a 7-hydroxycoumarin-BSA 
surface. An overlay plot of the sensorgrams for the free drug and glucuronide samples is 
shown in Figure 4.8.
The binding of the sample containing free drug is much lower than that of the glucuronide 
sample, which gives the same response as the control, in which no 7-hydroxycoumarin was 
present. This demonstrates that - within the parameters of the BIAcore assay - the antibody 
exhibits no cross-reactivity to the glucuronidated form of 7-hydroxycoumarin.
4.5.3 Optimisation of enzyme buffer molarity
The enzyme [3-glucuronidase can be used to deconjugate 7-hydroxycoumarin glucuronide, 
producing free 7-hydroxycoumarin and glucuronic acid. The enzyme has an optimum pH of 
5.0, and in previously reported HPLC and CE assays (Egan and O'Kennedy, 1992; Bogan et 
al., 1995) has been used at a concentration of 5000 units/ml in 1M sodium acetate, pH 5.0. 
In an immunologically-based assay, however, a buffer of such high ionic strenth might 
reasonably be expected to interfere with antibody activity. To investigate the optimal 
molarity of enzyme buffer, 7-hydroxycoumarin glucuronide solutions at a range of 
concentrations (50, 40 and 20 fag/ml) were added to equal volumes of enzyme solution in 
differing molarities of buffer (5,000 U/ml p-glucuronidase in 10 mM, 100 mM and 1 M 
sodium acetate, pH 5.0). These samples were incubated for 2 hours at 37°C, then mixed 
with antibody and injected over a 7-hydroxycoumarin-BSA surface (Figure 4.9).
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Figure 4.7 An overlay plot showing the interaction of polyclonal serum with a 7- 
hydroxycoumarin-BSA surface (10000 RU immobilised), and a native BSA surface 
(13000 RU immobilised). The degree of non-specific binding of antibody to BSA (4 RU) 
is not significant when compared to the response on the conjugate surface (235 RU).
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Figure 4.8 Overlay plot demonstrating the degree of cross reactivity of polyclonal 
antiserum with 7-hydroxycoumarin glucuronide. Antibody was mixed with both free and 
glucuronidated forms of 7-hydroxycoumarin and injected over an immobilised 7- 
hydroxycoumarin-BSA surface. No unbound antibody remains in the free drug sample (- 
6 RU), and the signal from the glucuronide sample (323 RU) indicates that the polyclonal 
antibody does not display any significant cross-reactivity for 7-hydroxycoumarin. The 
small negative signal for the 7-hydroxycoumarin sample represents some removal of non- 
covalently bound conjugate from the sensor surface.
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Figure 4.9 Optimisation of enzyme buffer molarity. Human serum was spiked with 50, 
40 and 20 jag/ml of 7-hydroxycoumarin glucuronide and these samples were mixed with 
5000 units/ml of p-glucuronidase in lOmM, lOOmM and 1M sodium acetate, pH 5.0. 
Antibody was then added to the samples, and they were injected over a 7- 
hydroxycoumarin-BSA surface. The samples in lOOmM sodium acetate show good 
differences in response for the different concentrations, whereas lOmM acetate seems 
insufficient to buffer the enzyme, and the ionic strength of 1 M sodium acetate appears to 
disrupt antibody-antigen binding.
Log of 7-OHC conc (ug/ml)
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The results show that enzyme in 10 mM sodium acetate is not deconjugating the 
glucuronide at higher concentrations, presumably due to insufficient buffering power. The 
three samples in 1 M acetate, however, give virtually the same response, suggesting that the 
ionic strength of the enzyme solution is disrupting antibody-antigen interactions. 100 mM 
soldium acetate was chosen as the enzyme buffer for the assay, as the response for this set of 
samples clearly increases with increased concentration of glucuronide conjugate. An 
incubation time for samples with enzyme solution of 2 hours at 37°C was chosen to ensure 
that the enzyme reaction had run to completion.
4.5.4 Removal of serum non-specific binding
The use of a complex matrix such as human serum in the assay introduced problems with 
non-specific binding. Injections of neat serum over BIAcore sensor chips, both 
underivatised and with immobilised conjugate, resulted in high background responses due to 
binding of components in the serum to the protein moiety of 7-hydroxycoumarin-BSA and 
to the dextran layer on the chips.
In order to reduce these interactions, which would be damaging to assay performance, a 
diluent buffer containing BSA, carboxymethylated dextran and Tween 20 was prepared. 
Human serum was mixed and incubated for 10 minutes at room temperature with equal 
volumes of both PBS and diluent buffer (PBS containing 4% (w/v) BSA, 4 mg/ml 
carboxymethylated dextran and 0.2% (v/v) Tween 20), and both solutions were injected 
over an immobilised 7-hydroxycoumarin-BSA surface (Figure 4.10). Preincubation with 
the mixture of protein, CM-dextran and detergent effectively removed the non-specific 
binding of the serum sample. To avoid additional dilution and incubation steps in the assay, 
this mixture was used as the antibody diluent buffer, and the incubation time of samples 
with antibody was extended from 5 minutes to 10 minutes.
4.5.5 Efficiency of regeneration
One minute pulses of 5 mM NaOH, 20 mM HC1 and 5 mM NaOH in sequence were 
injected over the sensor chip surface after each standard and sample injection to remove 
bound antibody.
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Figure 4.10 Removal of non-specific serum binding by diluent buffer. Human serum 
was mixed 1:1 with both PBS and diluent buffer (PBS containing 4% (w/v) BSA, 4 
mg/ml CM-dextran and 0.02% (v/v) Tween 20), and passed over an immobilised 7- 
hydroxycoumarin surface. Pre-mixing of sample with the diluent buffer effectively 
removes non-specific binding of serum components to the sensor surface. Although the 
sample containing diluent buffer produces a high initial bulk refractive index change (due 
to its protein content), no significant change in relative response is seen after the injection. 
The small negative signal (-6 RU) is probably due to the removal of non-covalently bound 
conjugate from the surface by the action of the detergent.
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To assess the efficiency of this regeneration process, antibody solution (1/200 in PBS) was 
injected over this surface and regenerated, and this cycle was repeated for 65 cycles. The 
absolute response after regeneration decreased by only 2% over the 65 cycles, and Figure
4.11 shows that the signal produced by binding of antibody stayed within 20% of the initial 
response for 64 cycles. This indicates that the surface is stable over 64 regeneration cycles.
4.5.6 Linear range
The final optimised immunoassay format for 7-hydroxycoumarin is as shown in Figure 
4.12, and is described in section 2.9.3. An overlay plot of the binding curves for a typical 
set of standards is shown in Figure 4.13, and a standard curve of relative response against 
concentration of 7-hydroxycoumarin in serum is given in Figure 4.14. The assay is linear 
over the range 0.5 - 80 jig/ml, with typical r2 values of 0.99.
4.5.7 Recoveries of 7-hydroxycoumarin from spiked samples
The percentage recoveries of 7-hydroxycoumarin from samples spiked with 7- 
hydroxycoumarin glucuronide were calculated as described in section 2.9.3. Known 
amounts of 7-hydroxycoumarin glucuronide were added to human serum and these spiked 
samples, along with standards containing unconjugated 7-hydroxycoumarin, were mixed 
with P-glucuronidase and assayed for free drug. Their concentrations were read from the 
standard curve, and the percentage recoveries were calculated from the ratio of the 
molecular weights of both metabolites (Table 4.2). The calculated recoveries for a set of 
three replicates of five spiked samples were in the range 95.4 -  103.2%.
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Figure 4.11 Regeneration profile for an immobilised 7-hydroxycoumarin-BSA surface. 
A 1/200 dilution of purified polyclonal anti-7-hydroxycoumarin was injected over the 
surface, and regenerated with 5 mM NaOH and 20 mM HC1. After 64 cycles of binding 
and regeneration, the response after injection of antibody (130.5 RU) was within 20% of 
the original signal (156.8 RU).
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Figure 4.12 Flow diagram o f  BIAcore 7-hydroxycoumarin immunoassay.
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Figure 4.13 An overlay plot for a typical set o f  binding curves. 7-hydroxycoumarin 
standards containing 0.5 - 80 ug/ml o f  free drug were mixed with antibody and injected 
over a 7-hydroxycoumarin-BSA surface.
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Figure 4.14 Linear range o f  the BIAcore 7-hydroxycoumarin assay in serum. Standards 
from 0.5 - 80 |xg/ml were prepared, mixed with p-glucuronidase and antibody and 
injected over the sensor surface. BIA Concentration Evaluation software was used to fit 
the data to a smoothed spline model.
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Table 4.2 Percentage recoveries for the BIAcore 7-hydroxycoumarin assay. Human 
serum was spiked with varying concentrations o f  7-hydroxycoumarin glucuronide, 0- 
glucuronide was then added, and the samples assayed for deconjugated 7- 
hydroxycoumarin. Percentage recoveries were determined on the basis o f  the ratio 
between the molecular weights o f  the two metabolites. Standard variations (S.D.s) were 
calculated for three replicates o f  each sample.
7-OHC concentration 
(pg/ml)
% Recovery ± S.D. 
(n=3)
Coefficient of variation
(%)
37.08 97.8 ± 4 .7 4.84
18.54 95.4 + 8.4 8.85
13.91 99.8 ± 5 .8 5.83
9.27 103.2 ± 6 .0 5.81
4.64 101.9 ± 0 .0 0.0
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4.5.8 Intra-day variability
The intra-day variability o f  the assay was investigated by running a set o f five standards 
across the linear range five times in one day, and determining the coefficient o f  variation 
(CV) between the calculated 7-hydroxycoumarin concentrations for each set o f  five (Table 
4.3). Intra-day CVs ranged from 1.93% to 8.2%.
4.5.9 Inter-day variability
The inter-day variability o f  the assay was investigated by running five sets o f  standards 
across the linear range five times on five different days, and determining the CV between 
the calculated 7-hydroxycoumarin concentrations for the standards from each o f  the five 
curves (Table 4.4). Intra-day CVs ranged from 5.02% to 8.76%.
4.6 Urine analysis
The quantitative determination o f  7-hydroxycoumarin in urine samples was also 
investigated. Using a method otherwise identical to that for analysis in serum, standards and 
samples were prepared in control urine and assayed for the presence o f  free drug, following 
treatment with (3-glucuronidase. Although a standard curve with an r2 value o f  0.99 and a 
linear range o f  0.5 - 50 jag/ml (Figure 4.15) could be constructed, and recoveries in the 
range 95 - 105% were demonstrated, analysis in urine displayed very poor reproducibility.
1 6 6
Table 4.3 Intra-day coefficients o f variation for the BIAcore 7-hydroxycoumarin assay. 
Five sets o f  five standards were run on the same day and the coefficients o f  variation 
(CVs) between the calculated concentrations from the standard curve were determined.
7-OHC concentration 
(Hg/ml)
Calculated mean ± S.D.
(jag/ml)
Coefficient of variation
(%)
5 5.36 ±0.39 7.26
10 9.95 ±0.15 1.93
15 14.29 ± 0.54 3.78
20 19.19 ±0.68 3.44
40 41.11 ±3.34 8.20
Table 4.4 Inter-day coefficients o f  variation for the BIAcore 7-hydroxycoumarin assay. 
Five sets o f  five standards were run on five different days, and the CVs between the 
calculated values from each standard curve were calculated.
7-OHC concentration 
Og/ml)
Calculated mean ± S.D.
(|ig/ml)
Coefficient of variation
(%)
5 4.62 ± 0.29 6.31
10 11.22 ±0.56 5.02
15 15.99 ±1.40 8.76
20 18.66 ± 1.00 5.02
40 39.16 ±2.23 6.31
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Figure 4.15 Standard curve for BIAcore 7-hydroxycoumarin immunoassay in urine. 
Free drug was spiked into neat control urine, and the samples were assayed without an 
extraction step. The linear range is 5- 100 (J.g/ml, although the method is not very 
reproducible, probably as a result o f  batch-to-batch differences in pH and ionic strength o f  
control urine.
Log of 7-OHC conc (ug/ml)
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4.7 Discussion
A  model system for 7-hydroxycoumarin detection in PBS was first established. The first 
step in setting up the immunoassay system was the immobilisation o f  7-hydroxycoumarin 
BSA. The results o f  the preconcentration study (Figure 4.3) show that electrostatic binding 
o f the drug-protein conjugate is not evident until the pH o f  solution is lowered to 4.5. 
Comparing this to the pi for native BSA (5.1) demonstrates the effect o f  chemically 
modifying the protein, underlining the need for preliminary optimisation o f  preconcentration 
in order to conserve sample and save time. By using the RECOVERY facility on the 
BIAcore during these investigations, the quantity o f  conjugate used can be kept to a 
minimum.
Immobilisation o f  7-hydroxycoumarin was carried out by means o f  a defined chemisty, and 
was highly reproducible, resulting in approximately 10,000 RU o f  conjugate being bound to 
the chip. This responds to a protein concentration at the sensor surface o f  10 ng/mm2.
A  model inhibition immunoassay was then developed, in which 7-hydroxycoumarin 
standards in PBS were mixed with polyclonal antiserum to the drug and injected over the 
immobilised surface. The high concentration o f  antibody used (700 jag/ml) is due to the fact 
that the antibody preparation was only partially purified by protein G chromatography, and 
also reflects the small number o f  specific antibodies present in antisera raised against a drug- 
carrier immunogen (Heiko Reinartz, Personal communication). The assay had a linear 
range o f  100 ng/ml to 50 p.g/ml, and displayed excellent linearity.
Having shown that the polyclonal antibody was suitable for use in an assay o f  this type, and 
that the antibody-antigen binding was regenerable, the aim was to develop a method for 
detection o f total 7-hydroxycoumarin in complex biological matrices.
The main limiting factor in the sensitivity o f any immunoassay is the affinity and specificity 
o f the antibody used. Figure 4.7 shows that there is no binding o f polyclonal antibody to 
immobilised BSA. It is interesting to note, however, that in the course o f  screening for 
monoclonal antibody production by ELISA (see Chapter Three) - an assay format involving 
long incubation steps - the same antibody was shown to bind significantly to control wells 
coated with BSA. The short contact time between sample and sensor surface in the BIAcore 
system appears to minimise this non-specific interaction.
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The antibody was also shown not to bind significantly to 7-hydroxycoumarin glucuronide 
(Figure 4.8). This finding (not surprising, in view o f the fact that glucuronic acid is attached 
at the 7-position) meant that, as with all o f  the other immunologically-based detection 
methods discussed above, deconjugation o f the glucuronide conjugate by p-glucuronidase 
would be necessary for determination o f total 7-hydroxycoumarin content o f  samples. 
Reinartz e t  a l .  (1996) used 5000 units/ml o f enzyme in 1 M sodium acetate, pH 5.0, in an 
antigen-inhibition ELISA for estimation o f  total 7-hydroxycoumarin, but performed a 1:10 
dilution o f  sample prior to addition o f  sample to microtitre plate wells. Several molarities o f  
enzyme buffer were investigated for use in the BIAcore assay (Figure 4.9), in an attempt to 
find an concentration o f sodium acetate at which both the enyme reaction and the antibody- 
antigen interaction could occur, thus removing the need for dilution or other pretreatment o f  
sample. 100 mM sodium acetate was found to be suitable.
The majority o f  the previously reported methods o f  7-hydroxycoumarin analysis have 
involved sample clean-up, in the form o f extraction and reconstitution, dilution, freeze- 
drying, or precipitation o f  proteins with TCA. I f such a step were to be avoided for the 
BIAcore immunoassay, it was clear that the background binding o f  serum components to 
the sensor surface would have to be reduced. Human serum gave a significant binding 
signal when injected over both underivatised flow cells and 7-hydroxycoumarin-BSA 
surfaces. It was thought that the addition o f  carboxylated dextran and BSA to serum 
samples might absorb out substances which were binding to these components, and Figure 
4.10 shows that incubation with CM-dextran and BSA in a diluent buffer, together with the 
detergent effects o f  Tween 20, effectively remove non-specific binding o f  serum. This 
mixture was then used as the antibody diluent.
When an inhibitive immunoassay incorporating deconjugation and removal o f non-specific 
binding in neat serum samples was performed, it had a linear range o f  500 ng/ml to 80 
ja,g/ml. The limit o f detection is thus 2.5 times higher than that for the model system (taking 
into account the extra dilution step with enzyme). In addition, by comparing Figures 4.6 
and 4.4, it can be seen that the relative responses for the standards in the model system range 
from 100 - 600 RU, whereas those for the assay in serum are between 10 and 170 RU. 
However, by the time the more complex sample is injected over the chip surface, it contains 
serum, 7-hydroxycoumarin, p-glucuronidase, sodium acetate, PBS, CM-dextran, BSA,
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Tween 20 and polyclonal antibody, and immunoanalytical detection in such a complex 
matrix is obviously only achieved at the expense o f  sensitivity.
The regeneration o f  immunosensors is o f  critical importance for their performance. The 
antibody-antigen interaction at the sensor surface in this assay was disrupted by brief (1 
minute) pulses o f  alternating low molarity base and acid. The change in pH between the 
two solutions is sufficient to regenerate the surface. Wong e t  a l .  (1997) recommended that 
the two criteria o f  baseline shift and binding capacity should be used for evaluating 
regeneration:. The absolute response o f  immobilised 7-hydroxycoumarin-BSA after 65 
regeneration cycles decreases by only 2%, while Figure 4.11 shows that the rebinding o f  
antibody to this surface remains within 20% o f the initial response for 64 cycles. Wong e t  
a l .  considered an immobilised surface to be stable while the rebinding signal was within this 
20% value.
When samples containing 7-hydroxycoumarin glucuronide were assayed along with a range 
o f 7-hydroxycoumarin standards, the recoveries o f free drug were all close to 100%, over 3 
replicates (Table 4.2). This indicates that the deconjugation process is highly efficient. 
Inter-day and intra-day coefficients o f  variation for the method are all below 8.76% for 5 
replicates (Tables 4.3 and 4.4). Both the percentage recoveries and coefficients are within 
the limits recommended by Wong e t  a l .  (1997).
Overall, the BIAcore inhibitive immunoassay for quantitative determination o f  total 7- 
hydroxycoumarin in serum compares well with the analytical methods listed in Table 4.1. 
Although some o f  the other techniques do have lower limits o f  detection, all o f  these (with 
the exception o f  the method o f Gamache e t  a l . ,  1993) involve some type o f  sample clean-up. 
In particular, the method described here has a lower limit o f detection than the other three 
immunosensors discussed. O f all the antibody-based methods reported, only that o f  
Reinartz e t  a l .  (1996) has a lower limit o f  quantification. This may, as mentioned above, be 
due to the dilution step involved, or it may reflect the greater sensitivity o f  ELISA compared 
to BIAcore. Wagner e t  a l .  (1995) reported increased sensitivity in their inhibitive BIAcore 
immunoassay when they used monoclonal antibodies in place o f  polyclonal antiserum. The 
use o f monoclonal antibodies in this assay might result in enhanced sensitivity, although the 
greater affinity o f  these antibodies may create problems with regeneration (see Chapter 5).
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Although the BIAcore method was used to construct a standard curve in neat urine with a 
linear range o f  5 - 100 |J,g/ml and an r2 value o f  0.99, it proved difficult to reproduce this 
assay using different batches o f  urine. It seems that batch-to-batch variations in the pH and 
ionic strenth o f  urine interfere with the antibody-antigen interaction. Although it would be 
possible to adjust the pH o f control urine used in the preparation o f  standards, the smaller 
volumes o f  patient samples might be problematic, and it appears that non-immunological 
methods o f  detection, such as HPLC and CE, are inherently more suitable for the analysis o f  
neat urine samples.
One o f  the most noteworthy attributes o f  the BIAcore immunoassay is its degree o f  
automation. Standards, samples, enzyme, antibody and regeneration solutions are prepared 
and placed in the BIAcore sample racks. An automated method then controls addition of, 
and incubation with, both enzyme and antibody, injection o f sample, and regeneration o f the 
sensor surface. The temperature o f the enzyme/sample mixtures is maintained at 37°C by 
means o f  an attached waterbath. These factors make this method o f analysis easier to 
perform than any o f the others discussed previously, and allow less opportunity for operator 
error.
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4.8 Summary
A model system for the detection o f  7-hydroxycoumarin using BIAcore was established. 7- 
hydroxycoumarin-BSA was immobilised on the sensor chip and 7-hydroxycoumarin was 
premixed with a polyclonal anti-7-hydroxycoumarin antibody and injected over the surface. 
Excess antibody bound to the immobilised conjugate, generating an SPR signal inversely 
proportional to the amount o f  7-hydroxycoumarin in the sample.
An inhibition immunoassay for the determination o f total 7-hydroxycoumarin in human 
serum samples was then developed. A  diluent buffer to minimise the non-specific binding 
o f serum components to the sensor surface was included in the assay. The regeneration o f  
the sensor surface was investigated, and the baseline shift and rebinding capacity were 
found to be acceptable over 64 cycles. Recoveries o f  free drug from samples spiked with 7- 
hydroxycoumarin-glucuronide were close to 100%, and inter- and intra-day coefficients o f  
variation were less than 8.76% for 5 replicates. The assay had a measuring range o f 0.5 -  80 
[j.g/ml.
In conclusion, then, the BIAcore-based immunoassay for 7-hydroxycoumarin described was 
easily regenerable, reproducible, entailed no sample clean-up, and compared well to 
established methods o f  analysis.
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C H A P T E R  5
COMPARATIVE BlAcore AND ELISA STUDIES O N  
A N T I - A F L A T O X I N  A N T I B O D I E S
5.1 Introduction
In this chapter, a variety o f  immunoassay formats were investigated on the BIAcore, using 
commercially available polyclonal and monoclonal antibodies to aflatoxin B, - a mycotoxin 
and member o f the coumarin family. The high affinity o f  both antibody preparations for the 
antigen presented severe difficulties in the regeneration o f the sensor surface, and no 
meaningful quantitative or kinetic data could be obtained. In a series o f comparative studies 
with established ELISA techniques, both antibodies were used to construct standard curves 
for free and conjugated toxin, using both sandwich and competitive assay formats. The 
results presented indicate the lack o f suitability o f  the antibodies investigated for regenerable 
biosensor applications.
The antibodies were used to develop an ELISA-based model system for the initial 
optimisation o f  BIAcore regeneration conditions. The regeneration o f  antibody and toxin- 
protein conjugate surfaces was mirrored on 96-well microtitre plates, and a competitive 
ELISA system was employed to calculate the equilibrium dissociation constant for the 
monoclonal anti-aflatoxin antibody. Preliminary investigations o f  this type can be used to 
considerably reduce the expense and time o f  BIAcore experiments.
5.2 Chemistry, occurrence and toxicity of aflatoxins
The aflatoxins are a group o f  highly toxic secondary fungal metabolites that occur in 
A s p e r g i l l u s  species. They are members o f  the coumarin family, and the most commonly 
occurring compound is aflatoxin B : (AFBj), which is produced by certain strains o f  A .  
f l a v u s  and A .  p a r a s i t i c u s .  The structure o f  AFBt is shown below:
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Other aflatoxins - designated B2, G, and G2 - are also produced, but AFB, is generally 
present in the largest quantity, and is definitely the most toxic.
A range o f  metabolites o f  AFB, have been isolated. AFM, (or 4-hydroxy-AFB^ is a major 
metabolite o f  AFB, in rats and cows, among other species (de Iongh e t  a l ,  1964). AFQ, 
and AFP, have been shown to be major metabolites o f  AFB, in the mouse and Rhesus 
monkey (Dalezios e t  a l ,  1971; Hsieh e t  a l ,  1974). Other metabolites o f  the toxin include 
aflatoxicol, deshydroaflatoxin D l5 AFB2a and AFG2a.
Under high humidity and temperature conditions, A .  f l a v u s  and A .  p a r a s i t i c u s  can grow on 
certain foodstuffs, predominantly peanuts, tree nuts (e.g. Brazil nuts and pistachio nuts), and 
oilseeds, such as com. The consequent contamination o f  these foods with aflatoxins is o f  
major concern, particularly for the health o f  livestock. Aflatoxins have also been considered 
for use as biological weapons (Paddle, 1996).
At the molecular level, aflatoxins interfere with the replication and transcription o f nucleic 
acids, protein and lipid metabolism, and enzyme activity. The effects o f  aflatoxin poisoning 
in animals include cirrhosis, acute necrosis, and carcinoma o f the liver. In addition, Silvotti 
e t  a l .  (1997), in a study on piglets fed with aflatoxins, discovered a range o f  
immunotoxicological effects, including impairment o f  macrophage and granulocyte 
function.
The first recorded outbreak o f  aflatoxicosis occurred in 1960, when 100,000 turkeys in 
England died as a result o f  consuming contaminated groundnut meal (Austwick, 1978). 
Although a wide range o f  LD50s has been reported for different species, most are in the 
region o f  0 .5 -1 0  mg/kg body weight.
AFB! has been shown to be a potent carcinogen in fish, birds, rodents and non-human 
primates (Newbome and Butler, 1969). The carcinogenic effects o f  the toxin are known to 
require metabolic activation. This probably occurs by conversion o f  AFB, into its 2,3- 
epoxide, which binds strongly to nucleic acids (Martin and Gamer, 1977), although a more 
recent study has demonstrated 8,9-epoxidation by lipoxygenase, pointing to another possible 
route for hepatocarcinogenesis (Roy and Kulkami, 1997).
As aflatoxin contamination o f foodstuffs for human consumption rarely reaches very high 
levels, little is known o f  the effects o f  acute aflatoxin poisoning in man. Several outbreaks 
o f aflatoxicosis have occurred, however, the most notable taking place in India in 1974. In
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some 150 villages in neighbouring districts in the northwest o f  the country 108 o f  the 397 
individuals affected died. The symptoms o f the poisoning included fever, jaundice, oedema, 
vomiting and inflammation o f the liver. The cause o f the outbreak was contaminated com, 
and it was estimated that the average daily dietary intake o f  AFB, was at least 55 pg/kg 
body weight, for an undetermined number o f days.
Although the main cause o f  hepatocarcinoma in man is known to be the hepatitis B virus, it 
is thought that, in areas o f  where high exposure is common, aflatoxin exposure interacts 
with the virus to increase the incidence o f  the disease (Peers e t  a h ,  1987). In a large-scale 
study in Shanghai, Ross e t  a l .  (1992) found a definite correlation between urinary levels o f  
aflatoxin B„ its metabolites AFP! and AFM„ and their DNA-adducts, and liver cancer.
5.3 Detection of aflatoxins
Many o f  the detection systems employed for the analysis o f  aflatoxins have been 
chromatographic in nature. Column chromatography followed by TLC was the method o f  
choice for early aflatoxin studies. Silica plates were developed in chloroform:acetone (9:1), 
and quantitation was achieved by fluorodensitometry and use o f  internal standards.
More recently, ease o f  use and automation have led to HPLC being widely used for the 
measurement o f  aflatoxins. Although absorbance at 360-365 nm can be used for the 
determination o f  AFB, and AFB2, the greater sensitivity o f  detection o f  fluorescence has 
made it a more popular alternative. Pre- or post-column derivatisation has frequently been 
used to increase the fluorescence signal.
Roch e t  a l .  (1995) found that pre-column derivatisation o f  AFBt and AFB2 resulted in a 
sensitive HPLC assay, with a limit o f  quantification for AFB, o f  1.1 pg/kg o f  groundnut 
meal. Samples were extracted into acetone:water (85:15) before analysis.
HPLC separation with precolumn derivatisation using trifluoroacetic acid and detection o f  
fluorescence was used by Torres Espinosa e t  a h  (1995) to quantify AFB, levels in extracted 
com samples, with a limit o f o f detection o f  5 ng/g.
Cepeda e t  a h  (1996) used HPLC separation with a methanol:water mobile phase, together 
with fluorescent detection (following post-column addition o f  cyclodextrins to enhance 
fluorescence) to measure aflatoxin levels in extracted food samples, with a limit o f  detection 
o f 4 mg/1.
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Niedwetzki e t  a l .  (1994) used an immunoaffinity column for sample clean-up prior to HPLC 
analysis, with post-column derivatisation and fluorescent detection. This assay was carried 
out on filtered nut and fruit extracts, using an automated workstation.
Kussak e t  a l .  (1995a) also employed an immunoaffinity column for pre-column clean-up o f  
urine samples prior to HPLC analysis with post-column bromine derivatisation and 
fluorescence detection. Recoveries o f  103% and a limit o f  quantification for AFB, o f  6.8 
pg/ml were reported with this method. In a separate study, Kussak e t  a l .  (1995b) also used 
an immunoaffinity column for clean-up o f dust and urine samples before HPLC separation 
and detection by electrospray ionisation tandem mass spectrometry, with a detection limit o f  
AFB, o f4 p g .
The use o f  antibodies in aflatoxin analysis has not been confined to sample clean-up for 
HPLC. As discussed in Chapter 4, immunoanalytical techniques, i f  correctly designed, can 
facilitate analyte detection in complex matrices without laborious extraction procedures. A  
variety o f  immunoassays for the determination o f  aflatoxins have been reported. Many o f  
these, however, are semi-quantitative methods o f  analysis, with "cut-off concentrations 
corresponding to hazardous toxin levels in particular foodstuffs. The average legal limit for 
AFB, in food products is 10 (.ig/kg, with some variations between countries (Van Egmond, 
1989).
A semi-quantitative enzyme-linked immunosorbent assay for aflatoxins has been reported 
by Trucksess and Stack (1994). Com samples were extracted into methanol:water (80:20) 
and the extracts, together with HRP-labelled aflatoxin, were added to polyclonal antisera 
immobilised on a filter membrane. After washing with water, a chromogenic substrate 
(containing hydrogen peroxide and tetramethylbenzidine) was added. Test samples with an 
AFB, content o f  greater than 20 ng/g failed to produce any colour change after a 1 minute 
incubation.
Another semi-quantitative immunoassay system was described by Abouzied and Pestka 
(1994). In this assay, monoclonal anti-aflatoxin antibodies were immobilised on 
nitrocellulose membranes, and a competition between AFB, in extracted com samples and 
HRP-labelled AFB, was set up. The colour intensity upon addition o f  chromogenic 
substrate was inversely proportional to the amount o f mycotoxin present. The limit o f  
detection o f  this method was 0.5 ng/ml.
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Schneider e t  a l .  (1995) reported a "dipstick" type enzyme immunoassay for APB,. This 
semi-quantitative assay involves immobilising antibodies to AFB, (among other 
mycotoxins) onto a dipstick membrane. The dipstick is then immersed in a test-tube 
containing extracted sample and labelled toxin, followed by a second incubation with 
substrate. Complete suppression o f  colour formation indicated a positive detection o f  
aflatoxin. The detection limit o f  the assay was 30 ng/g in wheat samples. A similar dip- 
strip assay format was described by Sashidar (1993), with a limit o f  quantification for AFBi 
o f 10 ppb.
Ram e t  a l .  (1986) reported a competitive ELISA for quantitative determination o f  aflatoxin 
B, in com and cottonseed extract, which utilised polyclonal antibodies and had a limit o f  
detection o f  1 mg/ml.
Ward e t  a l .  (1990) described the production o f  polyclonal and monoclonal antibodies to 
AFBls and their use in a microtitre plate-based quantitative ELISA. They reported limits o f  
detection for their model system o f 1 pg/ml with both types o f  antibody.
Ramakrishna e t  a l .  (1990) used monoclonal antibodies to measure aflatoxin in extracted 
barley samples. They reported a limit o f  detection for aflatoxin Bj o f  100 pg/ml/.
Bacigalupo e t  a l .  (1994) developed two different immunoassay formats to detect AFB, in 
extracts o f  soya seeds, dried figs and raisins. Using polyclonal antibodies in a time-resolved 
fluoroimmunoassay, they reported a limit o f quantification o f  0.5 p.g/kg, while a limit o f  
detection o f  0.2 fag/kg was achieved with an immunoenzymatic assay.
5.4 Enzyme-linked immunosorbent assay (ELISA)
The production and characterisation o f  polyclonal and monoclonal antibodies have been 
discussed in Chapter 3. Enzyme-linked immunosorbent assay (ELISA) - an analytical 
technique which exploits the sensitivity and specificity o f  the antibody-antigen interaction - 
has been reviewed by O'Kennedy (1989) and Gosling (1990). Basically, either antibody or 
its complementary antigen is labelled with an enzyme, and the interaction is allowed to 
proceed. A  chromogenic substrate is then added, which generates colour upon reaction with 
enzyme. The amount o f  coloured product formed is then determined by measuring the 
absorbance at a particular wavelength, and is directly proportional to the concentration o f  
the labelled component.
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In this chapter, a variety o f  ELISA formats are used, both for the quantitative determination 
o f AFB„ and to calculate an equilibrium affinity constant for the interaction between 
monoclonal anti-AFB, and free toxin. The ELIS As described here are heterogeneous 
assays, in which one component is immobilised by passive adsorption onto the wells o f  a 
96-well polystyrene microtitre plate, and subsequent washing steps are needed to separate 
free from surface-bound interactants. ELISA systems can be divided into two categories: 
non-competitive ("sandwich") and competitive assays.
A  typical sandwich assay format is depicted in Figure 5.1. Antibody is first immobilised on 
the wells o f  a microtitre plate. The remaining surface o f  the plate is then "blocked" by 
addition o f  a high molecular weight protein or mixture o f  proteins - typically bovine serum 
albumin (BSA) or foetal calf serum (FCS). Sample containing antigen is then added to the 
wells. A  second antibody against the analyte (which interacts with a different epitope) is 
then allowed to bind. Finally, an anti-species antibody to the secondary antibody, labelled 
with an enzyme, is added, and, following incubation with chromogenic substrate, the 
absorbance o f  each well is measured. In between each o f these steps, the wells o f the plate 
are washed with a detergent-containing solution to remove any unbound antibody or 
antigen.
Utilising a labelled secondary antibody can reduce the number o f steps in a sandwich assay; 
but the ready availability o f  commercial labelled anti-species antibodies, together with the 
inherent risks to activity posed by enzyme conjugation, make the use o f  anti-species 
antibodies a more acceptable option, affording greater sensitivity.
Ideally, the addition o f secondary antibody should introduce an amplification effect. For 
optimum assay performance, an immobilised monoclonal antibody should be used for 
capture o f  analyte, and a polyclonal antiserum (or heterogenous mixture o f  monoclonal 
antibodies) for secondary binding. The interaction o f the polyclonal antibody at multiple 
epitopes w ill then increase the response. If the situation is reversed - i.e. coating with 
polyclonal antibody and secondary addition o f  monoclonal antibody - then the number o f  
sites available for monoclonal antibody binding may be reduced.
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Figure 5.1 Schematic diagram o f a typical sandwich ELISA format. (1) Wells o f  an 
ELISA plate are coated with antibody. (2) Antigen is added and allowed to bind, after 
which a secondary antibody is added (3). An enzyme-labelled ([§) anti-species antibody 
is then allowed to bind to the secondary antibody, and the colour generated upon addition 
o f chromogenic substrate is directly proportional to the amount o f  antigen present (4). 
The wells are washed between every step to remove unbound components.
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The absorption o f  antibodies onto the walls o f  a microtitre plate well is an essentially 
random process, and the conformation o f  many o f  the immunoglobulins may prevent the 
binding o f  antigens to their actives sites. This type o f  conformational problem may be 
overcome by using an initial "capture" molecule to correctly orientate the antibodies.
The ability o f  protein A  to bind specifically to IgG has been discussed in section 3.5. By  
coating plates with protein A  or an Fc-specific anti-IgG antibody and then adding the 
primary antibody, the correct orientation o f  the Fab portion can be assured.
Figure 5.2 shows the type o f competitive ELISA format used in this chapter. Antigen is 
immobilised on the surface o f  a microtitre plate, which is then blocked as before. Solutions 
containing antigen are mixed with an excess o f  antibody, and this mixture is added to the 
wells. Unbound antibody is allowed to bind to immobilised antigen, and then an enzyme- 
labelled secondary antibody is added. The colour produced upon addition o f  chromogenic 
substrate is inversely proportional to the concentration o f  antigen in the original solution. 
As in the sandwich assay, the plates are washed between each step to remove unbound 
components. This type o f  assay is more properly known as an antigen inhibition ELISA, to 
distinguish it from a competitive ELISA format in which labelled and unlabelled antigen 
compete for binding sites on an immobilised antibody surface.
In general, competitive ELISA is the method o f  preference for detection o f  low molecular 
weight analytes such as drugs and toxins, as the small size o f  these molecules precludes the 
multiple-epitope binding necessary in a sandwich assay.
5.5 Measurement of antibody affinity by ELISA
The concept and theory o f  antibody affinity have been discussed in section 3.3. A  variety o f  
methodologies, including equilibrium dialysis, fluoroimmunoassay and radio-immunoassay, 
may be used to determine the affinity o f  an antibody for its specific antigen. The use o f  
BIAcore to calculate kinetic and affinity data was described in section 3.7. In this chapter, 
an ELISA method is used to calculate this value for a commercial monoclonal anti-AFB, 
antibody.
Van Heyningen e t  a l .  (1983) outlined a simple competitive ELISA procedure for ranking 
antibody affinities, which gave an approximate KD value.
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Figure 5.2 Schematic diagram o f a typical competitive ELISA format. (1) A  protein 
conjugate o f  a low molecular weight analyte is coated onto wells o f  an ELISA plate. 
Antibody and analyte are mixed (2) and added to the w ells, where immobilised and free 
antigen compete for antibody binding sites (3). An enzyme-labelled anti-species antibody 
is then added, and the colour generated upon addition o f  chromogenic substrate is 
inversely proportional to the amount o f  analyte present (4). The wells are washed 
between every step to remove unbound components.
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This method, however, relies upon interaction o f  antibody with immobilised antigen, and, as 
a result, is unsuitable for the calculation o f  true affinity constants. Friguet e t  a l .  (1985) 
described an improved ELISA method, which allows determination o f  the equilibrium 
dissociation constant by measuring the amount o f  free antibody in solution after equilibrium 
with antigen has been reached. In addition, this procedure can be used to calculate the 
dissociation constant even if  the absolute concentration o f antibody is not known.
The assay is based upon the assumption that monoclonal antibody at constant concentration 
will reach equilibrium i f  incubated with differing concentrations o f  antigen for a sufficient 
period o f time. The amount o f remaining unbound antibody in each equilibrium solution is 
then measured by ELISA.
Antigen is coated onto a wells o f  a microtitre plate, and aliquots o f  the antibody-antigen 
mixtures are added. Following incubation and washing, an enzyme-labelled secondary 
antibody is allowed to bind, chromogenic substrate is added, and the absorbance is recorded. 
In preliminary studies, Friguet e t  a l .  (1985) found a linear relationship between the amount 
o f antibody added to wells and the final absorbance reading. This allowed them to state that 
i f  antibody at a total concentration i 0 is incubated with antigen at a given concentration, then 
i ,  the free antibody concentration, w ill be equal to the absorbance A, as measured by 
ELISA, divided by A0 - the absorbance for antibody in the absence o f  antigen:
i  A
Equation 5.5.1 — =
K  A
This assumes that the equilibrium in the liquid phase is not disrupted in the course o f  the 
ELISA.
Using the mass conservation equations, the concentrations o f  bound antibody (x) and free 
antigen ( a )  at equilibrium can be calculated:
Equation 5.5.2 x  =  i 0 -  i
Equation 5.5.3 a  =  a 0 - x
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where a 0 is the total concentration o f antigen. The three values x ,  a  and i 0 can be related to 
Kd, the dissociation constant, by the Klotz equation (Klotz, 1953):
1 1 K d
Equation 5.5.4 — = — --------
x L  a  x i
From equation 5.5.1, x  and a  can be related to the absorbance readings from ELISA:
Equation 5.5.5 x  =  i a x  A 0 -  ——
Equation 5.5.6 a  =  a 0 -  i a x A 0 -  ——
A 0
Hence, equation 5.5.4 can be rewritten as:
Equation 5.5.7 A 0/A 0-A =  1 + KD/ (a0 - i Q  x A0-A / A0)
If the concentration o f  the antigen is much larger than that o f  the antibody, then a  can be 
approximated by a 0, and the previous equation becomes:
Equation 5.5.8 A0/A 0-A =  l + K D/ a Q
Therefore, by preincubating a constant concentration o f  antibody with at least a ten-fold 
molar excess o f  antigen, measuring the amount o f remaining unbound antibody by ELISA, 
and plotting the reciprocal o f the fraction o f free antibody (A0/A0-A) against the reciprocal 
o f the antigen concentration, a line with an intercept on the y-axis o f  1, and a slope o f  KD 
should be produced.
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Results
5.6 BIAcore studies
The interactions between polyclonal and monoclonal anti-AFB, antibodies and a protein 
conjugate of the toxin were investigated in a range of experimental formats which included 
direct immobilisation of both antibodies, use of protein A and anti-species antibody capture 
layers, and immobilisation of AFBRBSA. Running buffer and flow rate throughout were as 
described in section 2.9.4.
5.6.1 Direct immobilisation of monoclonal anti-AFB,
Monoclonal anti-AFB, was immobilised on the sensor chip surface as outlined in section 
2.9.2. In order to minimise any reduction in antibody activity, the pH of immobilisation 
buffer (10 mM sodium acetate/HCl) was adjusted to 5.3, and antibody was diluted 
immediately prior to injection over the derivatised chip surface.
As the molecular weight of aflatoxin (312.3) is too small for direct sensing, a BSA 
conjugate of the toxin was used in these studies. The degree of non-specific binding of the 
native form of the protein was first assessed by injecting a 4 minute pulse of 1 mg/ml BSA 
over the immobilised monoclonal antibody surface (Figure 5.3). No non-specific interaction 
was observed.
The binding of AFBr BSA to the immobilised antibody was then investigated. Figure 5.4 
shows the sensorgram obtained when a solution containing 7 |ag/ml of AFB,-BSA was 
injected over an immobilised antibody surface (-9000 RU) for 20 minutes. Approximately 
550 RU of conjugate is bound to the monoclonal antibody, and very little decrease in 
response is evident in the dissociation phase of the sensorgram. This indicates that there is a 
very low dissociation constant for the interaction.
Low molarity acid and base had previously been used to disrupt antibody-antigen binding in 
a BIAcore-based immunoassay (see Chapter 4). The effects of regeneration with sodium 
hydroxide are shown in Figure 5.5. Monoclonal antibody was immobilised (-14000 RU), 
and a 4 minute injection of AFBr BSA produces a binding signal of 342 RU. Injecting a 1 
minute pulse of 10 mM NaOH brings the signal down to 20 RU above baseline. 
Subsequent injection of another 20 p,l of toxin-protein conjugate, however, results in only 
36 RU of binding.
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Figure 5.3 Typical sensorgram to estimate the degree of non-specific binding of 
monoclonal anti-AFB, to BSA. Approximately 4,500 RU of antibody were immobilised, 
and a five minute pulse o f 1 mg/ml BSA was injected over the surface. No increase in 
signal relative to baseline is seen after the sample pulse has passed over the surface.
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Figure 5.4 Sensorgram showing the binding o f  AFBr B SA  to immobilised monoclonal 
anti-AFB,. A  20 minute injection o f  a 7 |ig/ml solution o f  conjugate over ths surface 
results in an increase in response o f  550 RU. The changes in signal at the beginning and 
end o f  the injection are due to differences in bulk refractive index between running buffer 
and sample. No significant decrease in signal is evident in the dissociation phase.
Time (Sec)
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Figure 5.5 Sensorgram illustrating the effects o f  regeneration with sodium hydroxide on 
an immobilised monoclonal anti-APB, surface. (A) A  4 minute injection o f  7 |J,g/ml 
AFBr BSA  produces a binding signal o f  342 RU. (B) Injection o f  a 1-minute pulse o f  
lOmM NaOH removes 322 RU o f bound conjugate, but a further injection o f  toxin- 
protein conjugate (C) results in a response o f  only 36 RU.
Time {Sec)
188
This suggests that although injection o f  10 mM NaOH is sufficient to almost completely 
regenerate the antibody surface, antibody activity is detrimentally affected by treatment with 
the base, to the extent that binding o f conjugate after regeneration produces only 10% o f the 
initial response.
The ability o f  a range o f  different solutions to regenerate the monoclonal antibody surface - 
on the basis o f  extremes o f pH, hydrophobicity, and ionic strength - was investigated. The 
results are given in Table 5.1. O f the solutions tested, only 10 mM sodium hydroxide 
proved to be an effective regeneration reagent. It appears that satisfactory regeneration o f  
the immobilised monoclonal antibody surface can only be achieved at the expense o f  
antibody activity.
5.6.2 Indirect immobilisation of monoclonal anti-AFBj via protein A
As regeneration o f  the monoclonal antibody surface proved problematic, the use o f  a capture 
molecule to indirectly immobilise the antibody, thus removing the necessity for 
regeneration, was investigated.
The use o f  protein A  to capture mouse and rabbit IgG in ELISA formats has been discussed 
in section 5.4. Protein A  was immobilised on the sensor chip surface as in section 2.9.2, 
giving a signal o f  5500 RU. 25 pi o f  a 1/100 dilution o f monoclonal antibody in PBS was 
injected over this surface, giving a response o f  1460 RU. A  subsequent injection o f a 7 
|ig/ml conjugate solution over the captured antibody, however, does not result in any 
binding signal (Figure 5.6). It can be seen from the sensorgram that the bound monoclonal 
antibody is dissociating from the protein A  surface too rapidly to allow any binding o f 
conjugate to be observed. This commercial antibody preparation is o f  the sub-class IgG,, a 
type o f  mouse immunoglobulin for which protein A  is known to have only a weak affinity.
5.6.3 Indirect immobilisation of monoclonal anti-AFB, via an anti-mouse
IgG antibody
A  1/200 dilution o f Fc-specific anti-mouse IgG antibody in 10 mM sodium acetate, pH 5.45, 
was immobilised on the chip surface as described in section 2.9.2, giving a signal o f -9000  
RU. Injection o f  a 1/50 dilution o f  monoclonal anti-AFB! for 10 minutes resulted in a 
binding signal o f  1200 RU.
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Table 5.1 Regeneration reagents tested on a monoclonal anti-AFB, surface. AFB,-BSA  
was passed over immobilised antibody surfaces, and the ability o f  various reagents to 
disrupt antibody-antigen binding was assessed. The amount o f  regeneration is reported in 
terms o f  the percentage o f  the initial binding signal removed or added by each injection.
Regeneration Reagent Contact Time Percentage Change in 
Reponse
lOmM HC1 2 min + 0.6%
lOmMNaOH 1 min - 93%
25% Ethanol 1 min - 3.7%
20% Acetonitrile 1 min - 8.6%
lOmMNaCl 1 min + 6.3%
20mM NaCl 1 min - 4.5%
50mM NaCl 1 min - 1.1%
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Figure 5.6 Sensorgram showing the dissociation o f  captured monoclonal anti-AFB, from 
an immobilised protein A  surface. (A) Monoclonal antibody was injected over a protein 
A  surface, with a binding signal o f  1463 RU. However, significant dissociation is visible, 
and following injection o f  a 7 (ig/ml solution o f  A FB r B SA  (B), the response has 
decreased to 990 RU above the initial baseline.
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When 7, 70 and 1000 (ig/ml solutions o f  AFB,-BSA conjugate were passed over this 
captured antibody, however, no significant binding was observed (Figure 5.7). Further 
injections o f  increasing concentrations o f  anti-AFB, over immobilised anti-mouse IgG 
surfaces showed that a signal o f 1200 RU was the saturation response for monoclonal 
antibody capture.
5.6.4 Direct immobilisation of polyclonal anti-AFBj
Polyclonal anti-AFB, was immobilised at a 1/200 dilution as in section 2.9.2. The 
immobilisation buffer used was 10 mM sodium acetate, pH 5.8, and approximately 10000 
RU o f antibody was covalently bound to the sensor chip. Injections o f  AFB,-BSA (at 
concentrations o f  7, 70 and 1000 (ig/ml) over this surface, however, resulted in no 
significant change in response.
The pH o f immobilisation buffer was increased to 6.8, and antibody diluted in buffer 
immediately prior to injection over the derivatised chip surface. Again, 10000 RU o f  
antibody were immobilised, but no signal was obtained when conjugate was passed over the 
IgG surface. Omission o f the capping step - treatment o f  the immobilised surface with 1M 
ethanolamine, pH 8.5, to remove non-covalently bound material - did not result in any 
increase in antibody activity.
The AFB,-BSA conjugate used was freshly reconstituted from lyophilisate, dialysed 
overnight at 4°C to remove any free toxin, and diluted in PBS containing 400 mM sodium 
chloride, in order to counteract any electrostatic repulsion between the highly-substituted 
conjugate and the carboxyl groups on the chip surface.
5.6.5 Indirect immobilisation of polyclonal anti-AFB, via protein A
As in section 5.6.2, protein A  was immobilised on the sensor chip. A  5 minute injection o f  
a 1/100 dilution o f  polyclonal anti-AFB, in PBS over this surface gave a response o f  
approximately 2000 RU, but further injections o f  7 and 70 pg/ml o f  AFB,-BSA over the 
captured antibody did not result in any binding (Figure 5.8).
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Figure 5.7 (A) Monoclonal anti-AFB, is injected over an immobilised Fc-specific anti­
mouse IgG surface, giving a response o f  1216 RU. 5 minute injections o f  7, 70 and 100 
|ag/ml o f  AFB,-BSA (B, C and D, respectively) over this captured antibody do not result 
in any binding. Differences in shape o f signal between B, C and D are due to differing 
bulk refractive indices.
Time (Sec)
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Figure 5.8 Sensorgram showing indirect immobilisation o f  polyclonal anti-AFB, on a 
protein A  surface. (A) A  5 minute injection o f  antibody over immobilised protein A  
results in a signal o f  approximately 2,000 RU. However, dissociation o f  antibody from 
this surface is significant, and can be seen as a rapid decrease in signal as soon as the 
sample injection has finished. A  steady decrease in signal continues during the injection 
o f  7 and 70 pg/ml solutions o f  AFB,-BSA over the chip (B and C, respectively), after 
which the signal has decreased by 550 RU.
Time (Sec)
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It can be seen from the sensorgram that - as with the attempt to utilise protein A  to indirectly 
immobilise monoclonal antibody - there is significant dissociation o f IgG from the protein 
A  surface, and that this dissociation is too rapid to allow any binding o f  antigen to antibody 
to be discerned.
5.6.6 Direct immobilisation of AFB,-BSA conjugate
As regeneration o f  immobilised antibody surfaces appears to be difficult to achieve while 
maintaining activity, investigation o f the antibody-antigen interaction by directly 
immobilising AFB,-BSA was examined.
A 200 pg/ml solution o f  AFBr BSA  in 10 mM sodium acetate, pH 3.9, was immobilised as 
in section 2.9.2. A  5 minute injection o f a 1/800 dilution o f  monoclonal anti-AFB, over this 
surface gave a binding signal o f  approximately 310 RU. From the data in Table 5.1, basic 
solutions appear to be the most effective at disrupting the bonds between monoclonal 
antibody and AFB,-BSA. A 1 minute pulse o f  75 mM NaOH, however, only removed 
about 90 RU o f antibody binding (Figure 5.9).
When repeated 1 minute pulses o f  100 and 200 mM NaOH had eventually brought the 
signal back to baseline level, another injection o f 1/800 polyclonal antibody gave a 
decreased signal o f  216 RU - indicating that the harsh regeneration conditions used had 
damaged the immobilised conjugate.
The binding o f  polyclonal antibodies to a conjugate surface was then examined. NaOH was 
again chosen as the regeneration agent. On a separate flow cell, approximately 2000 RU o f  
AFB,-BSA was immobilised.
The removal o f  bound polyclonal anti-AFB, from this surface using increasing molarities o f  
NaOH was investigated, and only 100 mM NaOH was found to give complete regeneration. 
Figure 5.10 shows repeated binding/regeneration cycles, using a 1/100 dilution o f  
polyclonal anti-AFB, and 100 mM NaOH, with varying contact times. Regeneration with a 
10 minute injection o f  100 mM NaOH (the flow rate here was reduced to 2 pl/min, in order 
to minimise sample consumption) seems to be the most effective.
In an attempt to develop a quantitative method for estimation o f  free AFB, analogous to that 
for 7-hydroxycoumarin described in Chapter 4, a fresh AFB,-BSA conjugate surface was 
immobilised, and a range o f standards o f free toxin (0 - 40 pg/ml in PBS) prepared.
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Figure 5.9 Sensorgram showing interaction o f  monoclonal anti-APB, with immobilised 
AFB,-BSA. (A) A  5 minute injection o f  antibody over the immobilised conjugate surface 
results in 309 RU o f  binding. (B) A  1 minute pulse o f  75 mM NaOH over the chip 
removes only 90 RU o f  bound IgG. The differences in shape between the two injection 
signals are due to the differing bulk refractive indices o f  the two solutions.
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Figure 5.10 Sensorgram showing binding/regeneration cycles for polyclonal anti-AFB, 
bound to immobilised AFB,-BSA. Antibody at a 1/100 dilution was injected over a 
conjugate surface, and lOmM NaOH was then passed over the chip. The contact times 
with regeneration reagent were (A) 15 minutes, (B, C) 12 minutes, and (D, E) 10 minutes. 
The antibody-binding signal decreases after A, B and C, but the response after D 
increases slightly, indicating that a contact time o f  10 minutes is optimal for this 
concentration o f  base.
Time (Sec)
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45 pi o f  each standard were then mixed and incubated with an equal volume o f polyclonal 
anti-AFB, (1/100 in PBS). After a 10 minute incubation period, 2 pi o f  this mixture was 
passed over the chip. A  10 minute injection o f  100 mM NaOH was then injected. The flow  
rate throughout was 2 pl/min. The change in response for each standard, and the signals 
after regeneration are given in Table 5.2. It can be seen that no standard curve can be 
constructed using these results, although the method seems to have worked in principle, 
with the 40 pg/ml standard giving a response o f  3 RU, and the 5 pg/ml standard a signal o f  
192 RU. The regeneration o f the surface appears to be responsible for the poor assay 
performance. The negative relative response values after treatment with 100 mM NaOH 
show that this regeneration strategy, which was optimised for the removal o f  200-300 RU o f  
bound antibody, is damaging the immobilised surface when lesser amounts o f  IgG are 
bound.
5.7 ELISA studies
The BIAcore results above demonstrate that regeneration o f  the two antibodies is 
problematic. To examine the efficiency o f  these antibody preparations in non-regenerable 
assay formats, a range o f  microtitre plate-based ELISA formats were employed. Both 
monoclonal and polyclonal antibodies were used in ELISAs for the quantitative 
determination o f  both free aflatoxin and the toxin-BSA conjugate. In addition, the 
regeneration o f immobilised antibody and conjugate, and the effects o f  the regeneration 
reagents on these surface were investigated.
An indirect ELISA method was also used to calculate the equilibrium dissociation constant 
o f the monoclonal antibody. Unless otherwise stated, two replicate analyses were 
performed for all o f  the ELISA studies reported in this chapter.
5.7.1 Competitive ELISA for AFB,
Competitive ELISAs for the determination o f  free AFB,, using both polyclonal and 
monoclonal antibodies, were carried out as described in section 2.7.6.
96-well microtitre plates were coated with AFB,-BSA and blocked with 5% (v/v) FCS. A  
range o f  standard solutions o f  AFB, - containing from 1 pg/ml to 10 pg/ml - were then 
prepared in PBS.
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Table 5.2 Results from attempted quantitative assay for free AFB,, with immobilised 
AFBr BSA  and premixing o f  toxin standards with polyclonal anti-AFB,. The responses 
after injection o f  the standard-antibody mixture over the conjugate surface and 
regeneration (10 minute injection o f  lOOmM NaOH) are shown for each standard.
AFBj Concentration 
(fxg/ml)
Standard Response 
(RU)
Regeneration Reponse 
(RU)
40 3 - 188.6
20 1.1 - 130.2
10 27.3 - 111.6
5 192.2 - 73.6
2.5 126.3 - 76.4
0 69.4 - 72.5
199
100 pi o f  each standard, together with 100 pi o f  a 1/10,000 dilution o f  polyclonal anti- 
AFB,, were added to each well and free and immobilised toxin allowed to compete for 
antibody binding sites.
HRP-labelled anti-rabbit antibody was then added, followed by a chromogenic substrate, 
and the absorbance o f  wells was measured. Figure 5.11 shows the standard curve obtained 
for the assay, which had a linear range o f 10 pg/ml to 50 ng/ml, and an r2 value o f  0.93.
A  similar assay was developed using the monoclonal anti-AFB, antibody, which was 
incubated together with standards at a dilution o f  1/40,000, and HRP-labelled anti-mouse 
antibody. The standard curve for this assay is shown in Figure 5.12, and has an r2 value o f  
0.99, with a linear range o f  1 - 800 ng/ml.
5.7.2 Direct sandwich ELISA for AFB,-BSA
Sandwich ELIS As for the determination o f AFB,-BSA, with direct coating o f both 
polyclonal and monoclonal antibodies, were performed as described in section 2.7.7.
A  96-well microtitre plate was coated with 100 pl/well o f  a 1/5000 dilution o f  polyclonal 
anti-AFB„ and blocked with 5% (v/v) FCS. A  range o f  standards o f  AFBr BSA (1 pg/ml to 
10 pg/ml) were prepared in PBS, and 100 pi o f  o f  each standard was added to appropriate 
wells, and incubated. 100 pl/well o f monoclonal anti-AFB, was then added, followed by 
HRP-labelled anti-mouse IgG, and a chromogenic substrate. The absorbance o f  wells at 405 
nm was then measured. Figure 5.13 shows the standard curve obtained from this assay, 
which has a linear range o f  1 -1 0 0  ng/ml and an r2 value o f  0.99.
In a similar assay, 100 pl/well o f  monoclonal anti-AFB, was coated onto a microtitre plate. 
Standards were added as before, followed by 100 pl/well o f  polyclonal anti-AFB,. HRP- 
labelled anti-rabbit was then added, and colour was developed and measured. This assay 
configuration gave a standard curve with a measuring range o f  1 - 400 ng/ml, and an r2 value 
o f 0.97, as shown in Figure 5.14.
5.7.3 Sandwich ELISA for AFB,-BSA using protein A capture
Sandwich ELISAs for AFB,-BSA in which immobilised protein A  was used to capture both 
polyclonal and monoclonal antibodies were carried out as in section 2.7.8.
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Figure 5.11 Standard curve from competitive ELISA for AFB, using a 1/10,000 dilution 
o f polyclonal antibody, The absorbance o f  w ells at 405 nm is inversely proportional to 
the amount o f  free toxin present. Results shown are the averages o f  duplicate analyses. 
The method has a linear range o f  10 pg/ml to 50 ng/ml.
Log AFBi conc (pg/ml)
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Figure 5.12 Standard curve from competitive ELISA for AFB, using a 1/4,000 dilution 
o f  monoclonal antibody. The absorbance o f  wells at 405 nm is inversely proportional to 
the amount o f  free toxin present. Results shown are the averages o f  duplicate analyses. 
The method has a linear range o f  1 to 800 ng/ml.
Log AFBi conc (ng/ml)
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Figure 5.13 Standard curve from sandwich ELISA for AFB,-BSA with direct coating o f  
polyclonal antibody. The absorbance o f wells at 405 nm is directly proportional to the 
amount o f  toxin-protein conjugate present. Results shown are the averages o f  duplicate 
analyses.
Log AFBi-BSA conc (ng/ml)
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Figure 5.14 Standard curve from sandwich ELISA for A FBr BSA  with direct coating o f  
monoclonal antibody. The absorbance o f  wells at 405 nm is directly proportional to the 
amount o f  toxin-protein conjugate present. Results shown are the averages o f  duplicate 
analyses. The assay has a linear range o f  1 -  400 ng/ml.
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Wells o f  a 96-well microtitre plate were coated with protein A  and blocked with FCS. 100 
pl/well o f  polyclonal anti-AFB, was then added. A  range o f  standards o f  AFB,-BSA, 
containing from 10 pg/ml to 1 pg/ml, were then prepared, and 100 pi o f  each solution was 
added to appropriate wells. 100 pl/well o f a mouse monoclonal anti-AFB, was then added, 
followed by an HRP-labelled anti-mouse antibody, and chromogenic substrate. Although 
there was a slight increase in response with increasing conjugate concentration, the 
maximum absorbance reading at 405 nm was 0.1, and it was not possible to construct a 
standard curve using the data obtained.
The capture o f  monoclonal antibody was also examined. Wells o f  a microtitre plate were 
coated with protein A, and 100 pl/well o f  monoclonal anti-AFB, was added. After 
incubation with a range o f  AFB,-BSA standards, polyclonal anti-AFB, was added, followed 
by an HRP-labelled anti-rabbit antibody, and chromogenic substrate.
There was no significant change in absorbance for the wells to which different 
concentrations o f  conjugate had been added, and no standard curve could be constructed.
5.7.4 Sandwich ELISA for AFB,-BSA using an anti-mouse antibody for
capture
A  sandwich ELISA for AFB,-BSA in which an immobilised anti-mouse antibody was used 
to capture monoclonal anti-AFB, was performed as in section 2.7.9.
A  96-well ELISA plate was coated with 100 pl/well o f a 1/5000 dilution o f Fc-specific anti­
mouse IgG antibody. After blocking with 5% FCS, 100 pl/well o f  a 1/5,000 dilution o f  
mouse monoclonal anti-AFB, in PBS was added.
A  range o f  standards o f  AFB,-BSA containing from 10 pg/ml to 1 pg/ml were then 
prepared, and 100 pi o f  each solution was added to appropriate wells. 100 pl/well o f  
polyclonal anti-AFB, was then added, followed by an HRP-labelled anti-rabbit antibody. 
After addition of, and incubation with, chromogenic substrate, the absorbance o f  the wells at 
405 nm was measured. Figure 5.15 shows the standard curve for AFB,-BSA constructed 
with these data, which has a linear range o f  10 ng/ml to 1 pg/ml, and an r2 value o f 0.98.
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Figure 5.15 Standard curve from sandwich ELISA for A FBr B SA  with initial coating o f  
wells with Fc-specific anti-mouse IgG, and subsequent capture o f  monoclonal anti-AFB!. 
The absorbance o f  wells at 405 nm is directly proportional to the amount o f  toxin-protein 
conjugate present. Results shown are the averages o f  duplicate analyses. The assay has a 
linear range o f  10 ng/ml to 1 |_ig/ml.
Log AFBi-BSA conc (ng/ml)
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5.7.5 Investigation of the efficiency and effects of regeneration by ELISA
BIAcore studies demonstrated that regeneration o f antibody-antigen binding with sodium 
hydroxide affected the activity o f the immobilised interactant. To corroborate these 
findings, ELISA methods were used to examine the efficiency o f  regeneration and effects o f  
pretreatment with sodium hydroxide on both immobilised antibody and conjugate surfaces. 
Sandwich ELISAs were performed as described in section 2.7.10, to investigate the 
regeneration o f immobilised polyclonal and monoclonal antibody surfaces. A  96-well 
microtitre plate was coated with polyclonal anti-AFBj. 100 pl/well o f  a 0.5 pg/ml solution 
o f AFBr BSA was added to the wells, and the plate was incubated at 37°C for 1 hour. A  
range o f  solutions containing from 5 mM to 1000 mM NaOH were prepared, and 100 
fil/well o f  each o f  the solutions were added to appropriate wells for 10 minutes, before being 
aspirated. After washing, monoclonal anti-AFB, was added to the wells, followed by HRP- 
labelled anti-mouse antibody and chromogenic substrate. This assay demonstrates the 
ability o f  the differing concentrations o f NaOH to disrupt the antibody-antigen interaction. 
The procedure was repeated with the NaOH solutions added to the plates after blocking, 
incubated for 10 minutes, and aspirated prior to addition o f  conjugate, in order to assess the 
effect o f  contact with base upon the ability o f the immobilised antibody to bind antigen.
An overlay plot o f  the absorbance at 405 nm against concentration o f NaOH for these two 
assays is given in Figure 5.16, and shows that increasing concentrations o f  NaOH up to 400 
mM result in increased levels o f  regeneration, while pretreatment o f  immobilised antibody 
with increasing molarities o f  base does result in some reduction o f its antigen-binding 
capacity, especially at the higher concentrations at which regeneration is most effective.
A  similar assay format was used to investigate the effects o f NaOH on immobilised 
monoclonal antibody. Monoclonal anti-AFB, was coated onto wells o f  a microtitre plate, 
and toxin-protein conjugate was then added. After treatment with base, polyclonal anti- 
AFB, was added, followed by HRP-labelled anti-rabbit antibody and chromogenic 
substrate. The assay was then repeated with the NaOH solutions added to the plate after 
blocking and before addition o f  conjugate. Figure 5.17 shows an overlay plot for the results 
o f the two assays.
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Figure 5.16 The effects o f  regeneration with sodium hydroxide on polyclonal anti-AFB, 
coated onto wells o f  a 96-well microtitre plate. Increasing concentrations o f  NaOH were 
added to coated wells before (“Pretreatment) and after (“Regeneration”) incubation with 
AFB,-BSA. The amount o f  bound conjugate was measured by sandwich ELISA, with 
addition o f  monoclonal anti-AFB, and HRP-labelled anti-mouse antibody. The results 
shown are the averages o f  duplicate analyses.
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Figure 5.17 The effects o f  regeneration with sodium hydroxide on monoclonal anti- 
APB, coated onto wells o f  a 96-well microtitre plate. Increasing concentrations o f  NaOH  
were added to coated wells before (“Pretreatment) and after (“Regeneration”) incubation 
with AFBr BSA. The amount o f  bound conjugate was measured by sandwich ELISA, 
with addition o f  polyclonal anti-AFB, and HRP-labelled anti-rabbit antibody. The results 
shown are the averages o f  duplicate analyses.
NaOH concentration (mM)
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From the graph it can be seen that regeneration occurs with lower concentrations o f  NaOH 
than those needed for the polyclonal antibody, but that the effect o f  treatment with base on 
the activity o f  the antibody is also more pronounced.
ELISAs to investigate the effects o f  regeneration on an immobilised AFB,-BSA surface 
were performed as described in section 2.7.11. Conjugate was coated onto wells o f  a 
microtitre plate, which were then blocked with 5% FCS. 100 pl/well o f  polyclonal anti- 
AFB, was then added to the wells, and incubated for 1 hour at 37°C. After washing, 100 ju.1 
o f a range o f  NaOH solutions (5 - 400 mM) was added to appropriate wells, incubated for 
10 minutes at room temperature, and then aspirated. Monoclonal anti-AFB, was then 
added, followed by HRP-labelled anti-mouse antibody and chromogenic substrate. The 
assay was then repeated with the NaOH solutions added to the plate after coating and before 
incubation with antibody. An overlay plot for the two assays is shown in Figure 5.18, and it 
can be seen that addition o f  increasing concentrations o f NaOH results in increased 
regeneration, while pretreatment o f  the conjugate surface with base slightly decreases the 
binding o f  polyclonal antibody at higher concentrations.
This procedure was repeated using monoclonal anti-AFB, as the primary antibody, and the 
results are shown in Figure 5.19. While the regeneration o f binding is again evident, 
pretreatment o f  the conjugate surface with increasingly concentrated solutions o f  NaOH 
does not seem to significantly affect interaction with the monoclonal antibody.
5.7.6 Determination of the affinity constant of monoclonal anti-AFB, by
ELISA
The equilibrium dissociation constant o f  monoclonal anti-AFB, was determined by a 
variation o f  the method o f Friguet e t  a l .  (1985), as described in section 2.7.12. The theory 
o f this method o f determining the affinity o f  an antibody when its absolute concentration is 
unknown is outlined in section 5.5. In their study, Friguet e t  a l .  found a linear relationship 
between the amount o f antibody added to wells and the absorbance values. Preliminary 
studies with the monoclonal anti-AFB, antibody, however, showed that a log linear plot 
gave the best straight line, necessitating a modification o f  the experimental procedure.
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Figure 5.18 The effects o f  regeneration with sodium hydroxide on AFBr BSA  coated 
onto wells o f  a 96-well microtitre plate. Increasing concentrations o f  NaOH were added 
to coated wells before (“Pretreatment) and after (“Regeneration”) incubation with 
polyclonal anti-AFB!. The amount o f  bound antibody was measured by ELISA, with 
addition o f  HRP-labelled anti-rabbit IgG. The results shown are the averages o f  
duplicate analyses.
NaOH concentration (mM)
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Figure 5.19 The effects o f  regeneration with sodium hydroxide on AFBr B SA  coated 
onto wells o f  a 96-well microtitre plate. Increasing concentrations o f  NaOH were added 
to coated wells before (“Pretreatment) and after (“Regeneration”) incubation with 
monoclonal anti-AFBj. The amount o f  bound antibody was measured by ELISA, with 
addition o f  HRP-labelled anti-mouse IgG. The results shown are the averages o f  
duplicate analyses.
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A  96-well microtitre plate was coated with AFB,-BSA. A  range o f  standard solutions, 
containing from 3.9 x 10'7 to 4 x 10^ M o f free AFB„ was prepared, and 100 |_il aliquots o f  
each standard were incubated overnight at room temperature with a 1/10,000 dilution o f  
monoclonal antibody, to allow equilibrium to be reached. These reaction mixtures were 
then added to the conjugate-coated wells. A  range o f  dilutions o f  monoclonal antibody were 
also prepared, and added to separate individual wells. After incubation, HRP-labelled anti­
mouse antibody and enzyme substrate were added, and the absorbance o f  wells at 405 nm 
was measured. Four replicates o f  both antibody dilutions and equilibrium mixtures were 
assayed, and coefficients o f variation were below 4%. The absorbances o f  wells containing 
different antibody concentrations were used to construct a standard curve, from which the 
amounts o f  free antibody in the equilibrium solutions were calculated. The reciprocal o f  the 
fraction o f free antibody in these solutions (i0/i0-i) was then plotted against the reciprocal o f  
the antigen concentration (l/a0). This Klotz plot is shown in Figure 5.20, and has an r2 value 
o f  0.99, and a y-axis intercept o f  0.99. The equilibrium dissociation constant (KD) for the 
monoclonal anti-AFB, antibody was calculated as 7 x 1 0 9 M.
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Figure 5.20 Klotz plot for monoclonal anti-AFBj. Antibody at constant concentration 
was incubated with a range o f  antigen standards. The amount o f  free antibody remaining 
in solution was calculated by indirect ELISA, from a separate antibody standard curve. 
The reciprocal o f  this value was plotted against the reciprocal o f  antigen concentration, 
and a value o f  7 x 10'9 M was obtained for the KD. The points shown are the averages o f  4 
replicate analyses.
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5.8 Discussion
The results presented in this chapter clearly indicate the lack o f suitability o f  the particular 
antibodies studied for use in a regenerable immunosensor, and highlight some general 
considerations to be taken into account when selecting the immunological component for 
such applications.
Monoclonal antibody to AFB, was immobilised on the BIAcore sensor chip, displayed no 
significant non-specific interaction, and injection o f  a protein conjugate o f  the toxin over 
this surface resulted in a strong binding signal (Figure 5.4). The lack o f a visible 
dissociation phase in this sensorgram, however, indicated a high affinity constant for the 
interaction, and after treatment with a variety o f  regeneration reagents, the binding proved to 
be reversible only at the expense o f  antibody activity. This high affinity did not affect the 
use o f  antibody in a non-regenerable immunoassay format, however, and a sandwich ELISA 
in which monoclonal antibody was directly coated onto wells o f  a microtitre plate (Figure 
5.14) displayed good linearity and sensitivity, with a measuring range o f  1 - 400 ng/ml for 
AFBr BSA.
In an attempt to circumvent the problems o f  regenerating a directly immobilised monoclonal 
antibody surface, two different capture molecules were used. Although initial binding o f  
antibody to protein A is high (Figure 5.6), the overall affinity o f the molecule for the isotype 
o f IgG used here is low, and the subsequent rapid dissociation makes binding o f toxin- 
protein conjugate impossible to visualise. Hence, attempts to perform a sandwich ELISA 
using immobilised protein A to capture monoclonal antibody were also unsuccessful. The 
low affinity o f  the ligand for mouse IgG, is such that when polyclonal antibody is added in a 
subsequent step, it displaces any remaining bound primary antibody, resulting in high 
background signals, and no change in absorbance between standards.
Although no such dissociation o f antibody captured with an Fc-specific anti-mouse IgG 
antibody is evident (Figure 5.7), binding o f  conjugate cannot be demonstrated. This appears 
to be due to the fact that a maximum o f 1200 RU o f monoclonal IgG can be captured by the 
immobilised anti-mouse antibody. This limits the amount o f  antigen which can bind, 
dramatically decreasing the effective binding capacity o f the surface. Comparison o f  the 
standard curves from the sandwich ELISAs carried out using direct coating o f  monoclonal
215
anti-AFB, and capture by anti-mouse antibody (Figures 5.14 and 5.15, respectively) show 
that the direct immobilisation format is 10-fold more sensitive.
When polyclonal anti-AFB! is immobilised on the BIAcore sensor chip, no binding o f  
toxin-protein conjugate to the antibody surface can be demonstrated. The pH o f  
immobilisation buffer was increased to 6.8, and the capping o f  unreacted NHS esters with 
ethanolamine was omitted, to avoid inactivation o f the antibody by contact with harsh 
reagents, but neither o f  these alterations promoted binding o f  conjugate, although 10000 RU 
o f polyclonal antibody was immobilised. A  sandwich ELISA in which polyclonal antibody 
was coated onto microtitre plates by passive adsorption, however, had a linear range o f 1 - 
100 ng/ml, with an r2 value o f 0.99. These results suggest that the NHS/EDC coupling o f  
polyclonal anti-AFB, to the chip surface is affecting the activity o f  the antibody.
In a study on antibody fragments, Kortt e t  a l .  (1997) immobilised a mouse anti-idiotype 
scFv fragment by this type o f non-specific amine coupling, and found that it displayed a 
significantly reduced affinity for its antigen, an anti-viral neuraminidase antibody designated 
NC41, compared to fragments which had been immobilised in a site-directed fashion via a 
C-terminal thiol residue. They also immobilised the NC41 antibody by EDC/NHS 
coupling, and found that this had no effect upon its affinity for the scFv fragment. Upon 
investigating the amino acid sequence o f  the two antibodies, they concluded that the activity 
o f the scFv was reduced as a result o f immobilisation through lysine residues within the 
CDR region. Similar findings with regard to the effect o f EDC/NHS immobilisation on 
antibody binding have been reported by Catimel e t  a l .  (1997).
The lack o f activity o f  immobilised polyclonal anti-AFBj, then, may be due to the fact that 
amine groups at the binding site o f the antibody have been coupled to the carboxylated 
dextran o f  the BIAcore chip by the non-specific nature o f the EDC/NHS immobilisation 
chemistry. Monoclonal anti-AFB l5 which is not inactivated by EDC/NHS immobilisation, 
may possess different functional groups in the antigen-binding site.
This problem could be avoided by using a capture molecule, but when indirect 
immobilisation o f  polyclonal anti-AFB! via protein A  was investigated (Figure 5.8), the 
dissociation o f  the rabbit IgG was significant, and no subsequent binding o f conjugate could 
be observed.
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As the immobilisation o f  antibodies had been shown to pose difficulties in terms o f 
regeneration and inactivation, and as strategies involving the use o f capture molecules had 
proved unsuccessful, immunosensor formats based on the immobilisation o f  the AFB,-BSA  
conjugate were investigated. Binding o f monoclonal antibody to immobilised conjugate 
was demonstrated (Figure 5.9), but harsh regeneration conditions were necessary to disrupt 
this interaction, after which treatment the signals from further injections o f  monoclonal 
antibody decreased. This indicated that the binding capacity o f  the immobilised conjugate 
surface had been damaged by contact with the 75 - 100 mM sodium hydroxide. In a 
competitive ELISA in which AFB,-BSA was coated onto microtitre plate wells and 
monoclonal antibody was mixed with free toxin, a linear measuring range o f  1 - 800 ng/ml 
and an r2 value o f  0.99 were obtained (Figure 5.12).
The binding o f polyclonal antibody to an immobilised AFB,-BSA surface was also 
examined. Although good binding signals were obtained (Figure 5.10), regeneration could 
not be achieved without affecting the antibody-binding capacity o f the conjugate surface. 
Regeneration conditions which were optimised for the removal o f  moderate levels o f  
antibody were found to be too harsh when only small amounts o f  polyclonal antiserum were 
bound, preventing the development o f an inhibitive BIAcore immunoassay for AFB,. In a 
competitive ELISA format, however, the polyclonal antibody gave a standard curve with 
adequate linearity and a measuring range o f  10 - 50000 pg/ml. This hundred-fold increase 
in sensitivity when using polyclonal rather than monoclonal antibodies is in agreement with 
the findings o f  Ward e t  a l  (1990), who reported that use o f  rabbit polyclonal antiserum in an 
ELISA for AFB, resulted in greater sensitivity than rat monoclonal antibody.
Apart from a general indication o f a high affinity constant in the case o f  monoclonal anti- 
AFB|, then, no useful information could be gained from the BIAcore studies o f  these two 
commercial antibody preparations, and no quantitative or kinetic experiments could be 
designed. Notwithstanding the limitations o f the various capture systems - i.e. rapid 
dissociation and low levels o f  indirect immobilisation - the main problem was that o f  
regeneration. One inherent difficulty with optical immunosensor systems is that o f  
assessing whether actual regeneration o f  antibody-antigen binding is taking place. Non- 
covalently bound material which remains at the sensor surface after immobilisation can be 
removed by reagents used for regeneration, and the resulting decrease in detector response
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may be mistaken for the reversal o f antibody-antigen binding. It is usually possible to 
correct for this effect by pre-treatment o f  the immobilised surface with the regeneration 
reagents to be used, but this is not feasible where a novel interaction, for which the 
regeneration conditions are unknown, is being studied. In addition, the covalent bonds 
linking the immobilised component to the dextran gel may be disrupted by harsh chemical 
treatment, again resulting in a reduced signal. For example, the binding o f  208 RU o f  
polyclonal anti-AFB, to immobilised toxin-protein conjugate was almost completely 
regenerated by treating the surface with a 10 minute injection o f lOOmM NaOH, but when 
only 27 RU o f antibody were bound to the surface, the same regeneration conditions 
brought the signal down to 111 RU below the baseline (Table 5.2), suggesting that some 
immobilised conjugate had been removed. The use o f high salt concentrations and organic 
solvents sometimes result in contraction o f the dextran gel, which can also give rise to 
confusing detector responses.
A series o f  ELISAs were performed to investigate the effects o f regeneration on 
immobilised antibody and conjugate. Comparison o f Figures 5.16 and 5.17 shows that 
when both polyclonal and monoclonal antibodies are coated onto microtitre plates, 
treatment with increasing concentrations o f  base results in increasing regeneration. 
However, the ability o f  both antibodies to bind to antigen is also clearly affected by contact 
with NaOH, the more pronounced effect on the monoclonal preparation perhaps being due 
to its homogeneity. When the AFB -BSA conjugate was coated onto wells (Figures 5.18 
and 5.19), regeneration o f both monoclonal and polyclonal antibody binding was evident, 
but pretreatment o f  the surface with base failed to significantly affect subsequent binding o f  
antibody. This result seems to belie the BIAcore findings, but it should be remembered that 
two different methods o f  immobilisation were involved. It appears that the covalent bonds 
formed by NHS esterification are more susceptible to treatment with base than are conjugate 
molecules passively adsorbed onto the polystyrene o f  microtitre plates.
One practical consideration that emerged from the BIAcore investigations undertaken here 
was that o f  the stability o f bio-conjugates. As discussed in section 3.4.1.1, these conjugates 
are o f integral importance in the study o f  low molecular weight analytes, but coupling 
chemistries can be unstable, and the breakdown o f these molecules can lead to misleading 
results. While AFB,-BSA was initially found to bind strongly to immobilised monoclonal
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anti-AFB,, the binding signal proved difficult to reproduce after the conjugate had been 
stored at 4°C for some weeks. When an aliquot o f the same batch o f conjugate was 
immobilised, injections o f antibody over this surface gave strong binding signals. It was 
thought that breakdown o f the conjugate might result in the presence o f  free aflatoxin, 
which could be preferentially binding to immobilised antibody. Such binding would not 
cause a change in SPR angle. Free toxin, however, would be washed away from 
immobilised conjugate by continuous buffer flow. This hypothesis was proved when stock 
AFBr BSA, purified by size exclusion chromatography on a PD-10 column (section 2.9.4), 
was found to bind to immobilised antibody. These results highlight the importance o f  
choosing a stable coupling chemistry.
The Klotz plot shown in Figure 5.20 gives a KD value o f  7 x 10'9 M for monoclonal anti- 
AFB,. This high affinity value is at the theoretical upper limit for diffusion-limited 
reactions - which has been shown to govern the association rate o f some hapten-antibody 
interactions (Kuby, 1997) - and confirms the inferences from BIAcore sensorgrams, as well 
as explaining the difficulty o f regeneration. The much-lauded advantages o f  specificity and 
sensitivity conferred by monoclonal antibodies must be balanced against the necessity for 
reversible binding which is a prerequisite for regenerable biosensor applications. Although 
this antibody preparation performed well in various ELISA formats, it is inherently 
unsuitable for BIAcore use. As discussed in Chapter 3, screening procedures for antibodies 
tend to select on the basis o f high affinity, but for antibodies which are to be used in 
biosensors, moderate affinity is preferable, and screening should, if  possible, be carried out 
with this in mind.
Given the high cost o f  sensor chips, preliminary ELISA studies on the interactants to be 
investigated in BIAcore experiments can provide an economical source o f  essential data. 
The ELISA method o f Friguet e t  a l .  (1985) for the calculation o f  antibody affinity constants 
should be employed initially to determine the suitability o f the proposed antibodies for use 
in BIAcore experiments. Antibodies with high affinity constants (in the range 108 to 109) 
are likely to be inherently unusable. The ability o f this method to measure antibody 
affinities in crude samples, such as hybridoma supernatant or ascitic fluid, can be used to 
select only antibodies with moderate affinity from a panel o f monoclonal antibodies for 
BIAcore investigations.
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Establishing optimal regeneration conditions on the BIAcore is generally a time-consuming 
task, involving the use o f  a number o f sensor chips. The results presented here show that 
microtitre plate-based ELISAs can be used to approximate the optimal regeneration 
conditions for immobilised antibody and antigen surfaces. The effects o f  these regeneration 
solutions on the activity o f immobilised biomolecules can also be assessed. While it is 
difficult to precisely relate the two formats in terms o f contact time with the sensor surface, 
initial ELISA studies o f  this type can be used to identify the most effective type and 
concentration o f regeneration reagent for the interaction.
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5.9 Summary
A  commercial monoclonal anti-aflatoxin B, preparation was immobilised on BIAcore 
sensor chips and injection o f  AFB,-BSA resulted in a binding signal. The antibody-antigen 
interaction proved too strong to regenerate, however, and the use o f  protein A as a capture 
agent was unsuccessful, due to high rates o f  dissociation. Anti-mouse IgG was also used to 
capture monoclonal anti-AFB,, but the amount o f antibody which could bind to this surface 
was not sufficient to allow antibody-antigen interactions to be observed.
Commercial polyclonal anti-AFB, was also immobilised, but the activity o f  the antibody 
was reduced by the use o f  non-specific amine coupling to the dextran layer o f  the sensor 
chip. Attempts to capture polyclonal antibody via anti-rabbit IgG antibodies were 
unsuccessful due to high dissociation rates.
AFB,-BSA was then immobilised on the sensor chip. Although binding o f  monoclonal 
antibody to this surface could be demonstrated, the harsh regeneration conditions which 
were necessary before re-using the chip considerably reduced the binding capacity o f  the 
surface. Similar results were obtained for binding o f the polyclonal antibody to an AFB,- 
BSA-coated surface.
Although not suitable for use with BIAcore, both polyclonal and monoclonal antibody 
preparations were successfully employed in quantitative ELISA techniques, in both 
competitive and sandwich assay formats.
ELISA methods were used to construct a model system for the optimisation o f  BIAcore 
regeneration conditions. The regeneration o f  immobilised antibody and conjugate BIAcore 
surfaces with NaOH and HC1 was mimicked on microtitre plates, and the method o f Friguet 
e t  a l .  (1985) was used to calculate the affinity constant o f a monoclonal antibody against 
AFBj. This type o f  ELISA study is proposed as an inexpensive preliminary investigative 
step for all BIAcore studies on antibody-antigen binding, which can help to minimise the 
use o f  costly sensor chips.
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CHAPTER 6
BIAcore STUDIES ON THE INTERACTION OF 
COUMARIN COMPOUNDS WITH DNA AND 
TOPOISOMERASE II
6.1 In tro d u ctio n
This chapter describes the use of BIAcore to examine interactions between coumarins and 
DNA. Plasmid DNA was extracted from bacterial cells and labelled with biotin. The 
biotin-labelled nucleic acid was bound to the sensor chip via an immobilised streptavidin 
surface. The effect of novobiocin upon the action of topoisomerase II -  an enzyme which 
catalyses the relaxation of supercoiled DNA -  was investigated. The unwinding of 
extracted plasmid DNA by topoisomerase II was demonstrated by agarose gel 
electrophoresis and Southern blotting. BIAcore was used to show the inhibition of 
enzyme activity by the coumarin antibiotic novobiocin, although the binding of enzyme 
to nucleic acid was transient, and no data on the kinetics of binding could be obtained.
The direct binding of protein conjugates of various coumarins to immobilised DNA was 
also investigated. No binding was observed upon injection of BSA conjugates of 
warfarin, coumarin, 7-hydroxycoumarin and aflatoxin Bi over the surface.
6.2 In tera c tio n s  o f  co u m a r in s w ith  D N A
Coumarin has been reported to cause DNA and chromosome damage in plant cells (Grigg, 
1978), although antimutagenic activity has also been claimed for the drug in E. coli. (Ohta 
et al., 1983). In a range of optical tests including spectrophotometric titration and circular 
dichromism, however, no binding of coumarin or 7-hydroxycoumarin to DNA in water-salt 
solutions could be detected (Y. Yevdokimov, Personal communication). The binding of 
furanocoumarins to DNA has been reported (Murray et al., 1982).
The photobinding of furanocoumarins to DNA in the presence of UV light has been widely 
documented (Murray et al., 1982). 5,7-dimethoxycoumarin has also been shown to possess 
photobinding activity (Jung et al., 1983), as have the pyrrolocoumarins (Gia et al., 1988)
As discussed in Chapter 5, the toxic activity of aflatoxin Bi (AFBi) has been ascribed to 
the binding of its epoxide metabolites to nucleic acids (Martin and Gamer, 1977, Roy and 
Kulkami, 1997). The identification and quantification of AFBi-DNA ad ducts is of 
importance as an indication of the risk of cancer. Although the toxicity of AFBi is due to 
its epoxide, the binding of underivatised AFBi to DNA has been investigated. In a range 
of studies using spectrophotometric methods (Clifford and Rees, 1966), equilibrium 
dialysis (Black and Jirgensons, 1967) and fluorescence techniques (Neeley et al., 1970), 
AFB] was found to bind weakly to double- and single-stranded nucleic acids, without 
intercalating or affecting the melting temperature (Tm) of DNA.
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6.3 C o u m a rin  a n tib io tic s  and  to p o iso m era se  in h ib it io n
The three coumarin antibiotics, novobiocin, coumermycin A, and chlorobiocin, are 
structurally related compounds which are produced by Streptomyces species. The 
structure of these three drugs is shown in Figure 6.1. The drugs are generally more active 
against Gram-positive than Gram-negative bacteria, as a result o f differences in 
permeability (Maxwell, 1993), and inhibit DNA replication by binding to topoisomerases, 
specialised enzymes responsible for relaxing and supercoiling DNA.
In vivo, DNA usually has a closed structure, with no free ends. Supercoiling occurs when 
the double helix is twisted about its own axis, and may be either or negative (in the 
opposite direction to the right-handed helix) or positive (in the same direction). Only 
negative supercoiling occurs in vivo, and it is caused by unwinding a number of turns of 
the double helix and joining the ends. In addition to producing a more compact form of 
DNA, this action facilitates the separation of the two strands of the DNA molecule. This 
strand separation is of critical importance for the replication, transcription and 
recombination of DNA. As a result, the presence of topoisomerases in cells has been 
shown to be necessary for their viability. The enzymes operate by making a break in a 
stretch of DNA, stabilising it, and passing another strand of DNA through this break prior 
to rejoining it. This action is thought to be non-specific, with the enzyme recognising any 
two regions of double-stranded DNA which cross over each other (Lewin, 1990). Type I 
topoisomerases introduce transient breaks in one strand of the DNA duplex, while type II 
topoisomerases make double-strand breaks. The action of many topoisomerases is ATP- 
dependant.
The rapidly-dividing nature of cancer cells, involving high levels of DNA replication, has 
made topoisomerases a target for anti-tumour strategies, while the prokaryotic equivalent 
-  DNA gyrase -  is being studied as a target for therapeutic anti-bacterial agents 
(Maxwell, 1997).
Bacterial DNA gyrase is an unusual member of the type II topoisomerases, in that it has 
the ability to perform the energetically unfavourable task of introducing negative 
supercoils into relaxed closed circular DNA. One molecule of the enzyme can introduce 
about 100 supercoils per minute into a molecule of DNA.
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Figure 6.1 Structure of the three coumarin antibiotics
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The supercoiling ability of DNA gyrase is dependent upon the hydrolysis of ATP; 
although the enzyme can still relax supercoiled DNA in its absence, and this reaction is 
not affected by the coumarin antibiotics.
DNA gyrase is made up of two subunits, and the active form of the enzyme is a tetramer. 
Coumarin antibiotics bind to the B subunit, and the novobiocin-binding site has been 
pinpointed to a 24 kDa sub-domain of the N-terminal fragment of the enzyme (Gormley 
et al., 1996). The novobiocin molecule is composed of three parts: a benzoic acid 
derivative, a coumarin residue, and a sugar (novobiose). Studies have shown that the 
coumarin portion (bearing the correct substituents) is the necessary component for 
binding DNA gyrase B. The mechanism of action of the coumarin antibiotics on DNA 
gyrase has been widely studied, and they have been found to function by competitively 
inhibiting the hydrolysis of ATP.
The inhibition of vaccinia topoisomerase, a type I eukaryotic enzyme, by coumarin 
antibiotics, occurs in a different manner. Novobiocin and coumermycin have been shown 
to interact with the enzyme in such a way as to block the binding of DNA (Sekiguchi et 
a l,  1996).
6.4  T h e  u se  o f  B IA co re  to  stu d y  n u c le ic  a c id  in tera c tio n s
BIAcore has been used to study a variety of DNA interactions, including hybridisation, 
binding of receptors and anti-DNA antibodies, and the action of enzymes. In most of the 
reported experiments, DNA or oligonucleotides have been biotinylated and bound to the 
sensor chip via immobilised avidin or streptavidin.
Biotin, also known as vitamin H, is a small molecule which acts as a coenzyme for 
transcarboxylase and ATP-dependent carboxylases. Avidin is a tetrameric glycoprotein 
which is found in eggs, and has four high affinity binding sites for biotin. Streptavidin is 
a related molecule which exhibits lower non-specific binding. Both molecules have been 
extensively used in biosensors for the immobilisation of biotinylated biomolecules 
(Ebersole et al., 1990; Rehak et al., 1994).
Wood (1993) first reported the use of BIAcore to visualise nucleic acid hybridisation. In 
this study, biotinylated oligonucleotides were captured on the sensor surface and the 
binding of complementary strands was observed within 7 minutes. Gotoh et al. (1995) 
described a method to determine the kinetic parameters in DNA hybridisation, which was 
sensitive to the presence of mismatches, and could detect even a single base-pair
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mismatch. In a study on the detection of HIV-1 genomic sequences, Bianchi et al. (1997) 
used an immobilised biotinylated oligonucleotide probe to produce a fast, reproducible 
method for the detection of HIV-1 complementary sequences in PCR products.
The presence in the body of high affinity autoantibodies specific for native double­
stranded DNA is diagnostic of the disease systemic lupus erythematosus (SLE). Barbas 
et al. (1995) generated human Fabs to DNA from combinatorial phage display libraries, 
and used BIAcore to derive kinetic data for their binding to immobilised oligonucleotides. 
Sibille et al. (1997) used a similar strategy to study murine monoclonal antibodies derived 
from lupus-prone mice.
The interaction between MutS -  a mismatch repair molecule from E. coli -  and a range of 
oligonucleotides immobilised on BIAcore was investigated by Babic et al. (1996). 
Cheskis et al. (1997) studied the binding of the ligand inducible transcription factor, 
eostrogen receptor (ER), to DNA immobilised on the BIAcore in the presence and 
absence of a variety of ligands.
Nilsson et al. (1995) used biotin-avidin capture of oligonucleotides to study a range of 
different types o f DNA manipulation. The assembly of a 69 base-pair fragment from 6 
smaller fragments was demonstrated. The action of DNA ligase to join together separate 
oligonucleotides was visualised in “real-time”, as were strand separation and 
hybridisation. Two types of DNA polymerase, T7 polymerase and Klenow fragment, 
were examined on BIAcore, and injection of the enzymes, together with dNTPs, over a 
single-stranded DNA surface, lead to an increase in signal, corresponding to the synthesis 
of a complementary strand of DNA. In addition, the cleavage of DNA by the restriction 
endonuclease Xhol was demonstrated. A mini-sequencing experiment was also 
described, in which Klenow fragment and one of four ddNTPs were injected over 
immobilised single-stranded DNA bearing a double-stranded overhang. This was carried 
out on four surfaces for each of the four ddNTPs, and subsequent injection of polymerase 
along with all four dNTPs resulted in one sensorgram where no signals for DNA 
synthesis could be seen. The ddNTP injected in this flow cell was found to be 
complementary to the first base in sequence.
Uracil-DNA glycosylase is a DNA repair enzyme which removes uracil bases from DNA. 
Panayotou et al. (1998) immobilised biotinylated DNA, with and without uracil, and 
injected mutated uracil-DNA glycosylase from herpes simplex virus, and reported that the 
enzyme recognised uracil in the DNA, and not DNA itself.
2 2 6
Pond et al. (1997) used BIAcore to investigate the binding of human topoisomerase I to 
DNA. Three different types of biotinylated double-stranded DNA were immobilised on a 
streptavidin surface, and the effect of the base content and concentration of Mg upon the 
binding of topoisomerase I was examined. The association and dissociation of the 
enzyme from DNA were found not to fit to simple models. The dissociation phase 
appeared to be biphasic in nature, and it was suggested that this was due to an initial high 
rate of dissociation of topoisomerase I from sites on DNA where it could not introduce 
single-strand breaks.
In the studies described below, supercoiled plasmid DNA was extracted from bacterial 
cells, labelled with biotin and bound to the BIAcore via immobilised streptavidin. The 
interaction of topoisomerase II, novobiocin and coumarin-protein conjugates with this 
surface was investigated.
R esu lts
6 .5  E x tra c tio n , p u r if ica tio n  an d  b io tin y la tio n  o f  su p erco iled  p la sm id  D N A
Supercoiled plasmid DNA was extracted from bacterial cells as described in section 2.11. 
E. coli cells of the strain TGI were used. These cells contained the plasmid pHENl, a
3,000 base-pair phage display vector which carries a gene for carbenicillin resistance. 
After culturing cells overnight, the plasmid DNA was extracted using a commercial mini­
column kit based on specific absorption of DNA onto a solid phase. The DNA was eluted 
from the mini-column with ultrapure water. The absorbance of the eluted material at 260 
nm and 280 nm was measured, and the average A260/280 ratio was found to be 1.75, 
indicating good purity of DNA. 10 ml of bacterial culture were purified at a time, and the 
average yield of DNA was 15 (j,g.
The extracted DNA was labelled with biotin using a commercial chemical labelling kit as 
outlined in section 2.12. A as-platinum compound of biotin with an easily cleavable 
nitrate ligand was added in a 1:1 ratio to purified DNA in aqueous solution. This results 
in the cleavage of the nitrate group, and coordinative binding to guanosine and adenosine 
bases. Theoretically, one in every four bases can be labelled by this method, although the 
actual labelling density is generally one in ten. The labelled DNA was separated from 
any remaining free biotin by precipitation.
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6 .6  In v estig a tio n  o f  to p o iso m era se  I I  an d  n o v o b io c in  a c tiv ity
Agarose gel electrophoresis and Southern blotting were used to demonstrate the 
relaxation of supercoiled DNA by topoisomerase II. Biotinylated DNA was then 
captured by streptavidin immobilised on the BIAcore sensor chip, and enzyme solutions, 
with and without novobiocin, were injected over the surface to examine the effect of the 
coumarin antibiotic on the binding of enzyme.
6.6.1 A g a r o se  g e l e lec tro p h o resis
The action of the enzyme was demonstrated using agarose gel electrophoresis as 
described in section 2.13. A commercial preparation of topoisomerase II from 
Drosophilia melanogaster was used. This is a dimeric protein with a molecular weight of 
166 kDa, and an absolute requirement for divalent cation and ATP. One unit of the 
enzyme is defined as the amount needed to fully relax 0.3 jag of supercoiled pBR322 
plasmid DNA in 15 minutes at 30°C (Osheroff et al., 1983).
3 |ig of biotinylated DNA was added to 40 units o f topoisomerase II together with 
enzyme reaction buffer (containing a final concentration of 10 mM Tris-HCl, pH 7.9, 50 
mM NaCl, 50 mM KC1, 5 mM MgCl2, 100 (iM EDTA, 15 ^g/ml BSA and 1 mM ATP). 
This solution was incubated for 45 minutes at 30°C. A sample of the reaction mixture 
was added to loading buffer and loaded onto a 1% (w/v) agarose gel containing 0.5 fig/ml 
of ethidium bromide, along with a sample of the original DNA extract, and biotinylated 
DNA. All samples were loaded at a concentration of 1.1 jig/ml. Markers containing X 
phage DNA digested with EcoR l and HinD3 restriction enzymes were also run. The gel 
was electophoresed at 80 mV, and photographed under ultraviolet light. The results are 
shown in Figure 6.2. It can be seen that the original extracted DNA and the biotinylated 
sample give almost identical bands, whereas the enzyme-treated sample lacks the lowest 
band. The different bands seen for the samples correspond to a variety of topological 
forms of DNA. Due to its topography, supercoiled DNA can move through the gel faster 
than the relaxed form, indicating that the topoisomerase II in sample 3 has relaxed the 
supercoiled plasmid DNA.
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Figure 6.2  A garose gel electrophoresis o f  extracted D N A  sam ples. Extracted p H E N l 
plasm id D N A  (1), b iotinylated  p lasm id D N A  (2 ) and sam ple treated w ith  topoisom erase  
II (3) w ere run along w ith  markers (d igested  X phage D N A ). Extracted and biotinylated  
sam ples g iv e  sim ilar bands, corresponding to  d iffering top o log ica l form s o f  D N A . The 
m ore supercoiled  the D N A  is, the faster it m o v es through the gel. T he absence o f  the 
low est band in  sam ple 3 dem onstrates that the en zym e has relaxed  supercoiled  D N A .
MARKERS
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6.6 .2  S o u th ern  b lo ttin g
The biotinylation of the plasmid DNA was assessed by Southern blotting. This was 
carried out as described in section 2.14. DNA from the agarose gel was transferred onto a 
nitrocellulose membrane by means of capillary transfer. The nitrocellulose was then 
blocked by incubation with 5% (w/v) milk powder. After washing, the membrane was 
incubated together with an avidin-alkaline phosphate conjugate, and colour was 
developed after addition of an insoluble alkaline phosphate substrate.
A photograph of the nitrocellulose blot is shown in Figure 6.3. The biotinylated DNA 
bound to the avidin conjugate, and although faint, a pattern of bands mirroring those on 
the agarose gel can be seen. The lowest band -  denoting supercoiled DNA -  is more 
distinct for the biotinylated sample than the enzyme treated one. The “smearing” of 
colour running down both lanes may be due to biotin dissociating from the labelled DNA, 
or the presence of free biotin as a result o f inefficient precipitation.
6.6 .3  B IA co re -b a sed  in v estig a tio n  o f  th e  e ffec t o f  n o v o b io c in  on  
to p o iso m er a se  II
DNA was captured on the sensor chip as outlined in section 2.9.5. Streptavidin was 
immobilised at a concentration of 50 (J-g/ml, giving a signal of approximately 15,000 RU. 
Biotinylated DNA at a concentration of 35 (.Lg/ml in ultrapure water was injected over this 
surface for 25 minutes, resulting in the binding of 980 RU of DNA. The biotin- 
streptavidin interaction is very rapid, and no binding curve is seen (Figure 6.4).
5 nM topoisomerase II in reaction buffer (see section 6.6.1) was injected over this surface 
with and without 500 (J-g/ml novobiocin. A negative control containing 500 p.g/ml 
novobiocin in PBS was also injected. The results are shown in Figure 6.5. The overlaid 
sensorgrams clearly show the effect of novobiocin on the topoisomerase-DNA 
interaction. The protein concentration in the two samples is the same, yet the initial bulk 
refractive index change for the sample without novobiocin is greater than that for the 
sample containing antibiotic. Binding of topoisomerase to the immobilised DNA is 
evident in the sample without antibiotic, and by just before the end of the injection, the 
signal for the sample containing novobiocin is 555 RU less than that for the antibiotic- 
free sample. The binding of topoisomerase II to DNA appears to be transient, however, 
as no increase in signal relative to baseline is seen after the sample pulse has passed over 
the surface.
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Figure 6.3 Southern b lotting o f  b iotin -labelled  D N A . B iotiny la ted  D N A , w ith  and 
w ithout topoisom erase II, w as transferred from  agarose g e l onto n itrocellu lose, w h ich  w as  
then probed w ith  an alkaline phosphatase conjugate o f  avidin. T he results confirm  the 
b iotinylation  o f  p lasm id  D N A , and the pattern o f  bands obtained mirrors those on  the gel. 
The lo w est band, w h ich  represents supercoiled  D N A , is  fainter for the enzym e-treated  
sam ple than the untreated one, dem onstrating the relaxation  o f  supercoiled  D N A  by  
topoisom erase II.
BIOTIN-
LABELLED BIOTIN-
DNA + LABELLED
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1
DNA
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Figure 6.4 Capture o f  biotinylated D N A  on a streptavidin surface. A pproxim ately
15,000 RU o f  streptavidin w ere im m obilised. A  25 m inute injection o f  35 p.g/ml 
biotinylated D N A  w as then passed over this surface. T he b inding o f  the b iotin  and avidin  
is very rapid, as no increase in signal can be seen  during the sam ple injection. The 
binding is m asked by the initial bulk refractive index change, reflectin g  the high affin ity  
o f  the interaction. 980  RU  o f  D N A  w ere captured
Time (Sec)
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F ig u re  6 .5  Overlay plot showing the effect of novobiocin on the action of topoisomerase 
II. Biotinylated DNA was immobilised on the sensor chip and 5 mM solutions of 
enzyme, with and without 500 |4g/ml novobiocin, were injected. A negative control 
containing 500 (ig/ml novobiocin in PBS was also passed over the surface. The inhibition 
of the topoisomerase-DNA interaction by novobiocin is demonstrated by the differences 
in binding signals. Although the protein concentration of the two samples is the same, the 
initial bulk refractive change is greater for the sample without novobiocin. A binding 
signal can be seen during for this sample, and, by the end of the injection, the response is 
555 RU greater than that for the antibiotic-containing sample.
Time (Sec)
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6.7  D ire c t in tera c tio n s  o f  co u m a r in -p ro te in  co n ju g a te s  w ith  B S A
The binding of a range of BSA conjugates to immobilised DNA was assessed on the 
BIAcore. Approximately 15,000 RU of biotinylated DNA was captured with streptavidin 
as in section 6.6.3. Sequential injections of 100 fig/m] of BSA, 7-hydroxycoumarin-BSA, 
coumarin-BSA, aflatoxin Bi-BSA and warfarin BSA were passed over the surface. The 
results are shown in Figure 6.6. Native BSA gave a binding signal of 630 RU, and the 
high level of dissociation observed immediately after the sample pulse has passed over 
the surface suggests that this is due to low affinity, non-specific, binding.
A large negative response (-487 RU) is seen after the injection of 7-hydroxycoumarin- 
BSA. A subsequent injection of 7-hydroxycoumarin-BSA over the DNA surface (data 
not shown), did not result in any such signal, indicating that the initial response was due 
to washing off of non-specifically bound native BSA from the first injection. No 
significant binding of any of the coumarin conjugates was observed.
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Figure 6.6 Interaction o f  coum arin-protein conjugates w ith  im m ob ilised  D N A . D N A  
w a s captured b y  im m ob ilised  streptavidin and 100 ( ig /m l so lu tion s o f  (A) B S A , (B) 7- 
h ydroxycoum arin-B SA , (C) coum arin-B SA , (D) aflatoxin  B l - B S A  and (E) warfarin- 
B S A  w ere injected over the surface. T he n o n -sp ec ific  b inding o f  native B S A  g iv es  a 
response o f  630 RU. T he large negative signal after in jection  o f  7-hydroxy coum arin- 
B S A  (B) is  due to the d issocia tion  o f  native B S A , as a subsequent in jection  o f  7 -  
h ydroxycoum arin -B SA  (not show n) did not g iv e  any ch an ge in  signal. N o n e  o f  the other 
coum arin conjugates gave any significant b ind ing signals.
Time (Sec)
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6.8 D iscu ss io n
The results presented here demonstrate the ease of immobilisation of biotin-labelled DNA 
on the BIAcore, and its use for the investigation of the properties of coumarin 
compounds. Commercial kits were used to extract and label plamid DNA, with good 
yields and purity.
The action of a topoisomerase II from the fruit fly Drosophilia melanogaster was 
investigated using agarose gel electrophoresis (Figure 6.2). The enzyme was shown to 
effectively relax the biotinylated DNA. A Southern blot using an avidin-alkaline 
phosphatase probe showed that the biotinylation of DNA had been successfully achieved 
(Figure 6.3). The smearing seen in the photograph could be due to the dissociation of 
biotin from the DNA or incomplete separation of bound from free biotin by ethanol 
precipitation.
DNA was then bound to the sensor chip surface. Streptavidin was first immobilised and 
biotinylated DNA passed over this surface. The binding of streptavidin and biotin is very 
rapid, and no binding curve is seen during the sample pulse (Figure 6.4). This type of 
interaction is characteristic of the these two binding partners, and similar sensorgrams 
were observed by Nilsson et al. (1995) when passing biotinylated DNA over immobilised 
streptavidin.
Topoisomerase and topoisomerase/novobiocin solutions were then injected over this 
surface (Figure 6.5). The sensorgrams show a definite, if transient, interaction between 
topoisomersase II and the supercoiled DNA. The addition of 500 |J.g/ml o f novobiocin to 
the enzyme results in a sensorgram with lower initial bulk refractive index change, and no 
apparent binding of the enzyme. Although a binding curve for topoisomerase II is 
obtained, no enzyme remains bound once the sample pulse has passed over the surface.
In contrast, Pond et al. (1997) reported binding signals of 500-600 RY for human 
topoisomerase binding to double stranded DNA. In this study, DNA from Micrococcus 
lysodeikticus, Clostridium perfringens and salmon testis were immobilised, and 
topoisomerase I from human placenta was injected at 50-800 nM. This molar 
concentration of enzyme was at least ten-fold greater than that of topoisomerase II in the 
current study. However, the sensorgrams of topoisomerase II injections clearly show a 
binding event, and it must be concluded that the transient nature of the binding is a 
property of this enyzme, and not a concentration-dependent effect.
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Although hardly conclusive, the results observed appear to indicate that the action of 
novobiocin upon eukaryotic topoisomerase II involves the blocking of DNA binding - as 
reported for vaccinia topoisomerase I by Sekiguchi et al. (1996) - rather than the 
inhibition of ATPase activity described for bacterial DNA gyrase (Maxwell, 1993). 
Vaccinia topoisomerase I was found to have one strong binding site and several weak 
binding sites for novobiocin, and these were thought to coincide with or overlap the DNA 
binding site. Unfortunately, the transient nature of the interaction observed for 
topoisomerase II makes the derivation of affinity data based on dissociation rates 
impossible.
The direct interaction between coumarin conjugates and immobilised DNA was then 
examined. BSA conjugates of coumarin, 7-hydroxycoumarin, warfarin and aflatoxin B| 
were injected over the surface and no binding was observed. The lack of binding of 
coumarin and 7-hydroxycoumarin agrees with the results of optical experiments on the 
binding of the drugs to DNA in water-salt solutions (Y. Yevdokimov, Personal 
communication). However, as discussed in section 6.2, the binding of aflatoxin Bi to DNA 
has been well documented. The low molecular weight of the coumarins is such that they 
must be conjugated to proteins in order to generate an SPR signal, and it seems likely that 
this conjugation prevents the normal interaction between coumarins and nucleic acid.
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6.9  S u m m a ry
Agarose gel electrophoresis and Southern blotting were used to demonstrate the 
relaxation of biotinylated DNA by topoisomerase II. This biotinylated DNA was then 
immobilised on the BIAcore surface, and the transient binding of topoisomerase to this 
surface, and its inhibition by novobiocin, were demonstrated. The direct binding of a 
range of BSA-coumarin conjugates to immobilised nucleic acid was also examined, with 
no interaction being observed.
A mechanism of action of novobiocin on topoisomerase II is suggested, which could 
benefit from further examination. The use of coumarin-BSA conjugates with long spacer 
arms to separate drug and protein could reduce steric hindrance and facilitate study of direct 
interactions between coumarins and DNA.
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C H A P T E R  7  
C O N C L U S I O N S
The work described in this thesis is mainly concerned with the production and 
applications of antibodies to members of the coumarin family. Chapter 3 describes the 
production and characterisation of some anti-coumarin antibodies. Polyclonal antiserum 
to 7-hydroxycoumarin was produced by immunisation of rabbits, and displayed a good 
degree of purity and adequate working dilution in a competitive ELISA. Attempts to 
generate monoclonal antibodies to the drug by somatic cell fusion, however, were 
unsuccessful. Hybridomas were obtained and cloned by limiting dilution, but the 
antibodies obtained bound only to drug-protein conjugate, and not to free drug. These 
findings agreed with other results generated in our laboratory, and with reports in the 
literature. It appears that for small, weakly immunogenic haptens such as the simple 
coumarins, the nature of the immunogen used, both in terms of carrier protein and 
coupling chemistry, and the solid-phase screening procedure employed are of critical 
importance. The detection limit of the BIAcore biosensor meant that it could not be used 
to replace traditional ELISA screening methods.
Also in chapter 3, the BIAcore was used to derive kinetic and affinity data for the 
interaction between a genetically-generated scFv antibody to a joint epitope on a 
coumarin-protein conjugate. The interaction between the two was found not to fit to the 
simple mathematical model for antibody-antigen binding, indicating that the binding of 
antibodies to combined epitopes such as these may prove difficult to characterise.
Chapter 3 also contained a study on the possibility of using BIAcore for the panning of 
naïve phage display libraries. Bacterial culture supernatant was passed over an 
immobilised coumarin-protein surface, and then a low pH buffer was injected to remove 
any specifically-bound phage. Due to the low numbers of specific phage present in a 
naïve library, no signal was observed upon passing the supernatant over the surface. 
However, phage counts on the eluate from BIAcore indicated that specific elution had 
taken place. It seems possible that the use of BIAcore over successive rounds of panning 
and enrichment might result in the isolation of specific phage with the desired specificity. 
Chapter 4 outlined the development of a novel method for the quantitative determination 
of 7-hydroxycoumarin in serum samples. The purified rabbit polyclonal anti-7- 
hydroxycoumarin antiserum produced in chapter 3 was used in an inhibitive BIAcore 
immunoassay for free drug. A model system in buffer was first established, and then the 
detection of drug in unextracted serum samples was optimised. The non-specific binding 
of serum components to the sensor chip surface was removed by use of a diluent buffer,
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and samples were pre-incubated with the enzyme p-glucuronidase to deconjugate 7- 
hydroxycoumarin-glucuronide prior to analysis. All steps, including the addition of, and 
incubation with, enzyme and antibody were carried out on the BIAcore. The method was 
reproducible, with good inter- and intra-day coefficients of variation, and excellent 
recovery of drug from spiked samples.
Chapter 5 described comparative BIAcore and ELISA studies on commercial antibody 
preparations against aflatoxin Bi a member of the coumarin family. A variety of assay 
formats were investigated on the BIAcore using monoclonal and polyclonal antibodies to 
the toxin. These formats included direct immobilisation of antibodies and antigen, as 
well as the use of anti-species antibodies and protein A. No regenerable immunosensor 
could be constructed, however, due to the difficulty of regenerating the bound antibodies. 
A series of ELISA studies were then carried out in which the same antibodies were 
successfully used in sandwich and competitive assays for the determination of free and 
protein-conjugated drug. These results highlighted the inherent unsuitability of high 
affinity antibodies for use in regenerable biosensors. An ELISA-based system for initial 
optimisation of BIAcore regeneration conditions was proposed, which -  together with the 
use of an indirect ELISA to determine the affinity of monoclonal antibodies -  could 
considerably reduce the time and expense of BIAcore experiments.
In chapter 6, some preliminary results dealing with BIAcore studies on the binding of 
coumarins to nucleic acids were presented. Plasmid DNA was extracted from bacterial 
cells, biotinylated and bound to the sensor surface via immobilised streptavidin. The 
binding of topoisomerase to this DNA was seen to be inhibited by the action of the 
coumarin antibiotic novobiocin, indicating a possible mechanism of action for the drug. 
The direct binding of a range of coumarin-protein conjugates to immobilised DNA was 
assessed, and none exhibited any significant interaction.
To summarise, then, some of the strengths and weaknesses of the BIAcore optical 
biosensor were highlighted. The instrument was used to perform an accurate and precise 
fully automated immunoassay for 7-hydroxycoumarin, which compared well with 
reported methods of detection. However, the sample throughput and automation of the 
BIAcore could not be used to speed up the screening of monoclonal antibodies from neat 
hybridoma supernatants, due to the low concentrations of antibody present. The system 
was also shown not to be compatible with the use of high affinity antibodies, due to 
difficulties with surface regeneration. This highlights the advisability of producing
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antibodies with moderate affinity for use in biosensor applications where regeneration is 
required.
There are inherent problems with the production of monoclonal antibodies to low 
molecular weight, weakly immunogenic haptens, and the results presented here suggest 
that biosensor-based screening and careful attention to choice of carrier protein and 
coupling chemistry are necessary to generate and select antibodies to free hapten.
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